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MYELOPROLIFERATIVE NEOPLASMS 
 
The myeloproliferative neoplasms (MPNs), are a group of hemopathies characterized 
by a clonal proliferation of hematopoietic stem cells that results in an augmentation of 
mature blood cells.  
According to the World Health Organization (WHO), among the myeloid neoplasms we 
can distinguish, (1, 2):  
1. Myeloproliferative Neoplasms 
 Chronic myelogenous leukemia, (CML); 
 Polycythemia Vera, (PV);  
 Primary myelofibrosis, (PMF);  
 Essential thrombocythemia, (ET);  
 Chronic neutrophilic leukemia;  
 Chronic eosinophilic leukemia, not otherwise specified;  
 Mastocytosis,  
 Unclassifiable MPNs, 
2. Myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of 
PDGFRA, PDGFRB, or FGFR1. 
3. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
 Chronic myelomonocytic leukemia 
 Atypical chronic myeloid leukemia, BCR-ABL1-negative 
 Juvenile myelomonocytic leukemia 
 Myelodysplastic/Myeloproliferative neoplasm unclassifiable 
4. Myelodisplastic syndrome (MDS) 
 
The only MPN with a specific gene abnormality is CML, which is characterized by the 
presence of the Philadelphia (Ph) chromosome which is a chromosomal translocation, 
t(9;22)(q34;q11) that fuses the abl gene from chromosome 9 with the bcr gene from 
chromosome 12 leading to the BCR-ABL1 fusion gene (3, 4). The other subtypes are known 
as Philadelphia negative (Ph-) MPNs. The most frequent are PV (35%) and ET (40% of total 
MPN patients). CML represents 16% of MPN cases and PMF just 5%. The rest are rare 
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diseases. The global incidence of Ph- MPNs is about 3 per 100,000 people newly diagnosed 
with any form of MPN. 
 
POLYCYTHEMIA VERA 
 
Polycythemia Vera is also known as the Osler-Vaquez disease in honor of the first ones 
to characterize it. Louis Henri Vaquez was a French physician who described for the first 
time a PV patient in 1892. This patient presented chronic cyanosis (congestion or 
ruddiness), vertigo, dyspnea, palpitations, hepatosplenomegaly and marked erythrocytosis. 
He thought that raised red blood cell count had to be due to an increased activation of 
hematopoiesis. The Osler term came out thanks to the first PV review by William Osler in 
1903: “Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity”. In 
Osler’s review, he included his own patients and other cases that had been previously 
reported (5, 6). 
In those days, PV was defined by chronic cyanosis, polycythemia, moderate 
splenomegaly, weakness, constipation, headache and vertigo. Nowadays it is characterized 
by clonal overproduction of mature erythrocytes and, moreover variable overproduction of 
leukocytes and platelets. The erythroid stem cells present erythropoietin (EPO) 
independence and hypersensitivity. EPO independence means that these cells are capable of 
going on with their cell cycles without the EPO stimulation. EPO hypersensitivity is 
referred to as the increased reaction of myeloid stem cells to very low concentrations of this 
cytokine (7). Clinically, it is characterized by splenomegaly, thrombohemorrhagic 
complications and pruritus. The average age in patients is 60 years. Usually, survival rate 
is about 15 years for older patients, excepting for cases with grave thrombohemorrhagic 
complications such as aggressive phlebotomy where the survival average is shortened. Life-
expectancy rises to 24 years in patients under 60 years old (8, 9). In addition, 5 to 15 % of 
patients evolve to Acute Myeloid Leukemia or to myelofibrosis (10).  
Diagnosis 
According to the 2008 World Health Organization (1, 2), the diagnosis of PV needs the 
presence of both major criteria and one minor criterion or the presence of one major 
criterion and two minor criteria: 
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Major criteria 
1. Hemoglobin > 18.5 g/dL in men, > 16.5 g/dL in women or other evidence of 
increased red cell volume. (Hemoglobin or hematocrit > 99th percentile of method-specific 
reference range for age, sex, altitude of residence or hemoglobin > 17 g/dL in men, 15 g/dL 
in women if associated with a documented and sustained increase of at least 2 g/dL from 
baseline that cannot be attributed to correction of iron deficiency or elevated red cell mass 
>25% above mean normal predicted value). 
2. Presence of JAK2V617F or other functionally similar mutation such as JAK2 exon 
12 mutation. 
Minor criteria 
1. Bone marrow biopsy showing hypercellularity for age with trilineage growth 
(panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation. 
2. Serum erythropoietin level below the reference range for normal. 
3. Endogenous erythroid colony formation in vitro. 
 
ESSENTIAL THROMBOCYTHEMIA 
 
This disease was described in 1934 by Emil Epstein and Alfred Goedel, two Australian 
pathologists; but it wasn’t until 1960 that two reviews regrouped the first diagnostic criteria 
for what they named “primary hemorrhagic thrombocythemia”: a history of 
thrombohemorrhagic events. These criteria included: splenomegaly or normal-size spleen; 
thrombocytosis without either erythrocytosis or leukocytosis; bone marrow panmyelosis 
with megakaryocytic hyperplasia without leukemic infiltration (6). 
Nowadays, it is named “Essential Thrombocythemia” and it is defined as a 
myeloproliferative neoplasm characterized by high count of platelets in peripheral blood 
with tendency to thrombosis and hemorrhage. The typical clinical signs are predisposition 
to vascular occlusive events such as cerebrovascular, coronary or in peripheral circulation; 
and hemorrhages. Some patients are asymptomatic whereas others may present headaches, 
visual disturbances, distal paresthesia, lightheadedness, erythromelalgia, chest pain, and 
thrombotic or hemorrhagic problems (like hematomas, bruising, ecchymosis, epistaxis, 
melena or hematemesis). It is a disease that may occur at any age although the median age 
at diagnosis is 65-70 years. The incidence is twice higher in women (ratio 2:1 females:males) 
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and the prevalence is about 30/100,000. The median survival is about 20 years for older 
patients and 33 for younger ones (under 60). The only risks that can cause mortality in 
these patients are hematologic complications like arterial and venous thrombosis, platelet 
mediated occlusions of the microcirculation and hemorrhages. Sometimes it can evolve to 
myelofibrosis, acute myeloid leukemia or PV reducing patients’ life expectancy (9, 11, 12). 
Diagnosis 
According to the WHO (1, 2), the diagnosis of ET must meet these four criteria:  
1. Sustained platelet count ≥ 450 x 109/L 
2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic 
lineage with increased number of enlarged, mature megakaryocytes. No significant increase 
or left-shift of neutrophil granulopoiesis or erythropoiesis. 
3. Not meeting WHO criteria for polycythemia vera, primary myelofibrosis, BCR-
ABL1–positive CML, or myelodysplastic syndrome, or other myeloid neoplasm. 
4. Demonstration of JAK2 V617F or other clonal marker, or in the absence of JAK2 
V617F, or no evidence of reactive thrombocytosis. 
 
PRIMARY MYELOFIBROSIS 
 
Primary myelofibrosis (PMF) is the last one of the three most important Ph- MPNs. 
Older terms used to name PMF were “agnogenic myeloid metaplasia”; “chronic idiopathic 
myelofibrosis” (used in the 2001 WHO on the classification of tumors of hematopoietic and 
lymphoid tissues); and “myelofibrosis with myeloid metaplasia”. It was in 2006 when the 
International Working Group for Myelofibrosis Research and Treatment reached a 
consensus to exclusively use the term of Primary Myelofibrosis. 
It was Gustav Heuck (a German surgeon) who gave the first description of PMF in 
1879, under the title of “Two cases of leukemia with peculiar blood and bone marrow 
findings”. His young patients presented massive splenomegaly, circulating nucleated red 
blood cells, and increased number of morphologically abnormal leukocytes. He realized that 
these patients differed from those described for CML because of the presence of marrow 
fibrosis and extensive extramedullary hematopoiesis. From that date, many other cases of 
PMF have been described in literature (6). 
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PMF is predominantly present in males and the age at diagnosis is usually over 60. 
Patients are characterized by the presence of anemia, high splenomegaly, 
leukoerythroblastosis, dacryocytosis, increased levels of serum lactate dehydrogenase 
(LDH), excess circulating blasts and stromal changes in the bone marrow such as collagen 
and reticulin fibrosis, osteosclerosis and angiogenesis. According to the Dynamic 
International Prognostic Scoring System for primary myelofibrosis (DIPSS-plus), risk 
factors measured at diagnosis include age over 65 years, hemoglobin levels under 10 g/dL, 
leukocyte count more than 25x109/L, number of circulating blasts ≥1%, presence of 
constitutional symptoms, red cell transfusion need, platelet count lower than 100x109/L and 
unfavorable karyotype (including complex karyotype or sole or two abnormalities that 
comprised +8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, or 11q23 rearrangement; all other 
cytogenetic abnormalities were considered favorable). These risk factors are used to define 
low (no risk factors), intermediate-1 (1 risk factor), intermediate-2 (2 or 3 risk factors), and 
high (4 risk factors) risk groups. Leukemic transformation risk was higher in the presence 
of unfavorable karyotype or platelet count under 100x109/L and in intermediate and high 
risk groups. Overall survival in low risk patients was around 17.5 years, 7.8 for the 
intermediate-1 risk group, 3.6 for the intermediate-2 and 1.8 for high risk patients. In young 
patients (aged under 60), the overall survival rises to 20 years in low risk patients and 14 in 
the intermediate-1 risk group (13, 14).  
Generally PMF patients have poorer prognosis than PV or ET patients. PMF is 
clinically indistinguishable from the fibrotic transformation of polycythemia vera or 
essential thrombocythemia. Some patients who are diagnosed of PMF probably are in the 
accelerated phase of previously unrecognized PV or ET (15). 
Diagnosis 
According to the WHO (1, 2), the diagnosis of PMF must meet the three major criteria 
and at least two minor criteria:  
Major criteria  
1. Presence of megakaryocyte proliferation and atypia, (small to large megakaryocytes 
with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly 
folded nuclei and dense clustering), usually accompanied by either reticulin or collagen 
fibrosis, or, in the absence of significant reticulin fibrosis, the megakaryocyte changes must 
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be accompanied by an increased bone marrow cellularity characterized by granulocytic 
proliferation and often decreased erythropoiesis.  
2. Not meeting WHO criteria for polycythemia vera, BCR-ABL1–positive chronic 
myelogenous leukemia, myelodysplastic syndrome, or other myeloid disorders. 
3. Demonstration of JAK2V617F or other clonal marker (e.g. MPLW515K/L), or, in 
the absence of the above clonal markers, no evidence that bone marrow fibrosis is secondary 
to infection, autoimmune disorder or other chronic inflammatory condition, hairy cell 
leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) 
myelopathies. 
Minor criteria  
1. Leukoerythroblastosis 
2. Increase in serum lactate dehydrogenase level. 
3. Anemia. 
4. Palpable splenomegaly 
 
GENETIC COMPLEXITY OF MPNs 
 
Myeloproliferative neoplasms are clinical entities genetically complex. In fact, more 
than one mutation is usually present in these patients. Furthermore, there are not exclusive 
mutations for one type of MPN, but rather mutations that exclude the presence of other 
ones. Patients could be classified according to their genetic profile (number and description 
of mutations and order of appearance) to determine their diagnosis, prognostic and 
treatment.  
The most important mutations in MPNs are grouped in four types depending on the 
action affected: signaling pathways, epigenetic regulation, splicing regulation and 
checkpoints, Figure 1. 
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Figure 1. Somatic mutations in MPNs affect four major processes: Signaling, epigenetics, 
splicing and checkpoints. 
 
Mutations implicated in signaling pathways 
 
JAK2 (16-20) 
Mutation in JAK2 exon 14 is the most frequent in MPNs. It is present in more than 
95% of PV patients and 50 to 60% of ET and PMF patients. It consists on the nucleotide 
change from Guanine to Thymine at position 1849. This causes the substitution of valine by 
phenylalanine at codon 617 in the Janus Kinase 2 (JAK2) protein.  
The JAK family is formed by 4 kinases, JAK1, 2, 3 and TYK2. They are attached to 
cytokine receptors. JAK2 is formed by up to seven JAK homology domains (JH1-JH7). The 
most important ones are the active kinase domain, JH1 and JH2, the catalytically inactive 
pseudokinase domain that negatively regulates JH1 (21). 
In a normal cell, erythropoietin binds its receptor which activates JAK2. It 
phosphorylates itself and also the erythropoietin receptor what initiates a cascade of 
erythroid-specific signaling promoting erythroid proliferation and differentiation by 
activation of STATs. This cascade is controlled thanks to a negative feedback by JAK2 itself. 
The key role of JAK2 in erythropoiesis is shown in JAK2 deficient mice that died at 
embryonic day 12.5 with complete absence of erythropoiesis (22). 
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The JAK2V617F mutation affects to the JH2 domain. This conversion implicates an 
autoinhibition of JH2 domain and thus, an inhibition of the downregulation of the 
erythropoietin signal. Due to this mutation; JAK2V617F progenitor cells become 
erythropoietin independent and can form erythropoietin-independent erythroid colonies. It 
also causes cytokine-independent activation of different pathways such as JAK-STAT, PI3K, 
AKT, MAPK and ERK which affect to gene transcription, apoptosis, cell cycle and 
differentiation (Figure 2) as it was showed in Ba/F3 EpoR and Ba/F3 EpoR JAK2V617F 
murine cells (17, 19, 23) and in gamma-2A human fibrosarcoma cells (17). 
Among the STATs, the STAT5 activation is compulsory for MPN establishment. 
Recent approaches suggest that STAT3 activation opposes thrombocytosis and promotes 
inflammation whereas STAT1 is associated with thrombocytosis. Conformingly, STAT1 
activation has been shown to be specifically activated in ET erythroid colonies but not in PV 
ones (21). Chen E et al. (24) showed that STAT1 inhibition in stem cells promoted 
erythropoiesis and reduced megakaryopoiesis. Thus, STAT1 activation via JAK2 promotes 
ET acquisition but not PV. The mechanisms why sometimes STAT1 is phosphorylated and 
sometimes it is not are not yet elucidated. 
In conclusion, JAK2V617F is directly related to MPN pathogenesis by promoting 
spontaneous proliferation of stem cells (15). However, the main issue remains incompletely 
solved: why the same mutation can lead to three different phenotypes. 
On the one hand, in PV patients, its presence is associated with higher hemoglobin 
levels, increased granulocytes, leukocytosis, endogenous erythroid colony formation, higher 
spleen size, higher bone marrow cellularity and inversely to lower platelet counts. On the 
other hand, it is also related to leukocytosis, higher spleen size and higher levels of 
hemoglobin in ET subjects besides older age at diagnosis and lower platelet count. In PMF, 
JAK2V617F patients require less red cell transfusion and present higher leukocyte counts 
than JAK2 wild type (25-27).  
According to Alshemmari et al. (28), ET patients had lower JAK2V617F allele burden 
(<50% of JAK2V617F cells) whereas for PV patients the allele burden average was 40%. 
High allele burden levels are related to myelofibrotic evolution, leukocytosis and high 
hemoglobin levels. Low allele burden is associated with high platelet counts. Furthermore, 
25% of PV patients are homozygous for JAK2V617F whereas ET patients are mostly 
heterozygous or present the wild type suggesting that higher levels of mutated JAK2 are 
related to an erythroid phenotype and lower ones to a megakaryocytic phenotype. Besides 
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this allele-burden-dependent mechanism, the presence of other acquired somatic mutations 
play very probably a role in these phenotypic variations, as well as in genetic background. 
 
 
 
Figure 2. Left, wild-type JAK2 is inactivated without erythropoietin stimulation. Center, wild-
type JAK2 is phosphorylated and activated by erythropoietin action; it can then activate some 
pathways such as STAT, PI3K and RAS-MAPK. Right, JAK2 V617F is autophosphorylated in 
absence of EPO signal and is capable to activate the same signaling pathways as the non-mutated 
receptor in presence of EPO. Figure taken from Campbell et al.(15). 
 
 
JAK2 exon 12 mutations were identified in JAK2V617F negative PV patients. (Its 
presence is rare in ET or PMF patients). These mutations are thought to modify the JH2 
structure and thus to alter its negative feedback function inducing a constitutive 
phosphorylation of JAK2 and STAT5 (29). These patients are characterized by erythroid 
myelopoiesis, lower serum erythropoietin levels, younger age at diagnosis and the 
possibility of progression to a secondary myelofibrosis (21, 27). 
 
MPL mutations (9, 21, 27) 
MPL is the Myeloproliferative Leukemia virus oncogene. It encodes for the 
thrombopoietin (TPO) receptor. Gain-of-function mutations have been discovered in exon 10 
with the substitution of a tryptophan at codon 515 to a leucine (MPLW515L), lysine 
(MPLW515K), asparagine (MPLW515N) or alanine (MPL W515A). At this position, there is 
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a group of 5 amino acids that are responsible for the cytosolic conformation of the MPL 
protein, (transmembrane protein). This receptor possesses an amphipathic domain 
R/KWQFP between the transmembrane and the cytosolic domains preventing JAK2 
activation in the absence of TPO. Mutations in this group of amino acids cause the 
spontaneous activation of the receptor, resulting in constitutive JAK-STAT activation as 
well as MAP-kinase ERK1, 2. This activation leads to megakaryocytic proliferation and thus 
thrombocytosis. 
These patients are associated with older age, female sex, higher platelet count, lower 
hemoglobin level, splenomegaly, myelofibrosis and an increased risk of thrombosis. They are 
found in about 3-5% of ET patients and in 10% of PMF ones. Their presence is rare in PV. 
Other mutations of this exon have been reported, (MPLW515S or MPLS505N) but at very 
low frequencies.  
 
CALR (30-34) 
Calreticulin is a Ca2+ binding chaperone located in the lumen of the endoplasmic 
reticulum (ER) that contributes to calcium homeostasis. Together with calnexin (another 
chaperone), and ERp57, they form the “calreticulin/calnexin cycle” responsible for the 
folding control of newly-synthesized proteins. When calnexin and calreticulin recognize 
misfolded proteins, they bind them to prevent their export to the Golgi apparatus and 
consequently, guaranteeing proper folding of newly synthesized glycoproteins. Calreticulin 
can also be found outside the ER, at the cell surface, in the cytoplasm or in extracellular 
compartments where it is suggested to play a role in proliferation, antigen presentation and 
complement activation, apoptosis and immunogenic cell death (35). 
CALR mutations are located in exon 9 and they are present in about 15 to 30% of ET 
and PMF subjects. Predominantly, 80% of these mutations are classified in two groups: type 
1 mutations which correspond to a 5-base-pair (bp) deletion and type 2 to 5-bp insertions. 
All mutations result in a novel amino acid sequence at the C-terminal. This new mutated 
peptide contains an important number or positively charged amino acids, whereas the 
native C-terminal peptide is principally negatively charged. Moreover, the new C-terminal 
part has lost the KDEL motif (lysine, aspartic acid, glutamic acid and leucine amino acid 
sequence). KDEL motif allows calreticulin to anchor to the ER. Consequently, mutant 
calreticulin is thought to modify its cellular location and to lose its Ca2+binding function. 
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CALR mutations are suggested to activate the JAK2(-)STAT pathway in myeloid stem 
cells as it was suggested by Ba/F3 CALR cell mutants (33). Moreover, JAK2(-)STAT 
activation was shown to have the same transcriptional signature in JAK2V617F and 
mutated CALR peripheral blood granulocytes suggesting a common transformation (Rampal 
et al. (36)). Nonetheless, Lau et al. (37) argued Rampal results as theirs showed completely 
different signatures of STAT activation in JAK2(+) and CALR(+) ET megakaryocytes. In 
addition, MARIMO cell line approaches showed that JAK2(-)STAT activation was not 
activated by calreticulin (Kollman et al. (38)). 
Generally, compared with JAK2V617F patients, CALR mutations arecorrelated with 
younger age, male predominance and high allele burden. They are also associated with 
higher platelet counts and serum erythropoietin, lower Hb and leukocyte levels and lower 
thrombosis risk. In addition, there is no significant difference in overall survival compared 
with JAK2V617F patients. Furthermore, phenotypical differences between both types of 
calreticulin mutations show that type 2 mutations are connected with younger patients and 
higher platelet counts whereas type 1 are linked to male sex. In these patients, there is no 
risk of polycythemic transformation (whereas the cumulative risk for JAK2V617F patients 
it is about 30%). In PMF, results on overall survival demonstrated differences between type 
1 and type 2 mutations but are contradictory (Cabagnols et al. 2015, (39) vs Tefferi et al. 
2014, (30, 40)). In addition, Cabagnols et al. study on 572 JAK2(-) MPN patients suggested 
that high CALR allele burdens and type 2 CALR mutations correlated with MF whereas low 
allele burdens with ET phenotypes. 
 
Vannuchi et al. 2014 (41) showed, using immunohistochemistry labelling of bone 
marrow biopsy, that calreticulin expression (mutated and non-mutated) was higher in 
megakaryocytes than in myeloid or erythroid lineages suggesting an important role for 
calreticulin in platelet function. They suggested that CALR mutations might use the JAK-
STAT signaling to contribute to the high platelet production in MPNs. This special link 
between CALR and megakaryocytes was confirmed by the study of Mondet et al. (42) who 
showed that endogenous megakaryocytic colonies (EMC) were more frequent in mutated 
CALR than in JAK2V617F or “triple negative” (JAK2(-), MPL- and CALR(-)) patients and 
among CALR mutated patients, type 2 induced more EMC than type 1. 
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CBL (21, 27, 43) 
The casitas B-cell lymphoma family (CBL) is composed by 3 proteins: CBL, CBL-b and 
CBL-c. The CBL gene is located at 11q23.3 and it encodes for a protein that principally is 
involved in negative regulation of the receptor tyrosine kinase mediated by E3 ubiquitin 
ligase activity. Mutations in this gene directly affect the region that is necessary for its E3 
ubiquitin ligase function. It appears to be mutated in about 6% of PMF patients and in some 
myeloid malignancies as juvenile monomyelocytic leukemia or chronic monomyelocytic 
leukemia but it is rare in PV and ET patients. It’s related to myelofibrosis with poor 
prognosis or in AML post MPN.  
 
LNK (21, 44) 
This gene is located at chromosome 12 at 12q24 loci. The lymphocyte adaptor protein 
(LNK) is part of the SH2B family. It negatively regulates TPO-MPL and EPO receptor 
signaling, thus it inhibits the JAK/STAT signaling. Furthermore, it negatively regulates 
JAK2 thanks to its SH2 domain. These loss-of-function mutations cover codons 208 to 234 
and can affect the C-terminal region; the SH2 domain or the PH domain. They seem to be 
involved in disease progression because they are not found in chronic states. In fact, some 
LNK mutations are found in about 13% of leukemic transformation of MPNs and in about 3 
to 6% in ET and PMF subjects. A recent study by Benton et al. (45) showed that PV patients 
with mutations in this chromosome (Ch12) are more likely for myelofibrosis progression. In 
general, patients with this mutation are classified as poor prognosis.  
 
SOCS 1, 2 and 3 (21) 
Suppressor of cytokine signaling (SOCS) proteins are negative regulators of JAK 
signaling. Loss of their activity results in an excess of signaling by cytokines. SOCS1 gene is 
located at 16p13.2; SOCS2 at 12q22 and SOCS3 at 17q23.3. Mutations in SOCS genes are 
rare in MPNs. Nevertheless, hypermethylation of CpG sites in these genes together with a 
decrease in their expression was found in PV and ET mutated and non-mutated JAK2. The 
frequencies of these methylations in PV patients are: 11-13% for SOCS1 gene; 28% for 
SOCS2 and 22% for SOCS3, in ET patients: 14-25% for SOCS1 gene; 28% for SOCS2 and 
10% for SOCS3, and in PMF patients: 17% for SOCS1 gene; 28% for SOCS2. 
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NRAS/KRAS (21) 
The RAS family is a group of membrane proteins associated with GTPases that 
controls numerous signaling pathways and cellular processes. The most common mutations 
are found in KRAS and NRAS genes at codons 12, 13 and 61. They involve the inhibition of 
the GTPase activity that avoids the inhibition of these proteins and thus, the continue 
activation of the effector pathways. It is not clear if these mutations promote the initiation 
or the progression of MPNs to acute leukemia. 
 
PTPN11 (46) 
PTPN11 is the protein tyrosine phosphatase non-receptor type 11. It encodes for src 
homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2). It regulates 
proliferation, apoptosis, and differentiation. 
Mutations in this gene are rare in ET and PV. Nonetheless, they have been described 
in PMF.  
 
NF1 (47) 
The tumor suppressor gene Neurofibromatosis-1 is located in the 17q11.2 chromosome. 
It is a negative regulator of the RAS pathway. Loss of NF1 may progress into a 
myeloproliferative neoplasm. It is related to an enhance risk of developing myeloid leukemia 
in some tumors, however, it is not yet clear if this is the case for MPNs and leukemic 
transformation. It is a rare mutation in MPNs. 
 
Mutations implicated in epigenetics regulation 
TET2 (21, 27, 48-50) 
TET “ten-eleven-translocation” genes are a group of three homologous human proteins 
(TET1, 2 and 3). TET2 gene comprises 11 exons and is located on chromosome 4q24. It 
encodes for a 2-oxoglutarate and Fe(II)-dependent hydroxylase whose function is to 
hydroxylate methylated cytosine. Therefore, TET2 mutations result in decreased 5-
hydroxymethylcytosine and thereby affect levels of DNA methylation.  
TET2 appears to be mutated in 16% of PV patients, 5 to 11% of ET and 18% of PMF 
ones. These mutations consist on nonsense, missense, insertions and deletions which lead to 
loss of function. They are associated with leukocytosis, splenomegaly, extra medullary 
hematopoiesis, poor overall survival, leukemic transformation and older patients. The order 
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in which TET2 loss and JAK2V617F appear seems to be important. When JAK2 is acquired 
before TET2 mutations, it is more likely that patients develop PV; however, when TET2 
goes first, it seems that it reduces the ability of JAK2 to up-regulate proliferation genes. 
Actually, mice studies revealed that TET2 loss increased self-renewal capacities of 
hematopoietic stem cells contrary to JAK2V617F which promotes proliferation and hardly 
reduces self-renewal of these cells. When these two mutations appeared together, TET2 
competes with JAK2V617F for restoring self-renewal and quieting cell proliferation. In fact, 
TET2-loss-induced self-renewal is thought to be a first event on disease initiation and 
progression (51) that produces a pre-leukemic state with clonal expansion of HSC that, 
depending on the secondary molecular events, would evolve to a MPN or other myeloid 
malignancies.  
 
IDH (21, 27, 49) 
IDH gene encodes for isocitrate dehydrogenases (IDH1 and IDH2). They are NADP+ 
dependent enzymes that catalyze the oxidative decarboxylation of isocitrate to α-
ketoglutarate. When mutated, they lose their affinity to isocitrate and catalyze the 
reduction of α-ketoglutarate (2HK) to 2-hdroxyglutatate (2HD), leading to an overproduction 
of 2HG instead of 2HK, which has been proposed to affect the function of some enzymes 
such as TET2 which are α-ketoglutarate-dependent. IDH1 an IDH2 are mutually exclusive 
mutations and are rare in PV and ET patients. Nonetheless they can be present in about 4% 
of PMF. One study has reported that the incidence of these two mutations is increased in 
blast transformation of MPNs (~22%) compared with its low incidence in chronic phase 
(1.9% in PV and 0.8% in ET). They are associated with decreased survival. 
 
ASXL1 (21, 27, 49, 52) 
ASXL1 gene is located on chromosome 20q11.1 and is similar to the Drosophila 
megalogaster additional sex combs gene. It is associated with the Polycomb repressive 
complex 2 (PRC2). The protein disrupts chromatin in localized areas, activating or 
suppressing the transcription activity. It is thought to have a soft role in hematopoiesis of 
myeloid stem cells. 
This protein appears in most hematopoietic cell types and its mutated homologue is 
related to MPNs (19 to 40% mutated cases in PMF). Nevertheless, it is just found in less 
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than 7% of PV patients and in 5 to 8% in ET patients. However, it is significantly associated 
with acute leukemia post MPN (15-20%) and thus considered as a poor prognostic factor. 
 
DNMT3A (49, 53)  
This gene is implicated in DNA methylation. Even though DNMT3A mutations are 
more common in AML and post-MPN AML, it also appears in chronic phase MPNs. In PV 
patients, it is mutated in 5 to 7% of patients. 
 
EZH2  (21, 49) 
EZH1 and EZH2 proteins are the catalytic members of the PRC2, which is implicated 
in some cellular processes such as proliferation or differentiation. It is a methyltransferase 
of histone H3 at lysine 27. In MPNs, these mutations are associated with loss of activity. 
They are found in 3 % of PV and 13% of PMF. 
 
SUZ12 (54)  
SUZ12 gene is located on chromosome 17q and encodes for a protein of the PRC2 as 
EZH2. Mutations and deletions in this region cause a dysfunction on PRC2 which seems to 
enhance hematopoietic stem cell activity. Mutations in this gene are not frequent in PV or 
ET patients. 
 
Mutations implicated in splicing regulation 
Some mutations have been discovered in MPNs in genes implicated on the RNA 
splicing machinery: SF3B1, SRSF2, U2AF65 and ZRSR2. They are thought to alter pre-
mRNA splicing although the mechanisms remain to be elucidated.  
They are rare in PV and ET; however, they are more frequent in PMF. 
SRSF2 is related to bad prognosis by promoting leukemic transformation of MPNs 
(55). 
 
Mutations implicated in checkpoints 
TP53 (21) 
The TP53 gene encodes for p53, a tumor suppressor protein that controls (among 
others) cell cycle and apoptosis. TP53 mutations are found in a big amount of cancers. They 
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are not associated with the chronic phase of MPNs but seem to play an important role in 
leukemic transformation of MPNs as they are found in 20-30% of leukemic transformations. 
 
Other gene mutations implicated in leukemic progression 
Some gene mutations are thought to be involved in leukemic transformation of MPNs. 
To be classified in this way, these mutations must be detected in blast cells but not in most 
of cells from the precursory MPN clone. These mutations are found in less than 10% of MPN 
patients in chronic phases. 
The most important genes implicated in leukemic transformation are: ASXL1, EZH2, 
IDH, TP53 and SRSF2, (already developed) IKZF1 and RUNX1. 
 
IKZF1 (21, 27) 
IKZF1, Ikaros family zinc finger 1 gene is located at chromosome 7p12. It encodes for 
the Ikaros transcription factor, which regulates lymphoid differentiation of B and T cells. 
IKZF1 deletions are prevalent in acute lymphoblastic leukemia (ALL), above all in BCR-
ABL positive cases. In leukemic transformation of MPNs they are described as late events 
in the progression of MPN to AML. 
 
RUNX1 (21, 56) 
The RUNX1 gene, also known as AML-1 or CBFA2 encodes for a transcription factor 
with an important role in the development of normal hematopoiesis. It is believed to be one 
of the most common mutations in the leukemic transformation.  
 
Generally these mutations are associated with bad prognosis (46). Nevertheless not all 
mutations have a prognostic value. What we can affirm is that the more mutations a patient 
has, the worse.  
 
Phenotypic and clinical impact of genetic modifications 
 
JAK2 and MPL mutations are known to be drivers of MPN disease in mice. Actually, 
the presence of only one of these mutations in HSC leads to PV or ET development whereas 
co-existence of more than one mutation predominantly produces PMF. Nevertheless, JAK2 
and MPL mutations may not be the first genetic alterations in MPNs. TET2, ASXL1 and 
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EZH2 can precede JAK2V617F mutations. Even, they can appear separately from JAK2 
mutations (21). When JAK2V617F is acquired before TET2 mutations, patients are more 
likely to develop PV (48). Moreover, CALR mutations are thought to be an early genetic 
event in MPNs (57). In addition, Lundberg et al. (57) showed, in a study of 197 MPN 
patients, that mutations in DNMT3A could also be acquired before JAK2V617F or coexisted 
as separate clones. They also found that IDH1 mutations occurred exclusively after 
JAK2V617F.  
Recently, a study on induced pluripotent stem cells and primary cells from patients 
showed that the overexpression of ATG2B and GSKIP genes induced spontaneous formation 
of colony forming unit-megakaryocytes (CFU-MK) enhancing hematopoietic progenitor 
differentiation by increasing sensitivity to thrombopoietin. The overexpression of these 
genes was demonstrated to cooperate with classical mutations (JAK2, MPL and CALR) to 
generate MPN phenotypes, predominantly ET. Moreover, they are also associated with 
myelofibrosis or AML progression (58).  
Mutations display a remarkable influence in clinical phenotypes of patients. In 
general, an increased number of somatic mutations is correlated with reduced overall 
survival, increased leukocyte counts and risk of leukemic transformation whereas patients 
that don’t present any detectable somatic mutation or only one mutation in JAK2, CALR, or 
MPL genes present good prognosis and low risk of leukemic transformation. The TP53 
mutation is associated with AML transformation and decreased in overall survival as well 
as TET2. ASXL1 mutations are related to lower hemoglobin levels and EZH2 with 
leukocytosis (57). JAK2V617F is present in almost all PV patients whereas ET and PMF are 
characterized by the presence of JAK2 mutation or other genetic abnormalities such as 
MPL, CALR or TET2 mutations.  
 
VASCULAR COMPLICATIONS  
 
PV and ET are chronic diseases in which global survival is weakly decreased (PV) or 
not (ET) compared with healthy patients. Nevertheless, they are characterized by a 
significant increase of vascular events. These consist on hemorrhagic events as well as 
arterial and venous thrombosis that usually are first signs that lead to diagnosis. They are 
the principal causes of morbidity and mortality in these hemopathies. In general, 
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thrombotic events are more frequent in PV patients than in ET ones and in older patients 
compared with younger ones. The annual incidence of these events varies from 1 to 10%. 
Some of the thrombohemorrhagic events are arterial thrombosis, (ischemic stroke, 
myocardial infarction, unstable angina pectoris, peripheral and visceral thromboembolism), 
venous thrombosis (deep venous thrombosis in legs and arms, pulmonary embolism, 
unusual sites venous thrombosis – mainly splanchnic vein thrombosis – superficial venous 
thrombosis) as well as microcirculatory disturbances (mainly in ET patients) such as 
erythromelalgia, ischemic attacks, visual or hearing defects, headache and peripheral 
paresthesia. Venous thrombosis at unusual sites are the most common in these patients. In 
fact, one of the most characteristic venous complications is abdominal venous thrombosis in 
splanchnic or portal veins, including Budd–Chiari syndrome affecting young women 
principally. Controversially, the prevalence of cerebral venous thrombosis is not well 
defined in MPNs. Some studies point that they are usual among MPN patients but recently, 
Dentali et al (59) concluded that these events are rarely found in MPN patients (60-62). 
 
Risk factors 
 Cardiovascular factors: Principally they are hypercholesterolemia, 
hypertension, smoking, and diabetes. They are present in about one third of PV 
patients with vascular complications. More precisely, smoking has been associated 
with an increased risk of arterial thrombotic events such as myocardial infarction, 
and hyperlipidemia was also related to arterial events in one clinical study (63). 
 
 Age and sex: younger patients (under 65) have less vascular complications 
than >65-year-old patients, and these last ones, less than >75-year-old ones. Male 
patients are associated with arterial thrombotic events such as myocardial 
infarctions and females with thrombosis in unusual sites such as splenic or portal 
veins. 
 
 Number of blood cells: In PV patients, control of hematocrit under 45% is 
necessary so as to reduce blood hyperviscosity that is related to vascular 
complications. Hyperviscosity enhances erythrocyte aggregation, what apart from 
disturbing blood flow; it also facilitates platelet activation and aggregation by easing 
platelets to interact with endothelial cells or other platelets that are more activated 
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in MPN patients. Furthermore, erythrocytosis linked to leukocytosis increases 
leukocyte proteases that could affect the integrity of endothelial cells. In fact, some 
abnormalities in the endothelium have been described in MPN patients such as 
increased expression of adhesion molecules in these modified endothelial cells that 
favors platelet and leukocyte arrest causing the secretion of procoagulant particles 
(61). In addition, PV erythrocytes have also been reported to hyperexpress adhesive 
molecules that could adhere to the endothelium and act in thrombotic events. In PV 
patients participating in the ECLAP study (European Collaboration on Low-Dose 
Aspirin in Polycythemia Vera), leukocytosis higher than 15x109/L was associated 
with an increased risk of major thrombosis as myocardial infarction. Similarly, in 
ET, arterial and venous thrombosis were associated with leukocytosis but not with 
platelet count or hemoglobin level. Conversely, extreme thrombocytosis 
(>1500x109/L) seems to reduce the risk of arterial thrombosis in ET. It may be 
caused by the fact that this excessive thrombocytosis could be secondary to an 
acquired von Willebrand Factor (vWF) deficiency. It is suggested that increased 
platelet binding to vWF facilitates platelet activation and promotes vWF multimer 
proteolysis consuming vWF and causing erratic vWF activity (60, 61, 64, 65). 
 
 Microparticles: They are 0.1-1µm membrane fragments released by activated 
cells especially from platelets and endothelial cells. They are increased in thrombotic 
ET patients. Additionally, these microparticles are associated with thrombin 
generation potential that causes a thrombo-modulin-resistant phenotype in PV and 
ET patients (61, 66).  
 
 
 Neutrophil Extracellular Traps (NETs): These are a mixture of DNA fibers 
including histones and antimicrobial proteins such as myeloperoxidase, neutrophil 
elastase and cathepsin G released as defense mechanisms against pathogens by 
dying neutrophils. They are capable of killing both Gram-positive and Gram-negative 
bacteria, fungi and of sequester viruses (67). Fuchs et al. 2007 (68), proved that NET 
production needed NADPH oxidase activation and ROS production. NETs have been 
strongly associated with thrombosis risk as they are shown to promote platelet 
adhesion, activation, and aggregation. Their correlation with deep vein thrombosis is 
BACKGROUND 
 
22 
 
explained as they can recruit red blood cells promoting fibrin deposition forming a 
red thrombus usually in deep veins (Fuchs et al. 2010 (69)). Demers et al. 2013 (70), 
showed that the stimulation of isolated neutrophils from mice with chronic 
myelogenous leukemia resulted in high levels of NET formation. They thought that 
the granulocyte colony-stimulating factor (G-CSF) could be a priming factor for NET 
generation. Furthermore, they also associated NET formation with thrombosis. 
 
 APC resistance: PC is a serine protease known to be a potent anticoagulant. It 
is activated by thrombin bound to the thrombomodulin receptor in the endothelium. 
APC complexes protein S (PS) so as to reduce clotting activation by proteolytic 
inactivation of coagulation factors V and VIII. APC resistance is thought to be caused 
by a decrease in free PS level. In fact, one study showed that ET patients presented 
higher thrombocytosis and PS cleavage than normal ones. Actually, a platelet 
protease is thought to be responsible for PS cleavage. In agreement, treatment with 
hydroxyurea decreased platelet and PS cleavage levels. It has been reported that ET 
and PV patients present high APC resistance, particularly mutated JAK2 ones and 
ET ones with a history of thrombosis. In fact, some studies have revealed a decrease 
in natural anticoagulants concentration in MPN patients.  
Both, elevated levels of microparticles and APC resistance are related to an 
increased risk of thrombosis. These both factors were especially increased in 
JAK2V617F PV and ET patients (61, 66). 
 
 JAK2 V617F: The role of this mutation in vascular complications is not well 
defined as clinical studies differ in their conclusions. For instance, Passamonti et al. 
(26), did not find a connection between JAK2V617F allele burden and risk of 
thrombosis in PV patients. They just concluded that advanced age is the only well-
known significant predictor of thrombosis. Kuriakose et al. 2012 (71), also reported 
that even though the thrombotic events were decreased in patients treated with 
pegylated interferon (IFN), JAK2V617F allele burden barely changed after 
treatment. Kittur et al. (72), also concluded that there is no significant bond between 
mutated JAK2 and arterial thrombosis (at diagnosis or post-diagnosis) or venous 
thrombosis at diagnosis; but there was a positive correlation in post-diagnosis venous 
thrombosis events. On the contrary, Vannucchi et al. 2007 (73), concluded that the 
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risk of cardiovascular events was higher in JAK2V617F PV patients. According to 
them, JAK2V617F ET patients are also associated with higher risk of vascular 
complications. Similar results were obtained by Takata et al. 2014 (74). Moreover, 
Borowczyk et al. 2015 (65), also associated JAK2V617F allele burden (>20%) with 
thrombohemorrhagic episodes as venous thromboembolisms and principally deep 
vein thrombosis.  
 
 CALR mutation: Rumi et al. (31), reported that thrombosis was twofold higher 
in JAKV617F PV and ET patients than in CALR mutated. Furthermore, the 
incidence of thrombosis at diagnosis in JAKV617F PV patients was also higher than 
in CALR mutated ET patients. In a similar study, Rotunno et al. (75) also concluded 
that CALR patients presented lower risk of thrombosis than those with JAK2 or 
MPL mutations. Therefore, CALR patients present low thrombotic risk. 
 
LEUKEMIC PROGRESSION 
 
Despite progresses in MPN management, 1% of ET and 4% of PV patients after 10-
year diagnosis and 4 to 8% after 18-years diagnosis evolve to secondary acute myeloid 
leukemia with an awful outcome: median survival of less than 6 months.  
Leukocytosis (WBC count over 15x109/L), advanced age and exposure to chemotherapy 
are poor prognostic factors for AML progression. Nevertheless, the mechanisms of leukemic 
transformation are not well defined yet. 
In general, JAK2/MPL-positive patients can evolve to JAK2-positive AML associated 
with the acquisition of additional genetic alterations but they can progress to JAK2 negative 
AML as well. This suggests that the leukemic clone could emerge from a “pre JAK2V617F 
cell” that has acquired secondarily the JAK2V617F mutation leading to the chronic phases, 
or that the leukemic cells developed from an independent clone that do not participate in 
the chronic phase. Passamonti et al. 2010 (26) showed that JAK2V617F allele burden is not 
connected to AML evolution.  
Some of the potential gene mutations that are thought to play a role in AML 
transformation are MYC, ETV6, and RUNX1, as well as high frequent mutations in post-
AML such as TET2, ASXL1, SRSF2, IDH1/2 and TP53. TP53 loss has been shown to be 
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strongly associated with leukemic transformation. Rampal et al. (76) demonstrated that the 
combination of JAK2V617F and loss of TP53 can cause leukemic transformation in mice. 
However, TP53 mutation is not frequently related to CALR mutations. Abdel-Wahab et al. 
2010 (77) studied the most frequent mutations in leukemic transformation and yielded that 
TET2 mutations were usually acquired at AML transformation. On the opposite, ASXL1 
mutations were detected in both MPN and AML states in most of the cases. The presence of 
more than one somatic mutation was also associated with poor prognosis and leukemic 
progression as well as TET2 presence (57). However, the mechanism of leukemic 
transformation remains poorly elucidated. Knowledge from new sequencing technologies 
might probably bring out the effects that other genetic alterations may have in this 
progression. 
 
Another well documented factor of leukemic transformation is the impact of 
chemotherapy. Finazzi et al. (10) reported the largest randomized trial in PV: The European 
Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) prospective project of 
1638 patients. In this study they demonstrated that treatment with the cytoreductive 
molecules pipobroman, busulfan or chlorambucil alone or combined with other drugs 
significantly increased the risk of leukemic and fibrotic transformation. Treatment with 
hydroxyurea alone did not increase this risk compared with patients treated with 
phlebotomy or interferon (the reference treatment with no influence in leukemic 
progression) but it did when combining hydroxyurea with cytoreductive agents. 
Nevertheless, this trial was criticized as the follow-up time was short (2.8 years). 
Furthermore, Kiladjian et al. (78) reported the results of a randomized trial initiated in 
1980 from the French Polycythemia Study Group (FPSG) in 285 PV patients with a median 
follow-up of more than 12 years. They concluded that the use of pipobroman significantly 
reduced overall survival as well as it increased leukemic or dysplastic evolution. Therefore 
this drug should be reserved for second-line treatment. Concerning hydroxyurea, they 
suggested that it could have an impact in dysplastic or leukemic evolution as the number of 
patients evolving to AML was 5.9% against 1.5% in those ones receiving phlebotomy as 
treatment. They stressed the role of the time of exposure since in the second overview they 
showed that the frequency of AML was significantly increased in comparison with their first 
analysis (median follow-up of 12 versus 2.8 years). In addition, they found a higher number 
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of patients treated with hydroxyurea that evolved to myelofibrosis compared with those 
treated with pipobroman. These patients are more likely to develop AML (79). 
 
MYELOFIBROTIC EVOLUTION 
 
The risk of myelofibrotic evolution in MPN is 6% after 15 years of diagnosis. 
Nevertheless, patients’ survival after myelofibrotic state and prognostic factors are not well 
defined nowadays. 
A clinical study of PV patients by Passamonti et al. 2008 (80) concluded that 
leukocytosis over 15x109/L at PV diagnosis was significantly correlated with myelofibrotic 
evolution. They sought that 96% of patients with myelosuppressive agents developed post-
PV myelofibrosis (MF). They also remarked that all post-PV myelofibrotic patients had high 
circulating CD34+ cell counts and high levels of serum lactate dehydrogenase (LDH). They 
developed a prognostic model to predict survival in PV patients that evolve to MF. This 
model is based on the fact that leukocyte count (more than 30x109/L), hemoglobin levels less 
than 100g/L and platelet count less than 100x109/L at diagnosis are useful markers to 
predict survival in these patients. Another clinical study of Passamonti et al. 2010 (26) 
highlighted that MPN patients that evolved to MF had high JAK2V617F allele burden 
(>50%) and that patients with homozygous JAK2V617F are more likely to develop 
myelofibrosis. Another study by Benton et al. (45), revealed that PV patients with 
chromosome 12 mutations such as those in loci 12q15 (HMGA2) and 12q24 (SH2B3 (LNK)), 
were more likely for myelofibrotic progression. 
A recent clinical approach of PV patients that evolved to MF (81), found that patients 
that followed this pathway were characterized by higher leucocyte count (12.4±4.4x109/L) 
and splenomegaly (mean size 1.6±3.3 cm). Other facts such as Hb levels, platelet count, 
diabetes, hypertension, LDH values or clinical facts such as advanced age, thrombocytosis 
or cardiovascular risk factors weren’t correlated with myelofibrotic evolution in this study.  
Summing up, leukocytosis at diagnosis is a risk factor to evolve into MF (as well as for 
leukemic transformation). 
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TREATMENT  
 
Despite clinical researches with new drugs, the only curative approach that exists 
nowadays for MPN patients is allogenic stem cell transplantation. It is reserved for 
intermediate-2 or high-risk myelofibrosis or patients that already have transformed to acute 
leukemia or myelodysplasia. In these cases, patients present a 3-year overall survival from 
39 to 67%. However, stem cell transplantation is also associated with morbidity due to 
GVHD (Graft versus host disease). Bad outcomes of allogenic stem cell transplantation are 
older age, AML diagnosed at transplant time and unrelated donor (82). 
In general, MPN treatment strategy is based on reducing the risk of vascular events 
which are the principal actors of mortality and morbidity and on the control of 
cardiovascular risk factors as smoking, hypertension, dyslipidemia or diabetes. 
First of all, PV and ET patients are classified as high vascular risk if they are over 60 
years old or/and have a history of vascular events. Low risk patients are under 60 and with 
no history of vascular events. 
Treatment is founded on the use of cytoreductive molecules. Hydroxyurea (HU) is the 
“historical” molecule commonly used. It blocks the ribonucleotide reductase inactivating 
DNA synthesis and thus producing cell death in S phase. It reduces myeloproliferation and 
displays a good efficacy and tolerability. It also reduces significantly thrombotic 
complications. However, it is lightly associated with leukemic progression (78).  
 
Interferon alfa 
 
The study of pegylated IFNα in both PV and ET is the aim of actual clinical researches 
in MPN treatment. It has been demonstrated that it is capable of normalizing platelet 
counts and leukocytosis; of reducing erythrocytosis (avoiding phlebotomies in PV patients) 
and splenomegaly. Furthermore, it is non leukemogenic. Interestingly, pegylated IFNα 
treated patients show a complete molecular response after 21 to 31 months in some 
patients. It is also remarkable that the pegylated form inhibits colony formation from JAK2 
mutated CD34+ cells from MPN patients (83, 84). On the contrary, in a clinical study by 
Kuriakose et al. (71), they didn’t observe any reduction of JAK2V617F allele burden when 
treating with peg-IFN. They suggested that it could be due to the fact that they used higher 
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doses resulting in clinical and hematologic responses but not in molecular ones. Moreover, 
JAK2 mutant erythroblasts from PV patients reduced STAT1 phosphorylation after IFNα 
treatment which may explain thrombocytosis reduction (24).  
 
Even it is a promising drug in MPN therapy, long-term treatments are usually 
required till complete remission and the adverse effects of this drug are fatigue, depression, 
weight loss and nausea. Lu et al. (85) proposed a combination of peg-IFNα with a MDM2 
antagonist, the RG7112 as IFN effects are associated with the activation of p53 pathway. 
On the one hand, IFNα stimulates p53 transcription through the activation of JAK1-
STAT1/2 and IRF-9 (interferon regulatory factor-9). On the other hand, in JAK2V617F cells 
through PI3K/Akt/mTOR pathway, it increases MDM2 expression degrading the p53 
protein. Therefore, Lu et al. 2014 (85) proposed an MDM2 antagonist combined with IFNα 
for MPN treatment that would raise p53 expression in IFNα treatments. Their results were 
encouraging; however no in vivo studies have been done for the moment (86). 
 
First approaches to determine the effects of IFN in CALR patients were studied by 
Cassinat et al. (87). Even though they could just treat two patients, their results showed a 
reduction in mutated CALR allele burden coupled to hematologic complete response 
(reduction of thrombocytosis) for more than 60 and 18 months (patients 1 and 2). 
Concluding, pegylated forms of interferon alfa represent a potential effective drug for JAK2 
and CALR mutated MPNs. 
 
JAK2 inhibitors (43) 
 
Since its discovery in 2005, JAK2 became a potential target to treat these diseases. 
Controlling its activation is the main purpose of new drug design. The principal problem is 
that there aren’t any specific drugs that target specifically mutated JAK2 so their use will 
disrupt normal hematopoiesis causing anemia or thrombocytopenia. These drugs are 
Adenosine Tri-Phosphate (ATP) mimetic JAK inhibitors binding to the active form of JAKs. 
Nowadays, ruxolitinib is the only JAK2 inhibitor approved by the U.S. Food and Drug 
Administration (FDA) in 2011 and the European Commission in 2012 based on two clinical 
trials. It was approved for intermediate-2 and high risk myelofibrosis (primitive or 
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secondary) as it proved to reduce splenomegaly and to ameliorate disease-related symptoms 
(88). It is also proposed in PV patients with intolerance to Hydroxyurea. 
 
Despite these advances and their potential efficacy; JAK inhibitors show little 
reduction of allele burden and myelofibrosis. In addition, they don’t seem to be capable of 
eliminating MPN-initiating cells as a mouse model showed (89). Thus they cannot be 
considered as effective treatment for disease eradication as peg-IFNα suggested. Moreover, 
they should be taken continuously to be effective as curative treatment. 
Finally, it seems that their impact is mainly mediated by their action on cytokine 
levels via JAK regulation. Ruxolitinib showed a large and rapid downregulation of cytokine 
levels in PMF patients (90) and murine models (91). In addition, the interruption on 
Ruxolitinib administration causes a huge increased in cytokines associated with a 
withdrawal syndrome (92). Furthermore, splenomegaly and symptom reduction were 
correlated with reductions of IL-1ra, MIP-1β, IL-6 and TNF-α (90). 
Another problem of these drugs is resistance. Deshpande et al. (93) showed that some 
JAK2 mutations presented resistance to these drugs in Ba/F3 cell models. 
 
Other clinical approaches studied SAR302503 (TG101348, fedratinib; Sanofi) which 
targets preferentially JAK2. Results showed that it improved myelofibrosis related 
symptoms, reduced spleen size and JAK2V617F allele burden. Nevertheless, the appearance 
of Gayet-Wernicke encephalopathy in some cases ended with its development. 
 
CEP701 (lestaurtinib; Cephalon) is a multikinase inhibitor. In a clinical phase II 
study, it displayed little reduction in spleen volume, myelofibrosis related symptoms, and 
leukocytosis, but it didn’t reduce either JAK2V617F allele burden or proinflammatory 
cytokine levels. In another clinical study of the same molecule, PV or ET patients showed a 
reduction of spleen size but not of thromboembolic events. 
 
CYT387 (Gilead Sciences) another JAK1/JAK2 inhibitor also exhibited reduction of 
spleen size, anemia, and myelofibrosis related symptoms in almost 50% of patients. It is 
remarkable that CYT387 was also effective in patients in whom ruxolitinib or SAR302503 
treatment had failed. 
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SB1518 (pacritinib; SBio) is a pyrimidine-based JAK2/FLT3 inhibitor. A phase II 
clinical trial presented reduction of spleen size and general symptoms with low frequency of 
myelosuppression. 
 
Moreover, other JAK inhibitors (LY2784544, NS018, AZD1480, BMS911543, 
tasocitinib, NVP-BSK805, INCB16562) are being studied in preclinical or clinical 
approaches. 
 
Other strategies (43) 
 
Targeting Heat-shock protein (HSP) 90 is an alternative to classic JAK inhibitors. 
This protein belongs to the HSP family proteins that control correct folding, intracellular 
disposition and proteolytic turnover of key regulators of cell growth and survival. It presents 
folding and chaperone activity in molecules such as JAK2. Therefore, Hsp-90 inhibitors aim 
to destabilize JAK2 and promote its proteolytic degradation. Some of these candidates are 
17-AGG, PU-H71, SNX5422 and NVP-AUY922.  
 
Previous approaches presented a decrease in JAK2 protein and inhibition of cell 
growth of JAK2V617F or MPLW515L-positive cell lines and JAK2V617F-positive primary 
MPN cells by PU-H71 treatment. These results weonal similar to the ones obtained with 
NVP-AUY922 in primary MPN cells and cell lines. Moreover, they can be used alone or in 
combination with JAK2 inhibitors such as TG101348 and PU-H71 which seemed to resolve 
the resistance problem and presented an additive antiproliferative effect in cell lines when 
used together. 
 
Hsp90 proteins are regulated by acetylation/deacetylation of their lysine residues. 
This process is controlled by histone acetyltransferases and HDACs. Next therapy 
strategies are then based on HDACs inhibitors. Several inhibitors of HDAC are already 
known such as givinostat (ITF235), panabinostat (LBH589), vorinostat (MK-0683), 
pracinostat (SB939), and abexinostat. First essays with givinostat showed a decreased in 
JAK2 protein level, its signaling pathways and growth inhibition in JAK2V617F-positive 
cell lines and primary MPN cells. The use of panabinostat gave similar results and showed 
more efficacy when combined with the JAK2 inhibitor TG101348.  
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Future strategies will target JAK2 effectors such as STAT5, MAPK/ERK, or 
PI3K/Akt/mTOR molecules or even their effectors such as Bcl-xl.  
 
Antioxidant strategies (43) 
 
The radical oxygen species (ROS) have been demonstrated to be increased in Ba/F3 
cells overexpressing JAK2V617F; in JAK2V617F-positive primary cells from PV and MF 
patients and in the progenitor compartment of JAK2V617F knock-in mouse model. ROS 
augmentation causes an increase in cell proliferation by promoting the G1/S transition, 
DNA double-strand damage and genomic instability. The use of the ROS scavenger agent, 
the N-acetylcysteine, in in vivo studies restored blood parameters and reduced DNA 
damage. Furthermore, it also reduced spleen size by decreasing JAK2V617F-positive 
hematopoietic progenitors in bone marrow. This strategy should be used combined with 
previous ones to avoid JAK2V617F MPN development.  
 
Main recommendations for therapeutic decisions in Ph- MPN treatment 
 
Polycythemia Vera treatment (83) 
 
Low risk patients will receive antiplatelet therapy by low-dose aspirin (100 mg/day) to 
reduce the risk of cardiovascular events and phlebotomy to maintain hematocrit levels 
under 45% to decrease blood viscosity. 
High risk patients will receive, as first line of choice, cytoreductive therapy, 
hydroxyurea or interferon alfa (IFNα). Hydroxyurea presents good efficacy and tolerance 
although it also may cause skin toxicity, resistance and risk of disease transformation in 
long periods of treatment. Related to IFNα, nowadays it is its pegylated forms that are used 
due to its better tolerance, (it has been well studied in hepatitis treatment). It presents high 
efficacy as it reduces JAK2V617F burden. JAK2 mutated patients are more sensitive to 
IFN-alfa than those with TET2 mutations which could be resistant. The disadvantages of 
this drug are its toxicity and contraindications and that it is not approved for PV treatment 
yet. 
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As second line therapy, there is another approved myelosuppressive drug for PV 
treatment. The use of busulfan, an alkylating agent, may be an option although it is thought 
to increase leukemic transformation. 
The Janus Kinase (JAK) 1 and 2 inhibitor Ruxolitinib can be chosen when patients are 
intolerant or resistant to hydroxyurea. Clinical essays show well tolerance, well control of 
hematocrit levels (under 35%), reduction of spleen levels, hematologic remission and 
decrease on PV related symptoms. The adverse events related to ruxolitinib are 
thrombocytopenia, dyspnea, anemia, asthenia, herpes zoster infection; basal-cell and 
squamous-cell carcinomas; non-melanoma skin cancer or precancerous skin conditions (94). 
 
Essential thrombocythemia treatment (83) 
 
Low risk patients will only receive low-dose aspirin if they present JAK2V617F or 
cardiovascular risk factors. If aspirin-resistance appears, anti-platelet agents can be 
considered as clopidogrel or even platelet-lowering agents as hydroxyurea in extreme cases 
of aspirin resistance. Antiplatelet drugs have been shown to decrease microvascular 
circulation disturbances in cerebral, coronary and peripheral circulation (61). If extreme 
thrombocytosis (more than 1500x109/L) is present, patients could suffer von Willebrand’s 
syndrome and they will receive cytoreductive therapy previous to antiplatelet one. 
For high risk patients, the use of hydroxyurea combined to aspirin is chosen as first 
line. It’s been demonstrated that together they reduce the rate of thrombosis. It is 
remarkable that JAK2V617F patients require lower doses of hydroxyurea. Anagrelide can 
be used in specific patients who are resistant or intolerant to hydroxyurea. 
Management of both diseases is resumed in Table 1. 
 
 PV ET 
All patients Management of cardiovascular risk factors 
Low-Risk Patients Aspirin Aspirin 
  Phlebotomy   
High-Risk Patients     
  First line HU or IFN-α HU (±aspirin) 
  Second line Switch HU or IFN-α Anagrelide 
  Ruxolitinib IFN-α 
Other Busulfan Busulfan 
Table 1. ET and PV treatment. Table modified from Kiladjian JJ 2015 and Tefferi et al. 2015 (9, 83). 
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Primary Myelofibrosis treatment (83, 95) 
 
The only curative treatment for this hemopathy is allogeneic hematopoietic stem cell 
transplantation which ends with bone marrow fibrosis, reaches molecular remission and 
restores nonmalignant hematopoiesis. It is the choice in intermediate-2 and high risk PMF 
groups.  
Therapy strategies treat anemia or other cytopenias, reduce splenomegaly and 
possible symptoms such as fever, fatigue, pruritus or weight loss. They also focus on 
reducing risk of leukemic transformation, thrombotic and bleeding complications. 
 
-Anemia: Usually PMF patients present hemoglobin values under 10 g/dL. First line of 
treatment will manage iron, vitamin B12 and folic acid deficiency if present, but transfusion 
remains the base of these patients with the inherent iron overload complications due to 
polytransfusion. Patients with low levels of endogenous erythropoietin (under 125 mU/mL) 
can be treated with recombinant human EPO. The use of androgens such as danazol has 
also been proved to reduce anemia. Other alternatives are immunomodulators such as low-
dose thalidomide combined with prednisolone that are first choice in patients with 
thrombocytopenia and lenalidomide combined with prednisone (first choice in 5q deletion 
patients). Finally, patients in whom anemia treatments are refractory to any therapy and 
are transfusion dependent, splenectomy may be their choice. 
 
-Splenomegaly: Hydroxyurea is the usual drug to reduce spleen size. However the 
remarkable impact of JAK2 inhibitors have lead this therapeutic class as a treatment of 
choice of splenomegaly and symptoms associated with PMF (or secondary myelofibrosis). 
Therefore, hydroxyurea is usually combined with JAK inhibitors. Other alternatives are 
splenectomy (related to significant mortality 25-30%) and splenic irradiation but it presents 
high risks of cytopenias. Low-dose irradiation is also used for symptomatic extramedullary 
hematopoiesis in other sites than spleen and liver such as skin or the central nervous 
system. 
 
-JAK2 inhibitors: Ruxolitinib is the only approved JAK2 inhibitor for PMF therapy 
and for treatment of myelofibrosis secondary to PV or ET. It reduces spleen size, common 
symptoms and increases overall survival when compared with patients taking placebo or 
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best available therapy. However, Ruxolitinib benefits are dose dependent and any stops in 
treatment will bring the symptoms back as well as splenomegaly. Common side effects are 
thrombocytopenia and anemia. Other JAK2 inhibitors currently in phase III studies are 
pacritinib (without megakaryocytic toxicity so avoids the thrombocytopenic risk of 
Ruxolitinib); or momelotinib which is thought to be useful in patients with transfusion-
dependent anemia. 
 
Management of possible complications in MPN treatment (95) 
 
 Acute thrombotic events: They should be treated as normal patients by an 
anticoagulant therapy. To prevent them, phlebotomy and low-dose aspirin are the 
main recommendations respectively. In severe cases such as acute cerebrovascular 
complications, acute platelet apheresis or erythropheresis can be performed coupled 
to cytoreductive therapy preferably hydroxyurea. Treatment by anticoagulants and 
antiplatelet drugs is advised as prevention.  
 
 Bleeding: It is mostly caused by acquired von Willebrand’s syndrome 
associated with high platelet counts (>1,500x109/L). Thus hydroxyurea is 
recommended as a platelet reduction agent. (Platelet apheresis is also accepted in 
cases of extreme thrombocytosis). 
 
 Pruritus: Antihistamines are the first choice. It can also be managed by 
selective serotonin re-uptake inhibitors or phototherapy combined with psoralen.  
 
 Leukemic transformation: These patients need to be treated in clinical 
specialized units and are currently included in the therapeutic protocol for secondary 
AML (post MPN/MDS). As said, the only curative treatment in leukemic progression 
is allogenic stem cell transplantation. However, Rampal et al. (76) showed that 
ruxolitinib and decitabine were effective drugs on post-acute leukemia murine 
models as well as the Hsp90 inhibitor PU-H71 suggesting that these new drugs may 
have an interest in combination with induction or consolidation of chemotherapy. 
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PREVIOUS REPORTED DYSFUNCTIONS IN MPNs 
 
As explained in the first part of the manuscript, molecular alterations drive the 
transformation of HSC leading to myeloproliferation. One important issue is to know if 
these molecular alterations could cause deregulations in protein expression (inducing 
proteome deregulations) or functional alterations of proteins that could contribute to the 
phenotype and the evolution of the disease. In this sense, several studies have reported 
alterations of proteome profiles in MPN patients correlated or not with their molecular 
status.  
In serum 
 
One “historical” example of these protein deregulations is the modification of 
erythropoietin serum value in PV patients. MPNs are physiopathologically characterized by 
an EPO independent proliferation of erythroid progenitors inducing a decrease on the 
secretion of EPO by renal cells. This protein modification has been validated as a marker of 
PV allowing, with good specificity and sensitivity, the discrimination between PV and 
secondary erythrocytosis (96). Even though some contradictory results exist in some 
patients, Tefferi et al. (97) suggested that serum erythropoietin levels were expected to be 
decreased in PV regardless of JAK2 mutation. Moreover, Hong et al. (98) also reported that 
patients with primary erythrocytosis or primary familial congenital polycythemia presented 
low serum EPO levels due to a defect on the hematopoietic progenitors. 
After JAK2V617F discovery, studies focused on the impact of JAK2V617F on MPN 
serum proteome in comparison with JAK2 wild type (wt). Mossuz et al. (99) demonstrated 
that a 28 kDa protein (Apolipoprotein A-1) was associated with the presence of the 
JAK2V617F mutation in PV patients, and that Apo-A1 levels were correlated with allele 
burden. Apo-A1 expression was higher in homozygous patients and in patients with an 
allele burden greater than 75%. Apolipoprotein A1 is the main component of high density 
lipoproteins (HDL) in plasma which are in charge of carrying lipids as cholesterol. 
Interestingly, they also correlated higher cholesterol levels with ≥75% JAK2 mutant allele 
suggesting that some metabolic alterations might be related to the presence of mutated 
JAK2. 
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Similar studies with ET serum did not provide the same results. Serum proteome of 
both V617F-positive and V617F-negative ET shared >85% of their protein profiles and did 
not display significant differences. Moreover, Apo-A1 levels were not impacted by the 
presence and allele burden of JAK2 mutation in ET patients. Nevertheless, there were 
significant differences between ET and PV serum proteomes (49% of serum proteins differed 
between JAK2V617F-PV and JAK2V617F-ET and 48% between JAK2(-) and PV) (100).  
Recently, other serum protein alterations concerning cytokines have been highlighted. 
Tefferi et al. (101) found significant elevated serum levels of twenty cytokines in PMF 
patients compared with controls and only one underexpressed cytokine, the IFN-γ. In 
addition, some of these increased cytokine levels were associated with prognosis factors. For 
instance, IL-8 was correlated with leukemia-free survival, constitutional symptoms and 1% 
circulating blasts. IL-2R, IL-12 were related to the need of transfusion; IL-2R and IL-8 with 
leukocytosis; IP-10 with thrombocytopenia and HGF, MIG and IL-1RA with splenomegaly. 
Moreover, high levels of seven of these cytokines were associated with JAK2V617F 
mutation (IL-1RA, IL-2R, IL-6, IL-12, HGF, IP-10, and MIG). Pourcelot et al. (102) showed 
that variations also occurred in PV and ET with a significant increase of cytokine levels 
compared with normal range values. Altogether, these data suggested that alteration of 
protein expression do exist in the serum of MPN patients and that the molecular status 
could impact in these alterations depending on the nature of the mutations and the type of 
MPN.  
In endothelial cells 
 
Endothelial cells may be the first activators of blood cells if there is any injure in the 
endothelium. It has been found high levels of P- and E-selectin in plasma from ET 
thrombotic patients. These two proteins are adhesion molecules expressed by endothelial 
cells. The fact that they are hyperexpressed suggests that they may have a role in the 
pathogenesis of thrombosis in ET. Furthermore, one research showed that plasma levels of 
Nitric Oxide (NO) were reduced in ET patients compared with controls. This study agreed 
with previous ones that showed that MPN patients with thrombotic complications had NO 
production impaired. NO is normally released by endothelial cells and acts as a platelet 
inhibitor to prevent thrombus formation. The fact that it is underexpressed in ET patients 
may contribute to thrombosis. In addition, treatment with hydroxyurea increased plasma 
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levels of NO. On the opposite, PV patients presented high plasmatic levels of NO compared 
with controls and they didn’t vary after hydroxyurea treatment. Actually, NO is associated 
with high hematocrit levels as it may be a compensatory mechanism for thrombotic risk 
situations (61). 
In white blood cells 
 
Thanks to Protein Pathway Array, Hui et al. (103) screened 15 proteins in peripheral 
blood neutrophils differently expressed between ET and control patients implicated in 
apoptosis and inflammatory pathways. They also found differences in protein expression in 
cycle signaling pathways when comparing ET patients with and without JAK2V617F 
mutation suggesting that this mutation contributes to malignant proliferation and cell cycle 
progression. Finally, they selected two proteins that could predict thrombosis in ET 
patients, the estrogen receptor beta and STAT3. 
Falanga et al. (104) studied the involvement of neutrophils in the pathogenesis of 
thrombotic predisposition of PV and ET. They showed that neutrophils presented high 
levels of CD11b, which is a maker of activation. Neutrophils also presented high levels of 
leukocyte alkaline phosphatase which suggested the idea of neutrophil degranulation 
raising plasma concentrations of elastase and myeloperoxidase. Moreover, activated 
neutrophils can bind platelets, what originates the formation of platelet-leukocyte 
complexes which are thought to be the cause of pro-thrombotic condition. Arellano-Rodrigo 
et al. (105) also found that ET patients presented higher expression of CD11b in neutrophils 
but not in patients with thrombosis. CD11b expression was also associated with 
JAK2V617F presence. Nevertheless, they found that CD11b expression was increased in 
monocytes from thrombotic patients as well as the monocyte tissue factor which may be 
involved in blood coagulation. In general, CD11b expression promotes leukocyte adherence 
to the endothelium, phagocytosis, aggregation, adhesion-dependent respiratory burst and 
degranulation. 
In platelets 
 
Abnormalities in MPN platelets such as reduced functionality or abnormal 
aggregation have been suspected since a long time. Recently, these data have been improved 
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showing reduced levels of membrane adhesion molecules such as glycoprotein Ib, IIb-IIIa, 
IV and VI; acquired storage pool disease and defective metabolism (61). In contrast, 
Arellano-Rodrigo et al. (105) found that in ET thrombotic patients, platelets presented 
increased expression on their surface of P-selectine in normal conditions and after 
stimulation by arachidonic acid but not after stimulation by ADP or collagen. P-selectine 
expression was also higher in mutated JAK2 patients. Moreover, ET patients also had more 
platelet-neutrophil and platelet-monocyte complexes and higher platelet counts. However, 
Falanga et al. (61) reported that platelet response to in vitro stimulation was decreased 
compared with healthy control platelets. Thus, even if these platelets showed activate-state 
makers, the fact of being constantly activated may decrease their functions. 
It has also been reported that platelets of JAK2 mutated MPN patients showed higher 
capacity of thrombin generation (which is associated with higher platelet activation). It was 
also related to JAK2V617F allele burden. This effect was reduced by hydroxyurea (61).  
In red blood cells 
 
Studies focused on red blood cell dysfunctions are rare but very informative. Lutheran 
and basal cell adhesion molecule, Lu/BCAM is part of red blood cell (RBC) membrane 
antigens. It is formed by two glycoproteins of the immunoglobulin family expressed toward 
the end of erythropoiesis that are directly connected to the αI-spectrin from the spectrin-
based skeleton. Lu/BCAM is the erythroid receptor of Laminin 511/521. It is overexpressed 
on sickle RBCs where it adheres to laminin α5-chain what causes vaso-occlusive crises, the 
main complication in this disease. It has also been related to metastasis in some cancers 
(106). Moreover, Murphy et al. (107) showed that this adhesiveness was mediated by an 
increase in cAMP that activated the GTPase Rap1 which, in turn activated Lu/BCAM and 
caused enhanced laminin adhesion in sickle cell disease. It can also be activated by 
phosphorylation via Phosphokinase A (PKA) on serine 621. Similar events were described in 
hereditary spherocytosis (HS) by El Nemer et al. (108) who showed that splenectomized 
patients with HS presented dissociation of Lu/BCAM to the spectrin-based skeleton that 
resulted in increased cell adhesion to laminin.  
Wautier et al. (109) studied whether these processes may take place in PV RBCs being 
the cause of thrombotic complications such as cerebrovascular events which are frequent in 
PV. First, they showed that Lu/BCAM was constitutively phosphorylated in PV erythrocytes 
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and that these cells presented increased adhesion to human umbilical vein endothelial cells. 
(Figure 3). Moreover, they demonstrated that JAK2V617F in K562 cells enhanced 
Lu/BCAM expression and phosphorylation suggesting a possible link between this common 
mutation in PV and abnormal adhesion of RBCs via Lu/BCAM phosphorylation.  
To carry on with those findings, De Grandis et al. (110) (same study group) studied the 
relationship between the mechanisms of increased RBC adhesion via activated Lu/BCAM 
and JAK2V617F in PV. Using Ba/F3 JAK2 wild-type, Ba/F3 JAK2V617F and HEL cells, 
they showed that JAK2 mutation was the responsible for cell laminin adhesion via 
Lu/BCAM phosphorylation on serine 621. Furthermore, they demonstrated that Lu/BCAM 
phosphorylation was mediated by Rap1/Akt signaling and independent of EpoR expression. 
Altogether, their results suggested that increased adhesion of PV RBCs could be mediated 
by laminin-Lu/BCAM activation via an EpoR-independent Rap1/Akt signaling pathway 
activated by JAK2V617F (Figure 4). 
 
  
Figure 3. Microscopic image that shows that RBCs adhere more in PV patients than in normal 
subjects. (Wautier et al. (109)) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Diagram showing Lu/BCAM phosphorylation through JAK2 V617F – Rap1/Akt 
signaling pathway and its adhesion to laminin. 
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PROTEOMICS, the proteome study 
 
According to Wilkins et al. (111), the proteome is the ensemble of proteins expressed in 
a cell or a biological fluid and the term proteomics refers to the deep analysis of these 
proteins. Proteomic studies include detection, identification, quantification, and functional 
and structural characterization of proteins (112). It is an emerging strategy in the study of 
many human diseases because of its dynamic nature. Up to now, proteomic researches have 
been improving genomic studies which provide the analysis of more than 20,000 genes that 
constitute the human genome. Nevertheless, genomics just takes into account DNA 
information. It’s a fixed view of cells that reflects their activated genes at a defined time. In 
addition, from one gene we can encounter various protein species due to post translational 
modifications and all different among them. Therefore, proteomics reveals information 
missed in genome analysis such as alternative splicing, allelic variations and post-
translational modifications like phosphorylation, oxidation, ubiquitination and 
glycosylation. The proteome study better represents the impact of the environment on the 
function of cells than the picture of active genes.  
 
PROTEOMIC METHODS 
Assuming that Western blotting or immunodetection still represent choice methods for 
investigation of a small number of proteins, nowadays, mass spectrometry has established 
itself as the standard method to identify and quantify, in the same run, very high number of 
proteins from a biological sample. 
This technology, in continuous evolution, has provided tremendous results in the 
characterization of diverse proteomes thanks to the concomitant improvement of data 
processing tools.   
 
It was in 1988 when Tanaka et al. (113) first could achieve a mass spectrum. Since 
then, different techniques have evolved to improve accuracy, sensitivity and specificity to 
identify and quantify the different molecules (114). 
Mass spectrometry is based on the ionization of chemical compounds such as proteins, 
to generate gaseous charged molecules/fragments and to detect them depending on their 
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mass-charge ratio (m/z). This technique lets determine the molecule masses of free ions. 
Meanly, it is used to find out masses of particles or the composition of a sample. 
 
A mass spectrometer analyzer is formed by three main elements (Figure 5): 
 -The ion source: where it takes place the gaseous ion formation. There are 
many types that differ on the ionization method. For instance, bombarding the sample 
by photons as the LDI technique (laser desorption/ionization), or by electron impact 
(EI) or ESI (Electro Spray Ionisation) where samples are sprinkle into an electrical 
field. 
 -The mass analyzer: where ions are separated according to their m/z ratio. 
Analyzers can be coupled for tandem mass spectrometry (MS/MS) where the first 
analyzer will separate ions that then will pass through a collision cell that will 
fragment them. Finally, ion fragments will cross the second analyzer that will 
separate the ion fragments. Some of these analyzers are based on ion traps; magnetic 
and electric fields; or flight time as the Time-Of-Flight (TOF) spectrometers. 
 -The detector: It detects ion arrival and measures the quantity of ions 
providing data for calculating the abundances of each ion. These data are transformed 
into a spectrum where each pick represents the mass and quantity (intensity) of an 
ion. 
 
 
Figure 5. Mass spectrometer analyzer schema. Samples enter the ion source where they are 
ionized and throw to the mass analyzer that is coupled to the detector that will give a spectrum with 
the results. 
 
In this research, two different mass spectrometers were used: SELDI-TOF MS and 
LC-MS/MS coupled to LTQ Orbitrap. 
 
Ion 
Source 
Mass 
Analyzer 
Detector 
Ions 
Samples Spectrum 
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SELDI TOF MS (115)  
Surface-enhanced laser desorption/ionization mass spectrometer (SELDI-TOF MS) is 
composed by three main instruments: protein chip arrays, mass analyzer and data analysis 
software. It is based on the principle that proteins are captured on a solid-phase protein 
chip surface and ionized with a nitrogen laser to measure their molecular masses according 
to their times-of-flight; (Figure 6). 
 
 
Figure 6. Schema of SELDI-TOF MS process: proteins are placed on chips, ionized and 
detected on the MS. Molecular masses are calculated according to their times-of-flight. 
 
 
Protein chip arrays 
They are active surfaces that retain all classes of proteins. These arrays are made of 
aluminum strip with spots composed of a chemically or biochemically modified active 
surface, Figure 7. These surfaces are specially designed to retain proteins according to a 
general or specific physicochemical property of proteins. 
For example, in our study we used a weak anionic surface called: ProteinChip® CM10 
array that is known to interact with cationic proteins. 
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Figure 7. Different types of SELDI surfaces. 
 
Mass analyzer 
Once proteins are retained on the chip surface, a matrix solution is added and proteins 
can be then desorbed/ionized by a pulsed, UV, nitrogen laser. These ions are accelerated by 
an electro-static field during a short laser pulse. They leave the source and pass through a 
field-free drift region under vacuum where they are separated depending on their m/z ratio 
towards the ion detector. This occurs because of the fact that ions are accelerated with 
different velocities according to their mass-charge values. Therefore, knowing the 
acceleration voltage and the length of the drift region, the m/z ratio can be determined by 
measuring the flight time. Large ions with high m/z values, reach the detector later than 
smaller ones. Ions with identical masses start with a certain energy spread which affects to 
the peak width.  
 
LC MS/MS (116) 
Liquid chromatography-tandem mass spectrometry consists of two mass filters in 
tandem separated by a collision cell. The sample is ionized in the source. The most typical 
ionization sources are electrospray ionization and atmospheric pressure chemical ionization. 
Ions pass into the first mass filter which continues with a collision chamber followed by the 
second mass filter that ends in the detector. (Figure 8) 
Hydrophobic    Cation exchange      Anion exchange        Metal affinity        Normal phase 
PS-10 or PS-20            Antibody-antigen                 Receptor-ligand            DNA-protein 
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Figure 8. Tandem mass spectrometry schema. 
 
LC-MS/MS provides analytical specificity and high throughput (capacity, efficiency). 
Nevertheless sensitivity is not its strong point. In our case, we used LC-MS/MS coupled to 
an LTQ-Orbitrap Velos mass spectrometer. 
 
 
LTQ-ORBITRAP 
The LTQ-Orbitrap is a mass spectrometer with two electrodes, one external and 
another one internal which create an electrostatic champ. Ions are produced by an 
electrospray ion source; then they go through the source and pass into the storage 
quadrupole. It is an ion accumulator that when a sufficient number of ions have been 
stored, the storage is opened and ions are injected into the Orbitrap with a velocity 
perpendicular to the long axis. It gives the ions potential energy that they use to start axial 
oscillations around the inner electrode. On the one hand, ions of the same m/z ratio move 
around the inner electrode in the long axis for thousands of oscillations. On the other hand, 
in the radial direction, ions do not have the same oscillation magnitude. After this radial 
dephasing, the ion packet of a determinate m/z takes a ring shape. It moves from one half 
of the outer electrode to the other one creating a signal which is detected and analyzed by 
adequate software. Figure 9. 
 
 
 
Source MS1 
Collision 
cell 
MS2 Detector 
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Figure 9. LTQ-orbitrap mass spectrometer diagram. Samples are ionized and throw through 
the linear ion trap where they will be separated and launched through the Orbitrap. Then they will 
arrive to the mass spectrometer detector. 
. 
Nowadays there are plenty of different types of mass spectrometers which differ on the 
way they ionize samples, on the method used to separate ions and the way to detect them. 
The choice depends on the desired result. For instance, we first used SELDI-TOF-MS as it 
permits to screen lots of clinical samples in a short time. It is usually used for disease 
biomarker identification as it generates proteome patterns from biological fluids and 
compares them to recognize unique biomarkers related to a particular disease with just few 
amounts of sample. Nevertheless, this technique has not yet been successful in studying 
high-molecular-weight proteins and it does not have enough specificity. Therefore, we used 
it as a screening tool so as to classify samples according to their content of proteins of 
different masses (proteome profile). 
Once samples were analyzed by SELDI-TOF MS, we selected the richest ones to be 
analyzed by LC-MS/MS which provides more specificity.  
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ERYTHROCYTE PROTEOME 
 
Red blood cells or erythrocytes are myeloid mature blood cells specialized on carrying 
oxygen from lungs to all tissues. They are biconcave disks that remain around 120 days in 
blood circulation. In the bone marrow, pluripotent hematopoietic stem cells differentiate to 
create common myeloid progenitors that evolve to megakaryocytic/erythroid progenitors. 
These ones, thanks to specific growth factors, differentiate into erythroid burst forming 
units (BFU-E) and erythroid colony forming units (CFU-E) which evolve to intermediate 
forms of proerythroblasts and then to early and late erythroblasts. Finally, enucleation 
yields to reticulocytes which leave from the bone marrow to the peripheral blood and end in 
mature erythrocytes. At last stages of maturation, they have already lost some organelles 
such as mitochondrias; however large amounts of RNA assure the complete synthesis of 
hemoglobin to assure the main function of RBCs, the oxygen transport (117, 118).  
 
Despite hemoglobin (Hb) is well known to be the main protein in these cells, the study 
of all the proteins that remain in RBCs, even if they are inactivated because of useless, 
represents a curiosity. Indeed, many proteins are expressed in red blood cells to assure 
various mandatory functions for RBC integrity as initiation and maintenance of glycolysis, 
cation pumping against electrochemical gradients, synthesis of glutathione and other 
metabolites, nucleotide catabolism reactions, maintenance of Hb iron in its ferrous state, 
protection of enzymatic and structural proteins from oxidative denaturation and 
preservation of membrane phospholipid asymmetry. In this context, the investigation of this 
“hidden proteome” should be clearly informative. Actually, the study of RBC proteome is a 
challenge as hemoglobin comprises 97% of whole proteins and it masks many low abundant 
proteins. First attempts to characterize the RBC proteome could identify a total of 181 
proteins (half from the membrane and half from the cytoplasm) using ion trap tandem mass 
spectrometry coupled to liquid chromatography (119). Nevertheless, a huge amount of 
proteins remained hidden by hemoglobin. Thus, next approaches pre-fractionated RBC 
samples to deplete hemoglobin and enrich lysates in low abundant proteins. Bhattacharya 
et al. (120) depleted hemoglobin by cation exchange chromatography. Using 2D gels, they 
showed how Hb depletion let them visualize more than 600 spots that weren’t visible before 
the chromatography step. Ringrose et al. (121)  took advantage of the high Nickel-
hemoglobin affinity to successfully deplete Hb by nickel (II) columns. They also depleted 
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carbonic anhydrase-1, which represents 1% of total erythrocyte proteome, by ion exchange 
chromatography. Coupling both techniques let them identify 677 proteins by LTQ-FT-ICR 
MS/MS. 
 
Some commercial kits for hemoglobin depletion are available such as HemoglobindTM 
and HemoVoidTM. HemoglobindTM is based on a solid-phase that specifically binds 
hemoglobin. Alvarez Llamas et al. (122) could identify a total of 34 proteins from the 
cytosolic fraction of RBCs thanks to this method coupled to LC-MS/MS. HemoVoidTM is a 
silica-based matrix support that has multiple surfaces: hydrophobic, ionic, aromatic and 
polymer combinations. These ligands bind a huge range of proteins and whereas high 
abundant proteins such as hemoglobin fast saturate their binding sites, low abundant ones 
continue binding other ligands. Thanks to this depletion, Walpurgis et al. (123) could 
identify a total of 189 proteins by down-stream 2D PAGE analysis coupled to Orbitrap MS. 
 
Another method, the ProteoMinerTM, consists on beads coupled to a library of either 
amino-terminal hexapeptides or carboxylated peptides. This technique is based on the fact 
that each porous bead contains billions of copies of a unique hexapeptide ligand on its 
surface and each hexapeptide of each bead differs from the other ligands (of the other 
beads). The result is a library of millions of beads, each one with a different hexapeptide. 
Proteins theoretically have affinity for one or more beads. Therefore, high abundant 
proteins will soon saturate their binding sites meanwhile low abundant proteins will have 
their binding sites available. Once the excess of non-bound proteins is eliminated, samples 
result in an enrichment of low abundant proteins (Figure 10) (124). Thereby, Roux-Dalvai et 
al. (117) could identify a total of 1524 proteins by LC-MS/MS coupled to LTQ-Orbitrap from 
RBC lysates that had previously been treated by ProteoMinerTM. 
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Figure 10. Sample enrichment in low abundant proteins. Samples are incubated with beads 
coupled to different ligands. Washes remove unbound proteins. Elution will let recover bound 
proteins (125). 
 
 
Recently, a new technique has been validated by Zaccaria et al. (126) for the 
enrichment of low-abundant proteins in RBC lysates. This method, derived from the 
ProteoMinerTM, is founded on magnetic nanoparticles (10-200 nm) with a chemical surface 
which will interact with the proteins in the biological samples depending on the nature of 
the proteins. For instance, nanoparticle surfaces may be modified by varying porosity, 
surface charges and functional chemical groups such as hydrophobic residues or acids) 
(127). As a result of this interaction between proteins and chemical surface a “corona” is 
formed around the nanobeads. 
 
Thanks to the preanalytical treatment of RBC lysates with these magnetic 
nanoparticles, Zaccaria et al. (126) could identify 909 proteins by nano-LC-MS/MS from 
erythrocyte lysates. They showed how the proportion of high abundant proteins, and 
specifically Hb, had decreased in their samples as long as the proportion of low abundant 
proteins rose. The big advantage of this approach in comparison with ProteoMiner is its 
huge efficiency in low volume samples (they used 200 µL = 1 mg of RBC lysate whereas 
Roux-Dalvai et al. (117) used 200 mg). Other advantages are easy suspension, large surface 
area, slow sedimentation and uniform distribution of the particles in the suspension media. 
Moreover, thanks to their multi-domain core, they can be easily isolated by an external 
magnet. Another advantage is the possibility to make quantitative comparison of clinical 
samples after enrichment in minor proteins with high reproducibility (126). 
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As hemoglobin depletion technique in this research, I chose the magnetic nanoparticle 
fluidMAG-Q from Chemicel GmbH (Berlin, Germany) (Figure 11). It is a 200 nm particle in 
aqueous suspension with a positive surface. Its principal characteristics are summarized in 
Table 2. 
 
 
NP FluidMAG-Q 
Application Strong anion exchanger 
Core Magnetite 
Matrix Poly (diallyldimethil-
ammonium chloride) 
Functional 
group 
Quaternary amine group 
(R4N+) 
 
Table 2. Principal characteristics of fluidMAG-Q     Figure 11. FluidMAG-Q 
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OBJECTIVE 
 
The main objective of my work was to perform an investigation of protein alterations 
associated with Ph- MPNs. To fulfil this goal, we developed an integrative proteomic 
strategy based on high output mass spectrometry together with specific protein 
identification by western blotting. These approaches let us characterize and quantify 
proteome variations leading to functional alteration of pathways that could be involved in 
MPN pathogenesis. 
We explored the three “classical” Ph- MPNs in comparative analysis to identify either 
common alterations associated with MPNs or specific abnormalities of each MPN. We also 
integrated our data according to patient’s genotype so as to better characterize protein 
dysfunctions related to the two main driver mutations JAK2V617F and CALR (ins/del). 
This strategy was applied on two types of cells being directly impacted by clonal 
proliferation of hematopoietic stem cells, the erythrocytes and the granulocytes.  
Finally, we evaluated the results of Ph- MPN red blood cell deregulation of 
IQGAP1/Rho GTPase signaling in a model of transfected Ba/F3 cell lines expressing high 
levels of JAK2 (wild type or V617F) to investigate the specific impact of JAK2 mutations 
and the interest of therapies targeting JAK-STAT signaling for the regulation of this 
pathway.  
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BACKGROUND 
 
Red blood cells remain the “poor relation” of MPN researches. In absence of nuclear 
and nucleic acids, they avoid molecular investigations and consequently we lack information 
about these cells even though they represent the ultimate cells accumulating from clonal 
erythroid progenitors in MPNs. Hyperviscosity consequences due to their increased number 
in PV, clearly illustrates their pathogenic potential. Moreover, as red blood cells are the 
main cellular component of blood, they represent a huge “sponge” that is able to interact 
with and to adsorb plasma proteins released by damaged tissues giving biomolecular 
information about peripheral disturbances as inflammation or cell lysis. Therefore, they 
could be considered as witnesses of serum proteome modifications associated with diseases 
(126, 128). 
 
In this context, we tried to characterize protein deregulations in erythrocytes of Ph- 
MPN patients and to identify functional alteration of specific pathways that could be 
involved in MPN pathogenesis. High amounts of hemoglobin in RBCs, being a huge 
impediment, we used a validated new-published technique based on ferromagnetic particles 
covered by chemical surfaces that permits the enrichment in low-abundance proteins and 
hemoglobin depletion (126).  
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MATERIALS AND METHODS 
Patients 
All patients came from the clinical hematology department of the Grenoble University 
Hospital (CHU Grenoble) and were classified according to the 2008 WHO criteria (2) 
including molecular investigation of JAK2 (V617F, exon 12); MPL and CALR mutations and 
endogenous colony formation (erythroid and megakaryocytic colonies). 
For the quantitative mass spectrometry (MS) analysis, a first set of samples (training 
set) was selected including 10 PV, 9 ET and 12 control samples. In order to validate by 
Western blotting (WB) the data obtained by quantitative MS analysis, we selected a new 
independent set of 14 MPN samples comprised of 7 PV (PV1 to PV7) and 7 ET (ET1 to ET7). 
This set was referred to as the “retrospective set”. Samples from the training and the 
retrospective set were erythrocytes that had been cryoconserved at diagnosis (after ficoll 
gradient centrifugation for separation of granulocytes) in the center of biological resources 
of the CHU Grenoble with informed consent of patients. Next, to validate WB data obtained 
on the retrospective set and to avoid the possible bias induced by cryoconservation of red 
blood cells before lysis for protein extraction, we prospectively performed, on new patients 
with a suspicion of MPN, a special collection of erythrocyte lysates of fresh red blood cells 
obtained at the initial diagnosis consultation and lysed by hypotonic shock; (for the 
procedure of RBC preparation see below). Thereby, after diagnosis confirmation, we could 
select a prospective set of 16 samples including 8 PV (PV8 to PV15), 7 ET (ET8 to ET14) and 
1 primary myelofibrosis (PMF). 12 samples were JAK2V617F and 4 JAK2 wild type (WT) 
(ET8, ET11, ET14 and PV15). At the same time, when we collected the prospective set, we 
also selected a group of 10 control patients called control set and named C1 to C10. Finally, 
for the investigation of CALR mutations, we selected an additional set of 6 ET patients 
positive for this mutation (insertions or deletions). This set was referred to as the 
“calreticulin set”. 
 
Erythrocyte and Protein Preparation 
RBCs from peripheral blood were separated from polynuclear and mononuclear cells 
by ficoll gradient centrifugation. Cryoconserved erythrocyte samples from the training, 
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retrospective and calreticulin sets were lysed by repetitive freeze/thaw cycles followed by 
centrifugation at 36,000 g for 10 min to separate the red cell pellet. Supernatants containing 
the protein extracts were cryoconserved at -80°C before MS or WB analysis. All these 
samples were lysed at the same time to limit inter-experiment bias. Concerning RBCs of the 
control and prospective sets, the lysis was directly performed on fresh cells obtained after 
separation by ficoll gradient centrifugation of peripheral blood. RBCs were lysed by 
hypotonic shock with distilled water in the presence of protease and phosphatase inhibitors 
(cOmplete, EDTA-free and phospho-STOP, Roche). After centrifugation at 36,000 g for 10 
min, the protein extract of the supernatant was stored at -20ºC before WB. All protein 
extracts were quantified by BIORAD DCTM protein assay. 
 
Magnetic Nanoparticle Hemoglobin Depletion 
FluidMAG-Q (4112) was obtained from Chemicell GmbH, Berlin, Germany. RBC 
lysates from the training, retrospective and calreticulin sets were incubated with magnetic 
nanoparticles immediately after thawing. Nanoparticle incubation of the RBC lysates from 
the prospective and control sets was performed directly after the last centrifugation of fresh 
blood cells. Incubation was done as previously described by Villanueva et al. (129) (Figure I-
1). Briefly, samples (500 µL) were mixed with 500 µg of nanoparticles (20 µL) and 500 µL of 
1x PBS buffer solution (137 mM sodium chloride, 10 mM sodium phosphate, 2.7mM 
potassium chloride and 1.8 mM potassium phosphate, pH 7.4). The mix was incubated for 1 
hour at room temperature in movement up and down. Then, samples were centrifuged 2 
minutes at 9,500 g and supernatants were removed putting the tubes in a magnetized grille 
(MagnetoPURE, Chemicell GmbH, Berlin, Germany). Pellets were washed twice with buffer 
solution 1x PBS and twice with distilled water. Elution was carried out by 50µL of 2X 
Laemmli sample buffer (4 % SDS, 20 % glycerol, 10 % 2-mercaptoethanol, 0.004 % 
bromophenol blue, 0.125 M Tris HCl) and incubated one hour under gentle agitation. 
Samples were centrifuged and put on the magnetized grille to recover the supernatants. 
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Figure I-1. Nanoparticle incubation schema. Samples are incubated with magnetic 
nanoparticles for one hour. After centrifugation and thanks to a magnetized grille, supernatants are 
removed and discarded. Then, beads are washed three times before incubation with elution buffer for 
one hour. Finally, samples are centrifuged and supernatants are recovered. 
 
Proteomic Analysis 
Quantitative proteomic analysis was made by LC MS/MS (LTQ Orbitrap). Ten 
micrograms of RBC lysates were run on SDS-PAGE gel electrophoretic migration. The 
stacking bands were cut and washed in 100 mM ammonium bicarbonate. Cysteines were 
reduced and alkylated by 10 mM DTT (Dithiothreitol) for 35 min at 56 °C followed by 55mM 
iodoacetamide for 30 min at room temperature in the dark. Additional washing cycles were 
then performed and proteins were digested by modified sequencing grade trypsin (Promega) 
in ammonium bicarbonate overnight at 37°C. The resulting peptides were extracted from 
the gel by incubation in ammonium bicarbonate followed by two incubations in 10 % formic 
acid, acetonitrile (1:1). The three extracts were pooled with the initial supernatant, dried in 
SpeedVac, and resuspended with 5 % acetonitrile, 0.05 % trifluoroacetic acid. Peptide 
mixtures were analyzed by nano-LC-MS/MS using an ultimate3000 system (Dionex, 
Amsterdam, The Netherlands) coupled to an LTQ-Orbitrap Velos mass spectrometer 
(Thermo Scientific, Bremen, Germany). Samples were loaded on a C18 precolumn (300 µm 
inner diameter X 5 mm; Dionex) at 20 µl/min in 5 % acetonitrile, 0.05 % trifluoroaetic acid. 
After desalting, the precolumn was switched on line with the analytical C18 column (75 µm 
inner diameter X 15 cm; PepMap C18, Dionex) equilibrated in 95 % solvent A (5 % 
acetonitrile, 0.2 % formic acid) and 5 % solvent B (80 % acetonitrile, 0.2 % formic acid). 
Peptides were eluted using a 5-50 % gradient of solvent B during 80 min at a 300 nL/min 
flow rate. The LTQ-Orbitrap was operated in data-dependent acquisition mode with the 
Xcalibur software. Survey scan MS spectra (m/z mass range 300-2000) were acquired in the 
Elution Bead pull-down Washing Binding 
Bead 
suspension 
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Orbitrap with the resolution set to a value of 60,000 at m/z 400 (AGC target value of 1x106 
charges). The five most intense ions per survey with a charge state greater than one were 
selected for collision-induced dissociation (CID) fragmentation, and the resulting fragments 
were analyzed in the linear trap (LTQ). Collision energy was set to 35% for MS/MS. 
Dynamic exclusion was used within 60 s to prevent repetitive selection of the same peptide. 
 
Protein identification and quantification 
Data were searched against all entries in the International Protein Index (IPI) human 
v3.34 protein. For protein quantification, we used Mascot File parsing and Quantification 
(MFPaQ) version 4.0. Protein hits were validated when they satisfied one of the following 
criteria:  
A) Identification with at least one top ranking peptide of a minimal length of 5 
amino acids and with a Mascot score higher than the identity threshold at p=0.001 
(99.9 % probability), 
B) or at least two top ranking peptides each of a minimal length of 5 amino acids 
with a Mascot score higher than the identity threshold at p=0.05 (95 % probability). 
When several proteins matched exactly the same set of peptides, only one of them was 
reported in the final protein lists. Furthermore, homologous Mascot protein hits were 
validated and included in the final list only if they were additionally assigned to a specific 
top ranking peptide with Mascot score higher than the identity threshold at p=0.001. 
Quantification of peptide ions was based on calculated extracted ion chromatogram 
(XIC) areas values. To compare the abundance of different proteins or to represent the 
abundance profile of one protein in different samples, a protein abundance index (PAI) was 
calculated defined as the average of XIC area values for three intense reference tryptic 
peptides identified for this protein. 
 
Biomarker selection 
After protein identification and quantification, means of the area values from the 
same peptide were compared using student’s t tests. Means were defined as significantly 
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different when unequal T-test was lower than the t references for a confidence interval=95% 
and the ratio between the two means was above 2 or below 0.5.  
 
Functional analysis 
LC-MS/MS results were loaded on Ingenuity Pathway Analysis (IPA) software. It 
enabled us to identify, analyze and understand the whole data. It helped us to know in 
which biological pathways the identified proteins participate; which of the proteins interact 
with each other directly or through intermediate molecules; which upstream regulators can 
explain their expression pattern; which downstream diseases or processes are likely 
increased or decreased by the increase or decrease of the abundance of these proteins and 
the effects of possible protein modifications.  
 
Statistical analysis  
Mean comparison was performed by student’s t test by GraphPad Prism software with 
a confidence interval of 95 %. 
 
Western-Blotting 
Samples were heated 5 minutes at 95°C. Next, they were run on SDS-PAGE gels and 
transferred to nitrocellulose membranes for 1 hour. Blocking was carried out with TBS-
Tween 20 - 5% skimmed milk for 1 hour at room temperature and incubated with primary 
antibodies diluted in TBS-Tween 20 - 1% skimmed milk overnight at 4°C. Then, membranes 
were incubated with Horseradish peroxidase (HRP) labeled secondary antibodies during 90 
minutes at room temperature. Development was made with ECL (enhanced 
chemiluminescent) Western Blotting Substrate from Pierce. β-actin was used as loading 
control. 
 
Immunoprecipitation 
250 µL of RBC lysates were incubated 1 hour at 4°C under gentle agitation with the 
corresponding primary antibodies. Later, 50 µL of protein A/G PLUS agarose beads or 
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protein A agarose beads (Santa Cruz Biotechnology) were added and incubated 1 hour at 
4°C under agitation. Three washes were done with lysis buffer (1 % NP-40, 10 mM KCl, 10 
mM HEPES, 0.1 mM EDTA + protease and phosphatase inhibitors) and centrifuged 1 
minute at 4°C at 800 g. Supernatants were discarded and beads were eluted with 50 µL of 
2x Laemmli Buffer with 2-mercaptoethanol heating 5 minutes at 95°C. After centrifugation, 
supernatants were recovered and analyzed by western blotting. Rac1, Cdc42 and Rho 
protein activation was determined by pull-down assays incubating with GST-PAK-PBD 
beads or GST-Rhotekin-RBD beads (Cytoskeleton, Inc.). GST-PAK-PBD contains residues 
67-150 of PAK, which corresponds to the CRIB motif - required for the high affinity 
interaction with GTP-Rac and GTP-Cdc42. GST-Rhotekin-RBD contains residues 7-89 of 
Rhotekin needed for the interaction with GTP-Rho. Control RhoA, Rac1, Cdc42 and Rho-
GDI were produced as described by Ligeti et al. (130). 
 
Antibodies  
-Primary antibodies: rabbit polyclonal anti-IQGAP1 (H-109) antibody (sc-10792) and 
mouse monoclonal anti-β-Actin-HRP (C4) antibody (sc-47778) were from Santa Cruz 
Biotechnology; mouse IgG1 anti-Cdc42 (610928) and mouse IgG2b anti-Rac1 (610651) were 
from BD Biosciences; rabbit monoclonal anti-JAK2 (D2E12) XP® antibody (#3230), rabbit 
monoclonal anti-phospho-JAK2 (Tyr1007/1008) (C80C3) antibody (#3776), rabbit 
monoclonal anti-phospho-PAK1 (Thr423)/PAK2 (Thr402) antibody (#2601) and rabbit 
monoclonal anti-PAK1 antibody (#2602) were from Cell Signaling Technology. Mouse 
monoclonal anti-IQGAP1 antibody, clone AF4 (#05-504) and rabbit monoclonal anti-
calreticulin antibody, clone EPR3924 (#MABT145) were from EMD Millipore.  
-Secondary antibodies: Goat anti-mouse IgG-HRP antibody (sc-2005) and goat anti-
rabbit IgG-HRP antibody (sc-2004) were from Santa Cruz Biotechnology. Protein A full-
length protein (Ab7456) was from Abcam. 
 
Rac1Q61L-GST Protein Production 
E. coli cells transformed with pGEX-Rac1Q61L plasmid were cultured in Luria Broth 
medium with 100 µg/mL ampicillin at 37°C. The lac operon was activated by adding 0.5 µM 
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of IPTG (Isopropyl β-D-1-thiogalactopyranoside) during 3 hours at 37°C under gentle 
agitation. Cell suspension was centrifuged 10 minutes at 2,000 g at 4°C. Supernatant was 
discarded and the cell pellet was washed and resuspended in 1x PBS (with protease 
inhibitors). Cell lysis was done by 3 cycles of 10 seconds of sonication at 60W at 4°C followed 
by ultracentrifugation (40 minutes at 100,000 g at 4°C). The recombinant protein was 
harvested in the supernatant. Next, it was incubated with Glutathione Sepharose beads 
(GE Healthcare) for one hour at 4°C, washed three times with 1x PBS, centrifuged at 500 g 
for 5 minutes and stored in a solution of 1x PBS-10% glycerol 1:1. 
 
KG1 and K562 Lysates 
K562 cells are an erythroleukemia cell line derived from a chronic myeloid leukemia 
patient in blast crisis. KG1 cells are also a cell line that comes from a bone marrow patient 
with erythroleukemia evolving to acute myelogenous leukemia. Cell lines were washed 
three times in 1x PBS, lysed with lysis buffer (20 µL/million cells) (50 mM HEPES - pH 7.5, 
5 mM MgCl2, 1 % Triton X-100, 10 µg/µl Leupeptine and protease inhibitors) for 20 minutes 
at 4°C, centrifuged 10 minutes at 1,000 g and quantified by BIORAD DCTM protein assay.   
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RESULTS 
1-RBC proteome of MPN patients display specific alterations of protein 
expression 
 
Quantitative analysis by LC MS/MS – LTQ Orbitrap let us identify and quantify a 
total of 1019 proteins. Student’s t tests were calculated to ascertain if there were significant 
differences in protein expression between the different groups of patients. Results showed 
that: 
-51 proteins were overexpressed in PV patients compared with controls. 
-85 proteins were overexpressed in ET patients compared with controls. 
-15 proteins were overexpressed in controls compared with PV patients. 
-50 proteins were overexpressed in controls compared with ET patients. 
-2 proteins were overexpressed in PV compared with ET patients. 
-14 proteins were overexpressed in ET compared with PV patients. 
 
In all cases, we considered a ratio > 2 with student’s t test p-values lower than 0.05. 
Moreover, we also compared protein profiles of JAK2(+) PV and ET patients with JAK2(-) 
ET patients. We found 17 proteins overexpressed in JAK2 positive PV patients compared 
with JAK2 negative ET ones; and 11 overexpressed in JAK2 negative ET patients compared 
with JAK2 positive PV ones (ratio>2; p-value<0.05). We also found 9 proteins overexpressed 
in JAK2 positive ET patients compared with JAK2 negative ones; and only 2 proteins were 
overexpressed in JAK2 negative ET patients compared with JAK2 positive ET ones 
(ratio>2; p-value<0.05). The list of all proteins is accessible in Supplemental Data I-1. 
Thanks to IPA software, we could evaluate which functional pathways were more 
affected by the deregulated proteins. (Lists of all deregulated pathways in Supplemental 
Data I-2). In general, examining PV vs controls and ET vs controls analysis; we remarked 
that the most deregulated proteins belonged to the RAS superfamily of GTPase signaling 
pathways; specially the Rho subfamily of GTPases (Table I-1). RABGGTA, RABEP-1 and 
IQGAP1 were the three proteins the most significantly overexpressed in both PV and ET 
patients compared with controls that belonged to the RAS GTPase family (Table I-2).  
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PV vs Control ET vs Control 
Ingenuity Canonical 
Pathways 
 -log(p-
value) 
Ratio 
Ingenuity Canonical 
Pathways 
 -log(p-
value) 
Ratio 
RAN Signaling 8,62E00 0.25 Actin Cytoskeleton Signaling 1,58E01 0.10 
Actin Cytoskeleton Signaling 8,35E00 0.05 Integrin Signaling 9,41E00 0.07 
Integrin Signaling 7,87E00 0.06 VEGF Signaling 8,17E00 0.11 
Regulation of Actin-based 
Motility by Rho 
4,63E00 0.07 
Regulation of Actin-based 
Motility by Rho 
7,77E00 0.11 
Protein Ubiquitination 
Pathway 
4,5E00 0.05 ILK Signaling 7,67E00 0.07 
Ephrin Receptor Signaling 4,4E00 0.04 RhoA Signaling 7,65E00 0.10 
VEGF Signaling 4,23E00 0.06 RAN Signaling 7,5E00 0.3 
Rac Signaling 3,95E00 0.05 
Sertoli Cell-Sertoli Cell 
Junction Signaling 
7,12E00 0.07 
RhoA Signaling 3,95E00 0.05 
Signaling by Rho Family 
GTPases 
6,74E00 0.05 
Axonal Guidance Signaling 3,84E00 0.03 
Germ Cell-Sertoli Cell 
Junction Signaling 
6,7E00 0.07 
fMLP Signaling in 
Neutrophils 
3,75E00 0.05 Rac Signaling 6,61E00 0.08 
Signaling by Rho Family 
GTPases 
3,68E00 0.03 RhoGDI Signaling 6,4E00 0.06 
CD28 Signaling in T Helper 
Cells 
3,63E00 0.05 Tight Junction Signaling 6,18E00 0.07 
Corticotropin Releasing 
Hormone Signaling 
3,57E00 0.04 
Clathrin-mediated 
Endocytosis Signaling 
5,92E00 0.06 
Synaptic Long Term 
Potentiation 
3,49E00 0.05 α-Adrenergic Signaling 5,91E00 0.09 
Apoptosis Signaling 3,37E00 0.05 Protein Kinase A Signaling 5,83E00 0.04 
Cdc42 Signaling 3,37E00 0.03 Coagulation System 5,71E00 0.16 
ERK/MAPK Signaling 3,36E00 0.03 
Cellular Effects of Sildenafil 
(Viagra) 
5,43E00 0.07 
Protein Kinase A Signaling 3,3E00 0.02 
Mechanisms of Viral Exit 
from Host Cells 
5,28E00 0.01 
CD27 Signaling in 
Lymphocytes 
3,27E00 0.07 FAK Signaling 5,21E00 0.08 
Fcγ Receptor-mediated 
Phagocytosis in Macrophages 
and Monocytes 
3,19E00 0.05 
NRF2-mediated Oxidative 
Stress Response 
5,2E00 0.06 
Table I-1. Top canonical deregulated pathways in PV or ET patients compared with controls. 
Pathways are ordered according to their p-value. Ratio means the number of molecules of the 
pathway that were found in our analysis (thus deregulated) in relation with the total number of 
proteins that belong to that pathway. Analysis was performed by IPA software.  
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Protein ID Gene name Protein name Ratio p-value 
IPI00022664 RABGGTA 
Rab geranylgeranyltransferase, 
alpha subunit 
PV-ET/Control: ∞ 
PV/C: 0.0001 
ET/C: 0.0001 
IPI00412712 RABEP1 
Rab GTPase-binding effector 
protein 1 or Rabaptin-4 or 
Rabaptin-5 or Rabaptin-5alpha 
ET/Control: 2.2 
ET/C: 0.014 
PV/C: 0.95 
IPI00009342 IQGAP1 
Ras GTPase-activating like 
protein 1 
PV/Control: 2.2 
ET/Control: 2.5 
PV/C: 0.047 
ET/C: 0.0008 
IPI00299048 IQGAP2 
Ras GTPase-activating like 
protein 2 
ET/Control: 1.8  
ET/PV: 1.9 
ET/C: 0.0019 
ET/PV: 0.003 
Table I-2. Overexpressed proteins of the RAS family of GTPases.  
 
2-IQGAP1 is overexpressed in MPN patients according to their JAK2 
status 
 
In a first time, in order to verify mass spectrometry results, we tried to confirm 
LC/MS-MS data by western blotting of RABGGTA and RABEP-1 but we failed to confirm 
deregulation of these two proteins in MPN samples. However, according to IPA analysis, 
Rho GTPase pathways were the most disturbed among this big family so we chose to dig 
deeply on the overexpression of IQGAP1 due to its role as a scaffold protein among this 
subfamily. 
We first performed western blot analysis of IQGAP1 expression in red blood cells of 
samples previously cryoconserved (the retrospective set) and, in a second time, to avoid bias 
potentially induced by cryoconservation we analyzed, as described in material and methods, 
fresh red blood cells from a new independent set of patients (the prospective and control 
sets). As shown in Figure I-2, IQGAP1 was expressed in almost all MPN patients at 
different levels in PV and ET patients without obvious variations between PV and ET. 
IQGAP1 was also found in globally all controls. In order to compare IQGAP1 expression 
between MPN patients and controls, IQGAP1/β-actin ratios were used to normalize IQGAP1 
concentrations. Using student’s t test, we confirmed that IQGAP1/β-actin ratios were 
significantly higher in MPN patients compared with controls. IQGAP1/β-actin mean ratio of 
all ET and PV patients (from both retrospective and prospective sets) was significantly 
higher compared with controls (p-value<0.01) (Figure I-3A and Supplemental Data I-3A). 
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When considering separately PV and ET, we didn’t find significant differences between 
them but we remarked that IQGAP1 was also overexpressed in PV and ET patients 
compared with controls (respectively PV vs control set, p<0.01 and ET vs control set, 
p<0.05). 
 
 
 
 
Figure I-2. IQGAP1 expression in retrospective, prospective and control samples. Samples 
were submitted to nanoparticle incubation followed by WB. B-actin acts as loading control and KG1 
acts as positive control. Molecular weights of target proteins: IQGAP1 189kDa, β-actin 42 kDa. 
Patients: A) Retrospective set: PV1, PV2, PV3, PV4, PV5, PV6 and ET1, ET2, ET3, ET5, ET6 and 
ET7. B) Prospective set: JAK2(+): PV8, PV9, PV10, PV11, PV12, PV13, PV14, ET9, ET10, ET12, 
ET13 and PMF1. JAK2(-): ET8, ET11, ET14 and PV15. C) Control set: C1, C2, C3, C4, C5, C6, C7, 
C8, C9, and C10. 
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Figure I-3. A) Comparison of IQGAP1/β-actin ratio means according to different sets of 
patients. IQGAP1/β-actin ratio means are represented by bars with their respective standard 
deviations denoted by error bars. Comparative analysis is made by student’s t test; (*p<0.05, ** 
p<0.01, ***p<0.005). B) Comparison of IQGAP1/β-actin rate means according to patients’ genotype. 
IQGAP1/β-actin ratio means are represented by bars with their respective standard deviations 
denoted by error bars. Comparative analysis is made by student’s t test; (* p<0.05, **p<0.01, **** 
p<0.0001). Patients: JAK2(+): Retrospective set: PV1, PV2, PV3, PV4, PV5, PV6 and ET1, ET2, ET3, 
ET5, ET6 and ET7. Prospective set: PV8, PV9, PV10, PV11, PV12, PV13, PV14, ET9, ET10, ET12 
and ET13. JAK2(-): Prospective set: ET8, ET11, ET14 and PV15. Control set: C1, C2, C3, C4, C5, C6, 
C7, C8, C9, and C10. 
 
 
Furthermore, we looked at IQGAP1 expression according to patient’s genotype. MPN 
patients were regrouped as: JAK2(+) and JAK2(-) and differences of IQGAP1 levels were 
evaluated by student’s t test on IQGAP1/β-actin ratios. Figure I-3B showed that there were 
significant differences in IQGAP1 expression between JAK2(+) and control patients (p<0.01) 
as well as between JAK2(-) and control patients (p=0.0001). We highlighted that JAK2(-) 
patients expressed significantly higher levels of IQGAP1 than JAK2(+) ones (p<0.05). 
(Figure I-3B and Supplemental Data I-3B). 
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3-IQGAP1 interacts selectively with Rho GTPase proteins in MPN RBCs  
 
IQGAP1 is a scaffold protein known to interact with small GTPase proteins of the Rho 
family of GTPases. (131-138). Therefore, we checked if these interactions took place in red 
blood cells from MPNs. To this end, we immunoprecipitated RBC lysates of MPNs with 
IQGAP1 followed by western blotting using antibodies against Rac1, Cdc42, RhoA and 
RhoGDI, an inhibitor that binds Rho family GTPases.  
Figure I-4 shows that IQGAP1 could form a complex with Rac1, Cdc42 and RhoA but 
not with RhoGDI in most of MPN samples independently of ET and PV diagnosis. In 
controls, immunoprecipitation assays showed that IQGAP1 was also able to co-precipitate 
with Rac1, Cdc42 and RhoA suggesting that IQGAP1 interaction with small Rho GTPase 
proteins is a functional pathway in normal erythrocytes.  
 
 
Figure I-4. IQGAP1 binding proteins in retrospective and prospective sets. RBC lysates were 
immunoprecipitated with IQGAP1 followed by WBs processed by Rac1 (A), Cdc42 (B), RhoA (C) or 
RhoGDI (D) antibodies. Molecular weights of targeted proteins: Rac1 21 kDa, Cdc42 21 kDa, RhoA 
22 kDa, RhoGDI 23 kDa. Patients: Retrospective set: PV4, PV6, PV7, ET4, ET5 and ET6. Prospective 
set: JAK2(+): PV9, PV11, PV13, PV14, PV8, ET10, ET12 and ET13. JAK2(-): ET8, ET11, ET14 and 
PV15. Control set: C1, C2, C3, C4, C5, C6, C7, C8, C9, and C10.  
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When interacting with Rho GTPase proteins, IQGAP1 is known to prevent their 
inactivation (133), thus we verified the activated state of Rho GTPase proteins in our RBC 
lysates. To this end, we pulled-down RBC lysates from a small subset of ET and PV patients 
(n=2) with GST-Rhotekin-RBD and GST-PAK-PBD agarose beads so as to detect activated 
RhoA (GTP-RhoA) and activated proteins Rac1 and Cdc42 respectively. As shown in Figure 
I-5A, Rac1 is activated in both MPNs (ET and PV) but neither RhoA nor Cdc42. As these 
results suggested a particular link between IQGAP1 and activated Rac1, we used the 
recombinant protein Rac1Q61L-GST, which is constitutively activated, coupled to Sepharose 
beads to pull-down proteins that bind activated Rac1 protein (GTP-Rac1). This test 
corroborated IQGAP1/GTP-Rac1 bond as IQGAP1 precipitated with Rac1Q61L-GST in PV, 
ET and control samples (Figure I-5B). 
 
 
 
Figure I-5. Pull-down assays of activated proteins of the Rho family. A) Ras activated 
proteins. RBC lysates were immunoprecipitated with GST-PAK-PBD (Rac and Cdc42) or GST-
Rhotekin-RBD (RhoA) agarose beads and eluted by Laemmli buffer. WBs were developed with Rac1, 
Cdc42 and RhoA antibodies. i) Rac1 is activated in ET and PV samples. ii) Cdc42 is not activated. 
iii) Samples are negative for activated RhoA. RhoA was used as positive control. Molecular weights 
of targeted proteins: Rac1 21 kDa, Cdc42 21 kDa, RhoA 22 kDa. B) GTP-Rac1 complexes. Rac1Q61L-
GST coupled to Sepharose beads was used to precipitate proteins that bind GTP-Rac1. IQGAP1 was 
detected in all patients after Rac1Q61L-GST precipitation. Molecular weight of IQGAP1: 189 kDa. 
Patients: Retrospective set: PV2, PV6, ET2 and ET4. Prospective set: JAK2(+): ET9 and ET10. 
Control set: C7 and C8. 
 
 
P21-activated kinase 1 (PAK1) has been described as a Rac1 effector and it is 
upregulated in some cancers (139, 140). Hence, we were interested in studying its 
connection with Rac1 in MPNs. First, RBC lysates were incubated with fluidMAG-Q 
followed by western blotting so as to check PAK1 presence in erythrocytes. As seen in 
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Figure I-6A, PAK1 was detected in all MPN samples. Then, we treated RBC lysates with 
Rac1Q61L-GST Sepharose beads. Rac1Q61L-GST-Sepharose-bead blots showed that both 
PAK1 and phosphorylated-PAK1 bound GTP-Rac1 (Figure I-6B). Moreover, we showed that 
both Rac1 and IQGAP1 co-precipitated with PAK1 when using PAK1 antibody to 
immunoprecipitate RBC proteins (Figure I-6C). Therefore, these data demonstrated the 
presence of P-PAK1-Rac1 and PAK1-IQGAP1 complexes in MPN RBCs. 
 
 
Figure I-6. A) PAK1 expression in MPN patients. RBC lysates were submitted to nanoparticle 
incubation followed by WB assays. Patients: MPN JAK2(+): 12-27; JAK2(-): 4-11, Calreticulin+ 4-6.  
KG1 acts as positive control. Molecular weights of target proteins: PAK1 60 kDa. B) GTP-Rac1 
complexes with PAK1 and P-PAK1. Rac1Q61L-GST coupled to Sepharose beads was used to 
precipitate proteins in RBC lysates. It was followed by western blotting developed by PAK1 and 
Phosphorylated PAK1 (P-PAK1). C) PAK1 immunoprecipitations. RBC lysates were 
immunoprecipitated with PAK1 and labeled by IQGAP1 or Rac1 antibodies. Patients: Prospective set: 
JAK2(+): PV9 and PV14; JAK2(-): ET8 and ET11. Calreticulin+ set: Calr4, Calr5 and Calr6. 
Molecular weights of targeted proteins: PAK1 and P-PAK1: ~60 kDa, IQGAP1 189 kDa, Rac1 21 kDa. 
K562 and KG1 cells were used as positive controls. 
 
 
4-Calreticulin but not JAK2 protein is expressed by MPN RBCs 
 
Recently, CALR mutations have been discovered in ET and PMF patients, (32, 33) and 
calreticulin (CALR) protein has been shown to be expressed in granulocytes (32, 141). 
However, any data exists about CALR expression in MPN red blood cells. In this context, we 
took advantage of our quantitative MS analysis of erythrocyte proteome to explore CALR 
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expression in our samples. We thereby found that CALR was effectively present in red blood 
cells without any significant differences in concentrations between controls, PV and ET 
patients according to MS results, (PV vs Controls, p=0.89; ET vs controls, p=0.65; PV vs ET, 
p=0.53). To confirm these data, we performed western blot assays in controls and MPN 
patients including CALR mutated (all ET patients, n=6) and CALR non mutated ones, (16 
MPNs and 10 controls). These latter ones were PV and ET patients either JAK2V617F 
positive or JAK2 wild type. Figure I-7A showed that CALR could be detected in almost all 
MPN patients independently of the presence or not of CALR mutation. CALR(+) patients 
seemed to express the highest levels of CALR protein but we could not see any double band 
in western blots, which theoretically appear in calreticulin-mutated samples and denote 
calreticulin insertions or deletions. JAK2 positive and JAK2 WT patients seemed to harbor 
the same profile of CALR expression. Finally, we found that control patients also expressed 
CALR protein (Figure I-7B). 
 
To quantify and compare Calreticulin expression, we used β-actin to normalize 
Calreticulin concentrations and, in similarity with IQGAP1 blots, Calreticulin/β-actin ratios 
were calculated between different subsets of patients. As shown in Supplemental Data I-4, 
Calreticulin expression was not found to differ significantly between MPNs and controls 
(p=0.8). Among MPNs, we did not observe significant differences between JAK2(+) and 
JAK2(-) patients (p=0.35), nor between JAK2(+) or JAK2(-) and CALR(+) (p=0.81 and 
p=0.08) respectively. Our only finding was that Calreticulin expression differed almost 
significantly in ET patients between CALR(+) and CALR(-) (p=0.0560).  
As JAK2 is one of the most important proteins implicated in unregulated cell 
proliferation in MPNs, we also verified its presence in RBC lysates but MS results didn’t 
present any data for JAK2 expression which was confirmed by JAK2 western blots of RBC 
lysates (Figure I-7C).  
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Figure I-7. Calreticulin expression in MPN and control patients. A) MPN samples. B) Control 
set of patients. B-actin acts as loading control. Molecular weights of target proteins: Calreticulin 48 
kDa, β-actin 42 kDa. Patients: Prospective set: JAK2(+): PV8, PV9, PV10, PV11, PV12, PV13, PV14, 
ET9, ET10, ET12, ET13 and PMF1. JAK2(-): ET8, ET11, ET14 and PV15. Calreticulin + set: Calr1, 
Calr2, Calr3, Calr4, Calr5 and Calr6. C) JAK2 expression in MPN patients. B-actin acts as loading 
control. Molecular weights of target proteins: JAK2 130 kDa, β-actin 42 kDa. Patients: Prospective 
set: JAK2(+): PV9, PV11, PV13, PV14 and ET13. JAK2(-): ET8, ET11, ET14 and PV15. Calreticulin + 
set: Calr1, Calr2, Calr3, Calr4 and Calr6. 
 
 
5-CALR mutated patients displayed distinct IQGAP1/Rho GTPase 
protein interactions compared with JAK2V617F ones 
 
Since the study of IQGAP1 expression showed different levels of expression according 
to the presence of the JAK2V617F mutation, we carried out an investigation of IQGAP1 
expression in CALR mutated patients by western blotting. As shown in Figure I-8, IQGAP1 
signals showed a heterogeneous pattern and they were quite low in CALR mutated patients, 
similar to what was observed in controls. Indeed, there were no significant differences of 
IQGAP1/β-actin ratio between CALR(+) and control patients (p=0.523) but there were 
between CALR(+) vs JAK2(+) (p<0.05) and CALR(+) vs JAK2(-) (p=0.001).  
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Figure I-8. IQGAP1 expression in CALR(+) samples. A) Samples were submitted to 
nanoparticle incubation followed by WB. B-actin acts as loading control and KG1 cell lysate acts as 
positive control. Molecular weights of target proteins: IQGAP1 189kDa, β-actin 42 kDa. B) 
IQGAP1/β-actin ratio means are represented by bars with their respective standard deviations. 
Student’s t tests (*p<0.05, ** p<0.01, ***p<0.005, ****p<0.001). Patients: JAK2(+): Retrospective set: 
PV1, PV2, PV3, PV4, PV5, PV6 and ET1, ET2, ET3, ET5, ET6 and ET7. Prospective set: PV8, PV9, 
PV10, PV11, PV12, PV13, PV14, ET9, ET10, ET12, ET13. JAK2(-): Prospective set: ET8, ET11, ET14 
and PV15. Calreticulin+ set: Calr1, Calr2, Calr3, Calr4, Calr5 and Calr6. Control set: C1, C2, C3, C4, 
C5, C6, C7, C8, C9, and C10. 
 
 
Then, we looked at potential links between IQGAP1 and CALR in RBCs by 
immunoprecipitation assays. Apparently, as shown in Figure I-9B, calreticulin mutated 
protein did not seem to be a partner of IQGAP1 since over 6 CALR(+) tested patients, only 
one showed a co-precipitation of CALR protein with IQGAP1. Similarly, in non-mutated 
CALR patients, we did not highlight any interaction (either direct or indirect) of both 
proteins (Figure I-9A). Interestingly, in control patients, CALR protein clearly co-precipated 
with IQGAP1 (Figure I-9C), suggesting that in non MPN subjects, CALR and IQGAP1 
proteins could interact with each other.  
Immunoprecipitation assays in CALR mutated patients between IQGAP1 and Rho 
GTPases showed that IQGAP1 gathered RhoA and Cdc42 in some patients but oddly no 
complexes were detected between IQGAP1 and Rac1 unlike what was observed in 
JAK2V617F patients (Figures I-10B to I-10D). We also found that Rac1 was not in an 
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activated state in CALR(+) samples (Figure I-10A). One other major observation was that in 
all CALR mutated samples, the Rho family inhibitory protein RhoGDI co-precipitated with 
IQGAP1 conversely to what was observed in all MPN patients without CALR mutation 
(Figure I-10E). 
 
 
Figure I-9. IQGAP1-Calreticulin relationship. RBC lysates were immunoprecipitated with 
IQGAP1 followed by WB revealed by Calreticulin antibodies. A) JAK2(+) patients. B) Calreticulin 
mutated samples. C) Control set. Patients: Prospective set: JAK2(+):PV11, PV13, PV14 and ET13; 
Calreticulin+ set: Calr1, Calr2, Calr3, Calr4, Calr5 and Calr6; Control set: C4, C7, C8. KG1 and K562 
were used as positive controls. 
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Figure I-10. Rho GTPase protein recruitment profile in JAK2(+)/CALR(+) patients. A) RBC 
lysates were pulled-down with GST-PAK-RBD agarose beads and developed by Rac1 antibody. B to 
E) RBC lysates were immunoprecipitated with IQGAP1, eluted by Laemmli buffer and followed by 
WBs developed by Rac1, Cdc42, RhoA or RhoGDI antibodies. Patients: Retrospective set: PV4, PV6, 
PV7, ET4, ET5 and ET6. Prospective set: JAK2(+): PV8, PV11, PV13, PV14, ET10 and ET13. JAK2(-
): ET8, ET11, ET14 and PV15. Calreticulin + set: Calr1, Calr2, Calr3, Calr4, Calr5 and Calr6. 
Molecular weights of targeted proteins: Rac1 21 kDa, Cdc42 21 kDa, RhoA 22 kDa, RhoGDI 23 kDa.  
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DISCUSSION 
 
This work aimed to characterize the RBC proteome of PV and ET compared with 
controls by an integrative proteomic approach using quantitative mass spectrometry 
analysis coupled to functional study of pathways targeted by protein deregulations. Indeed, 
functional alterations of blood cells play an important role in the pathogenesis of these 
diseases. However, the erythrocyte proteome has not yet been deeply studied in MPNs. 
 
We firstly found that RBCs of MPN patients expressed more than 1000 proteins and 
displayed significant deregulations of many protein levels. Consequently, several functional 
pathways were affected by these alterations. In particular, we underlined a deregulation of 
several members of the RAS superfamily of GTPases in RBCs suggesting that those 
pathways could play a significant role in MPN pathogenesis. The RAS GTPases constitute a 
big family composed by over 150 human proteins divided in 5 subfamilies: Ras, Rho, Rab, 
Ran and Arf (142) (Figure I-11). These members are capable of switching between an 
activated state when bound to GTP and an inactivated state when bound to GDP. These 
switches are regulated, on the one hand, by Guanine-Nucleotide-Exchange-Factors (GEFs) 
that promote the formation of the GTP form and then activate these proteins. On the other 
hand, GTPase-activating proteins (GAPs) promote the intrinsic GTPase activity of these 
proteins to convert bound GTP into GDP determining the GDP inactive form (143) (Figure I-
12).  
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Figure I-11: The RAS superfamily of GTPases. It comprises 153 human protein members and 
is subdivided in 5 subfamilies: Ras, Rho, Rab, Ran and Arf. Their principal functions are signaled on 
the figure. 
 
 
 
Figure I-12: RAS activation and inactivation. The switch between the inactive form (GDP 
linked) to the active form (GTP linked) is promoted by GEFs and the switch to the inactive form by 
GAPs. 
 
CHAPTER I - Ph-negative MPN red blood cells display deregulation of IQGAP1-Rho 
GTPase signaling depending on CALR/JAK2 status 
78 
 
RAS subfamilies  
 The Ras subfamily (142, 143) 
The Ras proteins or Ras sarcoma oncoproteins are involved in multiple processes 
including control gene expression and regulation of cell growth, differentiation and 
survival. Some of their principal effector pathways are the Raf/MEK/ERK pathway 
and the PI3K which are also activated by JAK2V617F (15). 
 
 The Rho subfamily (142) 
The Ras homologous (Rho) proteins regulate actin cytoskeleton remodeling, cellular 
movement, cell cycle progression and gene expression. Among the principal members 
we find RhoA, Rac1 and Cdc42. These two last ones are direct effectors of IQGAP1. 
Cdc42 binding to IQGAP1 has been implicated in modulation of cell architecture, 
exocytosis and cell growth (144). 
 
 The Rab subfamily (142) 
The Ras-like proteins in brain (Rab) are regulators of vesicular and membrane 
trafficking. They ease vesicle formation and budding from the donor compartment, 
transport, vesicle fusion and release of vesicle content. They are specifically localized 
in relation to their function. This localization depends on their grade of prenylation 
which is facilitated by RABGGTA. 
 
 The Ran subfamily (142) 
The Ras-like nuclear family (Ran) principally controls nucleocytoplasmic transport. 
 
 The Arf subfamily (142) 
The ADP-ribosylation factor (Arf) family regulates vesicular transport in endocytic 
and exocytic pathways, intracellular trafficking and actin remodeling. 
 
The Rab geranylgeranyltransferase alpha subunit – RABGGTA, the Rab GTPase-
binding effector protein 1 or Rabaptin-4 or Rabaptin-5 or Rabaptin-5alpha – RABEP1 and 
the Rho GTPase-activating-like protein IQGAP1 were the three potential candidates as 
MPN RBC biomarkers. 
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RABGGTA, which is absent in control samples, is a protein in charge of Rab protein 
prenylation that is needed for their function as it provides some hydrophobicity to Rab 
molecules to improve their insertion to membranes (145, 146). To accomplish this function, 
it makes a complex with Rab escort protein (REP). Pereira-Leal et al. (147) suggested that 
mutations in this gene and thus diminution of Rab proteins prenylation resulted in the 
Hermansky-Pudlak syndrome (HPS) with immunodeficiency and hypopigmentation. Detter 
et al. (148) have also discovered a mutation in RABGGTA gene which reduced its activity an 
80%; and resulted in gunmetal mice characterized by prolonged bleeding, thrombocytopenia 
and reduced platelet α- and δ- granule contents. These mice also presented 
hypopigmentation and altered platelet biogenesis (149). Therefore, gunmetal mouse models 
are considered a model for HPS characterized by albinism, bleeding and platelet 
deregulations (150). 
 
The protein Rabep1 which is the Rab GTPase-binding effector protein 1 also knew as 
Rabaptin-4 or Rabaptin-5 or Rabaptin-5-alpha is part of the Rab subfamily of GTPases 
which are involved in vesicular and membrane trafficking. Rabep1 interacts with the active 
form of Rab5 (GTP-linked), which is a small GTPase implicated in membrane docking or 
fusion of vesicles and early endosomes (151). This union stabilizes Rab5 in a GTP-bound 
(active) form by down-regulating GTP hydrolysis (152). Successive studies discovered that 
Rabex-5, a Rab5 nucleotide exchange factor is also implicated in this complex of Rab5 
activation. The association of Rabep1 to Rabex-5 stimulated GEF activity of Rabex-5 what 
increases Rabep1-Rabex-5 and Rab5 complex formation (153). 
 
Among these three proteins, IQGAP1 was chosen due to its role as a scaffold protein 
among the subfamily of Rho GTPases. Western blot analysis of IQGAP1 expression 
confirmed in two independent sets of patients that IQGAP1 was upregulated in both PV and 
ET compared with controls. In laboratory experiences, Wang et al. (144) showed that when 
in western blots IQGAP1 signal presents a double band; the upper one corresponds to 
phosphorylated IQGAP1 and thus, to the active form. Unexpectedly, in our experiences, 
almost all normal patients had double band, whereas just some MPN patients presented 
this double band. The double band appeared in Calreticulin mutated patients as well. 
Further investigations about its activation and phosphorylation should be done. 
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IQGAP1 belongs to the IQGAPs family besides IQGAP2 and IQGAP3. They regulate 
diverse processes such as cytokinesis, cell migration, vesicle trafficking and cytoskeletal 
dynamics. IQGAP1 is formed by several domains (Figure I-13): the calponin homology 
domain (CHD); IQGAP repeats; polyproline binding region (WW); IQ domain containing 
four IQ motifs; Ras GTPase-activating protein-related domain (GRD) and RasGAP C-
terminus (RGCT) (154). Even though IQGAP1 presents a domain similar to GTPase 
activating proteins (GAPs), IQGAPs don’t own any GAP activity. On the contrary, they are 
capable to bind GTP-bound Ras-like proteins of the Rho subfamily and keep them in their 
activated state (131). IQGAP1 is generally regulated by the calcium-binding protein 
calmodulin via the IQ motifs (154). This binding brings a conformational alteration that 
inhibits the binding of other targets to IQGAP1. It is also documented that Ca2+ regulation 
via calmodulin alters the subcellular localization of IQGAP1 influencing its functions (131, 
155). Interestingly, our mass spectrometry results showed that calmodulin is under-
expressed in ET samples comparing with controls (See Supplemental Data I-1); that could 
explain one part of IQGAP1 upregulation. It can also be regulated via phosphorylation. 
Growth factor receptors including EGFR (Endothelial growth factor receptor) and VEGFR 
(vascular endothelial growth factor receptor), when activated, they can phosphorylate 
IQGAP1 thanks to their tyrosine kinase activity, or induce IQGAP1 phosphorylation at 
Ser1443 through protein kinase C. Furthermore, IQGAP1 is required for EGFR 
phosphorylation after EGF stimuli (154). IQGAP1 phosphorylation via EGF-EGFR-PKC 
activates Cdc42 which seems to promote cell division.  
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Figure I-13. IQGAP1 domains and its effector proteins. It shows the different domains of 
IQGAP1 and the principal molecules that bind each domain. CHD: calponin homology domain; WW: 
polyproline binding region; IQ motif: calmodulin binding repeat; GRD: RasGAP related domain; 
RGCT: RasGAP C terminus (154). 
 
 
One could hence hypothesize that deregulation of IQGAP1 in MPNs may be directly 
linked to JAK2V617F mutation. In favor, we showed that JAK2V617F patients had 
effectively greater ratios of IQGAP1 expression (expressed as IQGAP1/β-actin ratios) than 
controls. However, we also observed that JAK2 WT patients displayed greater levels of 
IQGAP1 compared with controls and with JAK2V617F ones. In fact, the highest levels of 
IQGAP1 were observed in JAK2 WT patients. One explanation of these unexpected results 
might be that the overexpression of IQGAP1 was not directly linked to the presence of 
JAK2V617F mutation but probably to JAK2 protein itself, either WT or mutated. 
Nevertheless, JAK2 expression falls down as hematopoietic cells differentiate (and is not 
expressed anymore in RBCs). Moreover, the Erythropoietin receptor (EpoR) is present on 
immature cells of the erythroid line from BFU-E cells (Burst-Forming Unit-Erythroid cells) 
to erythroblasts and it has already disappeared in reticulocytes, the previous maturation 
state to RBC (156, 157). As JAK2 is directly bound to the EpoR, the disappearance of the 
receptor should affect JAK2 protein as well. In fact, we confirmed this disappearance by our 
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mass spectrometry analysis and western blot results: erythrocytes of MPNs and controls 
were devoid of JAK2.  
 
Since its discovery in ET and PMF patients, many studies have been carried out to 
understand how CALR mutation is involved in MPN pathogenesis. However, up to now, no 
study was made either on CALR expression in red blood cells of MPN patients or on the 
relationship between CALR status and IQGAP1. We firstly found that unlike JAK2 protein, 
CALR protein is present in the erythrocytes of most MPN patients. Interestingly, we also 
showed that CALR is present in non MPN erythrocytes at similar levels as in MPN ones 
(expressed as CALR/β-actin ratios). These data suggest that CALR protein is constitutively 
expressed in red blood cells and that its expression is not significantly altered in MPNs. 
However, we highlighted another remarkable different behavior of IQGAP1 protein in 
MPNs compared with controls. As seen in our experiments, no complexes were formed 
between CALR and IQGAP1 in MPN patients (apart from one over ten), whatever their 
molecular status were including triple negative patients. Conversely, we observed in all 
controls tested, that these two proteins co-precipitated suggesting that in non-MPN patients 
this interaction between CALR and IQGAP1 could occur physiologically. The fact that 
CALR(-)IQGAP1 interaction is altered in both JAK2(+) and CALR(+) although IQGAP1 is 
overexpressed only in JAK2(+) but not in CALR(+) patients suggests that high levels of 
IQGAP1 in MPNs are not the cause (or the only cause) of this defect of interaction. 
Qualitative alteration of IQGAP1 might impede IQGAP1/CALR interaction in MPNs.  
Concerning IQGAP1 expression in mutated CALR patients, our results showed that 
there were significant differences between JAK2(+) and CALR(+) (p<0.05); JAK2(-) and 
CALR(+) (p<0.005) but not between controls and CALR(+) (p=0.523). In fact, CALR(+) 
patients displayed the same levels of IQGAP1 as controls. Taking into account the whole 
data about IQGAP1 expression according to JAK2 and CALR status, we showed that its 
levels were dependent on patient’s genotype (JAK2 WT / CALR WT>JAK2V617F>CALR(+)) 
but seemed not or only partially linked to these two main driver mutations. The fact that 
JAK2 WT/CALR WT patients are those harboring the highest levels of IQGAP1 argues for 
the impact of an unknown molecular event on its expression. 
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IQGAP1 is overexpressed in several cancers such as colorectal carcinoma, breast 
cancer, astrocytoma and squamous cell carcinoma of head and neck (136). This upregulation 
may have consequences in effector pathways such as the MAPK/ERK kinases that are 
related to apoptosis, cell proliferation, survival, invasion and metastasis (136, 154, 158-160). 
Furthermore, previous studies have shown that IQGAP1 could bind the active form of 
Cdc42 and Rac1 (131-138). A whole review of all IQGAP1 interacting proteins is done by 
White et al. 2012 (154). Thereby IQGAP1/Cdc42 complex could promote mechanisms 
implicated in tumorigenesis such as cytokinesis, cell proliferation and migration (144, 161). 
To evaluate this hypothesis, we investigated if IQGAP1 could form a complex with Cdc42 
and Rac1 in our MPN patients. Our data demonstrated that IQGAP1 could actually form a 
complex with Rac1, Cdc42 and also RhoA, which all belong to the Rho subfamily of RAS 
GTPases. That is in agreement with Jacquemet et al. (133) and Ory et al. (162), who had 
previously reported the existence of IQGAP1-RhoA complex in tumor cells. We also disclosed 
that only Rac1 was present in its activated state in MPN samples but that both Cdc42 and 
RhoA weren’t activated, at least to a detectable level by our protocol. Our data also showed 
that IQGAP1 did not interact with the Rho inhibitory protein RhoGDI which could explain 
the fact that Rac1 was in an activated state in its complex with IQGAP1.  
 
To decipher the consequence of this IQGAP1/Rac1 interaction, we also investigated the 
p-21-activated kinase 1 (PAK1). PAK1 belongs to group I of PAK family and it is related to 
the Rho family of GTPases (139, 140). It can be activated by binding to activated GTPases 
such as Cdc42 and Rac1 which promote autophosphorylation and activation of PAK1 and 
release its autoinhibitory conformation (139, 163-165). Our experiments confirmed the 
interaction of Rac1 with PAK1 and they also showed that PAK1 bound IQGAP1, a 
connection that had already been described by Malarkannan et al. (166). This fact argued 
for a direct recruitment of PAK1 in the IQGAP1/Rac1 complex through its interaction with 
activated Rac1 in red blood cells. Indeed, in Rac1Q61L-GST-Sepharose-bead pull-down 
assays, both PAK1 and phosphorylated-PAK1 bound GTP-Rac1. Moreover, DerMardirossian 
et al. (167) found that the Rho GTPase dissociation inhibitor RhoGDI, which forms an 
inhibitory complex with Rac1, RhoA and Cdc42 (168), can be phosphorylated by PAK1 
resulting in dissociation of Rac1-RhoGDI complex and allowing Rac1 activation. 
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These data demonstrated, for the first time, to our knowledge, that in MPN red blood 
cells, IQGAP1 is able to recruit Rac1 and PAK1. The fact that IQGAP1 is overexpressed in 
most MPN patients provides a new molecular mechanism potentially implicated in MPN 
pathogenesis through an abnormal recruitment and activation of Rac1 and PAK1. Rho 
GTPases and in particular Rac1 are crucial for normal hematopoiesis. More precisely, Rac 
(and Cdc42) are necessary for hematopoietic stem and progenitor cell survival and 
proliferation and are also required for self-renewal and for cell cycle entry of quiescent (G0) 
(169). Rac1 is also a regulator of ROS production which has been shown to play a particular 
role in MPN signaling. Indeed, the presence of 8-oxo-guanines and DNA double-strand-
breaks that denote DNA oxidative damage, were reported as consequence of increased ROS 
production in PV and PMF CD34+ cells and Ba/F3-EpoR-JAK2V617F cells by Marty et al. 
(170). Moreover, they also showed that PI3K/Akt activation via JAK2V617F negatively 
regulated the Forkhead Box-O (FoxO3) transcription factor (an oxidative stress regulator) 
leading to a reduced expression of anti-oxidant enzymes in bone marrow cells of knock-in 
mice, that could cause a myeloproliferative syndrome in Foxo3-/- mice sensitive to the ROS 
scavenger N-acetyl-cysteine (171). 
Taking into account that red blood cells represent the terminal maturation stage of 
erythroid progenitors, their functional alterations are very probably evidence of genetic 
deregulations occurring in erythroid progenitors. Hence, our results about Rac1 
deregulation in red blood cells provide new original data about the mechanism of the 
oncogenic potential of Rac1 in MPNs that could occur through the imbalance of RhoA 
signaling associated with IQGAP1 disturbance. The fact that Rac1 is necessary for 
enucleation of erythroblasts (169), also suggest that abnormalities of red blood cell 
maturation could occur in MPNs.  
The p-21-activated kinases are a family of serine/threonine protein kinases which are 
part of several signaling pathways such as gene transcription or apoptosis important in 
oncogenesis. In fact, PAK1 upregulation has already been described in some cancers (139, 
140). PAK1 is also implicated in cell morphology and membrane cell motility. Similarly, Rho 
GTPases are important for actin organization and polymerization. Furthermore, Focal 
Adhesion Kinase (FAK) Pathways, which are activated by RhoA, also appeared deregulated 
in ET vs Controls (Table I-1). Altogether, these results suggest that disruption of the Rho 
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GTPases and PAK1 in red blood cells could lead to the alteration of membrane motility and 
adhesion which might participate to vascular complications frequently observed in MPNs. 
 
However, we showed that IQGAP1 was not overexpressed in CALR(+) patients 
suggesting that IQGAP1 could impact MPN pathogenesis through different molecular 
mechanisms depending on the driver mutation. Indeed, when exploring IQGAP1-Rho 
GTPases relationship in CALR mutated patients, we showed different results than the ones 
obtained in CARL(-)/JAK2V617F MPNs. Firstly, in CALR(+) patients, we showed that 
IQGAP1 immunoprecipitated with RhoGDI. The fact that RhoGDI formed a complex with 
IQGAP1 was not unexpected since Liu et al. (172) had already suggested that this Rho 
GTPase inhibitor could bind IQGAP1 thanks to its FERM domain. However, they couldn’t 
prove that these two proteins interact directly in mouse kidney cell lysates. We also 
hypothesized that there could be a link between mutated calreticulin and RhoGDI but these 
two proteins didn’t co-immunoprecipitate in calreticulin set. Moreover, we did not find any 
activated Rho protein in CALR(+) patients (Supplemental Data I-5) and CALR failed to bind 
activated Rac1 as well. The fact that when we added activated Rac1 to CALR(+) samples, 
GTP-Rac1 could pull-down IQGAP1 (Supplemental Data I-6) but that both proteins didn’t 
co-precipitate with IQGAP1 antibodies, could imply that Rac1 couldn’t bind IQGAP1 
because it was in a deactivated state in CALR(+) samples. This hypothesis was reinforced 
by the demonstrated interaction between IQGAP1 and RhoGDI in CALR(+) patients 
different from JAK2(+) ones. This fact strongly suggested that alternative recruitment of 
RhoGDI could explain differences in Rac1 activation between JAK2(+) and CALR(+) 
patients. We therefore supposed that in CALR mutated patients, although IQGAP1 was not 
overexpressed, it could recruit RhoGDI and that this complex may interfere with the 
activation of Rho GTPases. The link between CALR mutation and the recruitment of 
RhoGDI by IQGAP1 remains to be investigated. 
 
Taking all results together, we noticed that some remarkable differences arose 
between CALR mutated and JAK2V617F patients. In consequence, we grouped some results 
depending on the molecular status JAK2(+) or CALR(+) (Figure I-10). As IQGAP1/β-actin 
rate comparison indicated, IQGAP1 is overexpressed in JAK2(+) patients compared with 
calreticulin mutated ones (p<0.05). It is also outstanding that no difference in IQGAP1 
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expression was found between CALR(+) and normal patients (p>0.05). Thus, we can 
conclude that IQGAP1 is overexpressed in JAK2(+) MPNs but not in CALR(+) ones. 
Regarding IQGAP1 effectors, Rac1, Cdc42 and RhoA bound IQGAP1 in JAK2(+) patients 
but RhoGDI didn’t. On the contrary, in CALR(+) samples, IQGAP1 didn’t co-
immunoprecipitate with activated Rac1 but it did with RhoGDI. Moreover, Rac1 was 
activated in JAK2(+) subjects but not in CALR(+) ones. 
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CONCLUSION AND PERSPECTIVES 
 
In conclusion, our results demonstrated a deregulation of the Rho family of GTPases, 
specifically alterations of IQGAP1/Rac1 signaling in red blood cells of MPNs depending on 
JAK2 and CALR status. JAK2V617F patients displayed an up regulation of IQGAP1 that 
consequently recruited and activated Rac1 and the cytoskeleton motility protein PAK1. In 
CALR(+) patients, IQGAP1 was not overexpressed but it recruited RhoGDI which 
consequently impeded the activation of Rac1 and PAK1. These alterations may participate 
in vascular complications via alterations of erythrocyte adhesion due to deregulation of 
PAK1 activation or Rac1 dependent actin organization. The differential activation of 
IQGAP1/Rac1/PAK1 observed between JAK2(+) and CALR(+) patients could explain 
differences in vascular complications observed among these subgroups. These data 
demonstrate that, IQGAP1/Rac1/PAK1 signaling is implicated in MPN red blood cell 
pathogenesis and should be considered as a target for therapy. 
 
These results also stress out two issues: 
1-Does a link between JAK2 and IQGAP1 exist? 
According to JAK2 connection with IQGAP1 we couldn’t look into it as JAK2 was not 
present in our RBC lysates. As previously said, IQGAP1 could be phosphorylated via 
activation of EGFR either thank to its tyrosine kinase activity or via PKC at Ser1443 (154). 
Yamauchi et al. (173) reported that JAK2 phosphorylates EGFR activating it. As a result, 
the MAPK pathway is activated. Moreover, Brown et al. (131) also reported the activation of 
MAPK/ERK pathway by IQGAP1 as a consequence of EGFR activation. We could therefore 
hypothesized that JAK2V617F could indirectly phosphorylate IQGAP1 activating it and the 
effector pathways including MAPK pathway via JAK2 V617F dependent phosphorylation of 
EGFR. 
2-Is there any link between JAK2 and IQGAP1/Rho GTPase signaling? 
Once seen the different recruitment of the Rho GTPases by IQGAP1 depending on the 
molecular status either JAK2(+) or CALR(+), we wonder what role JAK2V617F plays on the 
control of IQGAP1/Rho GTPase signaling. It would also be interesting to decipher if there 
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are any differences between JAK2(+) and JAK2(-) on this pathway and which mechanisms 
are the responsible for IQGAP1/Rho GTPase signaling activation in MPNs. 
 
Altogether, our results and these issues suggest a new theoretical model of Rho 
GTPase signaling alterations in MPN erythrocytes (Figure I-14). 
 
 
 
 
Figure I-14. IQGAP1/Rho GTPase signaling alterations in MPN erythrocytes.  
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RESUME DU CHAPITRE I 
 
Dans cette première partie, nous avons sélectionné et validé une technique pour la 
déplétion indirecte d‘hémoglobine basée sur la capture de protéines par des nanobilles 
magnétiques présentant de surfaces chimiques particulières (126). Cette déplétion a été 
utilisée pour une analyse quantitative et qualitative par LC-MS/MS (LTQ Orbitrap) du 
protéome érythrocytaire de patients SMP. Cette étude a montré des dérégulations de la 
famille des Rho GTPases qui étaient significativement plus fortement exprimées chez les 
patients PV et TE. Plus particulièrement, la protéine IQGAP1, (Ras GTPase-activating like 
protein IQGAP1), était surexprimée chez les sujets TE-JAK2V617F et PV-JAK2V617F par 
rapport aux contrôles. Nous avons pu confirmer par western blot cette surexpression 
d’IQGAP1 entre les sujets PV-TE et les contrôles (p<0.05), et en plus, que des différences 
existaient en fonction du statut moléculaire des patients (JAK2 ou CALR).  
 
Par la suite, nous avons approfondi la nature des interactions entre IQGAP1 et des 
protéines Rho GTPases en montrant qu’IQGAP1 pouvait coprécipiter avec certaines de ces 
protéines mais de façon différente selon le statut des patients (JAK2(+) / CALR(+)). Pour 
aller plus loin, nous avons aussi étudié la protéine PAK1 qui est un effecteur des Rho 
GTPases, et ainsi confirmé ses liens avec Rac1 activé et IQGAP1 dans les globules rouges 
des patients.  
 
En conclusion, nos travaux mettent à jour la présence de dérégulations protéiques 
dans les érythrocytes des patients PV et TE. Ces résultats mettent en évidence le rôle 
potentiel des protéines GTPases dans la physiopathologie des SMP et leurs implications 
potentielles dans les dérégulations fonctionnelles du GR. Les différences entre les patients 
JAK2 mutés et les patients CALR mutés renforcent l’hypothèse de dérégulations  protéiques 
induites par les anomalies moléculaires, qui pourraient expliquer les différences 
phénotypiques et cliniques observées entre les patients JAK2(+) et CALR(+). 
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BACKGROUND 
 
The study of the erythrocyte proteome in Ph- MPNs let us quantify more than 1000 
proteins and to highlight an important deregulation of the RAS GTPase family, more 
precisely, an upregulation of the Ras activated protein IQGAP1. We saw how the 
recruitment of the Rho GTPases by IQGAP1 varied according to patient’s genotype. 
Apart from erythrocyte deregulations, other protein disruptions have also been 
reported in other blood cells such as granulocytes in these hemopathies. For instance, Hui et 
al. (103), thanks to Protein Pathway Array, could screen 15 proteins in peripheral blood 
neutrophils differently expressed between ET and control patients implicated in apoptosis 
and inflammatory pathways. They also found differences in protein expression in cycle 
signaling pathways when comparing ET patients with and without JAK2V617F mutation 
suggesting that this mutation contributes to malignant proliferation and cell cycle 
progression. 
Falanga et al. (104) studied the involvement of neutrophils in PV and ET pathogenesis 
of thrombotic predisposition. They showed that neutrophils presented high levels of CD11b, 
which is a maker of neutrophil activation. These cells also presented high levels of leukocyte 
alkaline phosphatase which suggested the idea of neutrophil degranulation. This fact raises 
plasma concentrations of elastase and myeloperoxidase. Moreover, activated neutrophils 
can bind platelets, what originates the formation of platelet-leukocyte complexes which are 
thought to be the cause of pro-thrombotic condition. Arellano-Rodrigo et al. (105) also found 
that ET patients presented higher expression of CD11b in neutrophils but not in patients 
with thrombosis. CD11b expression was also associated with JAK2V617F presence. 
Nevertheless, they found that CD11b expression was increased in monocytes from 
thrombotic patients as well as the monocyte tissue factor which may be involved in blood 
coagulation. In general, CD11b expression promotes leukocyte adherence to the 
endothelium, phagocytosis, aggregation, adhesion-dependent respiratory burst and 
degranulation. 
Furthermore, Gallardo et al. (174) found three upregulated proteins in PV compared 
with ET patients (HSP70, LTA4H and SERPINB1) besides other 58 proteins through 2D-
DIGE and mass spectrometry analysis. Moreover, using an HSP70 inhibitor they could 
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show that this protein had a potential role in the JAK2(-)STAT signaling pathway in the 
erythroid lineage. 
With this background and to go further in the characterization of the MPN proteome, 
we performed a proteomic study of Ph- MPN granulocytes. In order to improve proteomic 
data, we performed a comparative quantitative proteomic analysis using iTRAQ labeling 
method. In parallel, a transcriptomic analysis was performed on each sample through 
collaboration with the Institute of Medical Research in Belgrade, (Serbia). In order to deep 
on the impact of JAK2V617F, we analyzed patients harboring different allele burdens, from 
0 (non-mutated patients) to more than 80% (high allele burden). Finally, this analysis would 
let us compare the granulocyte and erythrocyte proteomes in order to see if there are any 
common deregulations that could be linked to MPN pathogenesis. 
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MATERIAL AND METHODS 
Patients 
A total of 24 patients were used for this study. All patients agreed to be part of the 
study and signed the informed consent. Patients were grouped according to their diagnosis: 
6 patients were diagnosed as PV with JAK2V617F with high mutant allele burden over 88% 
(range 88-93%; mean 92%); 5 ET patients with JAK2V617F mutation (allele burden 
between 35 and 50%, mean 40.5%); 6 PMF patients with JAK2V617F mutation (allele 
burden between 38 and 94%, mean 63%) and 7 patients diagnosed as ET or PMF but with 
no JAK2V617F mutation, (group named Mut0). (Table II.1) 
 
No Diagnosis JAK2V617F allele burden 
6 PV [88-93%], mean 92% 
5 ET [35-50%], mean 40.5% 
6 PMF [38-94%], mean 63% 
7 ET/PMF Mut0 0% 
 
Table II.1. Patients’ features for the proteomic study of granulocytes. 
 
Sample Preparation 
Thirty milliliters of peripheral blood were collected in 10% sodium citrate tubes. The 
maximum time interval between venipuncture and arrival in the laboratory was 2 hours. 
Lymphocytes were separated adding on top 15 ml of lymphocyte separation medium (PAA 
Laboratories GmbH, Pasching, Austria). After centrifugation (400 g, 20 min, 20°C), the 
pellet, which is composed of erythrocytes and granulocytes that migrated through the 
gradient, was submitted to erythrocyte lysis with lysing solution (0.15 M NH4Cl, 0.1 mM 
Na2EDTA, 12 mM NaHCO3). High quality of purified granulocytes was confirmed by 
cytospin preparations and Wright–Giemsa staining. Viability was measured with trypan-
blue (BioWhittaker). Granulocytes were washed twice with PBS and resuspended in 10ml 
cold PBS with 2 mM EDTA and 1 mM Na-orthovanadat and centrifuged 10 min at 1,000 g. 
The cell pellet was dried by inversion over paper towel, vortexed and placed on ice. Then, 
granulocytes were lysed with cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-
40, 2 mM EDTA, 50 mM NaF) with protease inhibitors (1 mM phenylmethylsulfonyl 
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fluoride PMSF, 10 mM -aminocaproic acid, 2 g/ml aprotinin, 50 g/ml leupeptin, 1 M 
pepstatin A) and phosphatase inhibitors (1 mM Na-orthovanadat) for 30 minutes at 4ºC. 
Cell suspensions were centrifuged at 10,000 g for 15 min at 4oC. The supernatant was 
transfered in cold eppendorfs, mixed and aliquoted into precolded small eppendorfs and 
frozen at -70oC. 
 
iTRAQ Labeling 
Next, the same amount of protein was taken from each patient to form four groups 
(PV, ET, PMF and Mut0) containing 250 µg of protein each. Proteins were precipitated with 
acetone and digested according to Applied Biosystems digestion protocol for iTRAQ 
marking: protein pellets were suspended in triethylammonium bicarbonate buffer (TEAB) 
500 mM 0.1% SDS pH 8.5. Cysteines were reduced with TCEP (tris(2-
carboxyethyl)phosphineand), alkylated with MMTS (methyl methanethiosulfonate) and 
proteins were digested by trypsin overnight. Then, groups were splitted in two subgroups of 
100 µg and marqued during 2 hours by an specific iTRAQ marquer (113 and 117 for the 
group Mut0; 115 and 119 for PV; 116 and 121 for ET and 114 and 118 for PMF). Then, 
samples were combined together and desalted in Sep-Pak C18 Cartridges (Waters®). 
Prefractionation of peptides prior to LC-MS/MS was done thanks to the 3100 off-gel 
fractionator (24 wells). The resulted fractions were desalted using C18 micro spincolumns 
Harvard Apparatus®.  
 
Protein Identification 
For the LC-MS/MS analysis, about 200 ng of each fraction were injected. Peptides 
were separated thanks to nano LC-MS/MS (Ultimate 3000, Dionex®, Amsterdam, The 
Netherlands) coupled to LTQ Orbitrap Velos mass spectrometer (Thermo Scientific®, 
Bremen, Germany). The LTQ-Orbitrap operated with the Xcalibur software. Survey scans 
MS spectra were acquired in the Orbitrap on the 300-2000 m/z range with 60,000 as value 
resolution. The five most intense ions per survey were selected for collision-induced 
dissociation (CID) fragmentation to be analyzed in the linear trap (LTQ). Dynamic exclusion 
was used within 60 seconds to prevent repetitive selection of the same peptide. 
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For protein analysis, we selected Mascot Daemon software (version 2.3.0, Matrix 
Science, London, UK). The following parameters were set for creation of the peak lists: 
parent ions in the mass range 400–4500, no grouping of MS/MS scans and threshold at 
1000. A peak list was created for each analyzed sample and individual Mascot searches 
were performed. Protein identification was performed comparing data with homo sapiens 
entries in Uniprot protein database (http://www.uniprot.org/). Protein hits were 
automatically validated if they satisfied one of the following criteria: identification with at 
least one top ranking peptide with a Mascot score of more than 39 (p-value < 0.001) or at 
least two top ranking peptides each with a Mascot score of more than 22 (p-value < 0.05). 
When several proteins matched exactly the same set of peptides, only one member of the 
protein group was reported in the final list. To evaluate the false positive rate in these 
experiments, all the initial database searches were performed using the "decoy" option of 
Mascot.  
 
Protein Quantification 
For peptide quantification, the intensity of the different ions (m/z: 114; 115; 116; 118; 
119 and 121) was divided by the intensity of the reporter ion (m/z: 117 – Mut0) for each 
measured compound. All ratios were normalized against the median intensity of reporters. 
Only proteins quantified with at least two peptide ratios for each condition were validated. 
Ratios were transformed into natural logarithms and plotted against the number of 
peptides subjected to MS/MS analysis. Proteins with natural log-transformed ion ratios 
differing by at least 2×SD (95% confidence) were considered significantly different from the 
random variation (ratio range between 0.76 and 1.24). Student’s t test was performed for 
ratio comparison corresponding to each replicate (i.e. 116/117 vs. 121/117). Only proteins 
without a significant difference between the replicates were maintained for comparison 
between subgroups of patients. 
 
Statistical Analysis  
Mean comparison was performed by student’s t test by GraphPad Prism software with 
a confidence interval of 95%. 
 
CHAPTER II - Proteomic study of granulocytes in Ph-negative MPNs 
98 
 
Functional Analysis 
MS results were loaded on Reactome software (http://www.reactome.org/). It enabled 
us to identify, analyze and understand the whole data. It helped us to know in which 
biological pathways the identified proteins participate; which of the proteins interact with 
each other directly or through intermediate molecules; which upstream regulators can 
explain their expression pattern; which downstream diseases or processes are likely up or 
down regulated by the increase or decrease of the abundance of these proteins and the 
effects of possible protein modifications. 
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RESULTS 
1-Granulocyte proteome of Ph- MPN patients displays alterations in 
protein expression 
 
Thanks to LC-MS/MS analysis we could identify 1048 proteins from Ph- MPN 
granulocytes. To quantify the differences of expression in these proteins, we calculated the 
ratios and the p-values (student’s t test) between the means of expression of each protein 
group. Table II.2 shows the number of proteins differently expressed between the four 
groups (PV, ET, PMF and Mut0).  
  
 
PV vs 
Mut0 
ET vs 
Mut0 
PMF vs 
Mut0 
PV vs PMF ET vs PMF PV vs ET 
N proteins 
p<0.01 
54 75 77 62 67 39 
N proteins 
p<0.05 
22 22 69 15 34 7 
Total 76 97 146 79 101 46 
Ratio 1.01±0.17 1.01±0.19 1.02±0.12 1.00±0.19 0.99±0.21 1.06±0.35 
Median 0.94 0.94 0.96 0.97 0.94 0.93 
Range [0.74-1.56] [0.36-1.60] [0.63-1.55] [0.64-1.69] [0.54-2.23] [0.66-2.85] 
Ratio>1 30 40 62 34 42 21 
Ratio<1 46 57 84 43 59 25 
 
Table II.2. Protein expression comparison between PV, ET, PMF and Mut0. 
 
In order to reinforce statistical analysis and to avoid technical bias, we calculated 
medians and standard deviations of ratios (i.e. 115/117 and 119/117 for PV). Thereby we 
obtained a range of ratios from 0.76 to 1.24 corresponding to ±2 SD of the ratio value. 
Therefore, we defined as high significant difference between two peptides when the ratio of 
the two values was under 0.76 or over 1.24 and the student’s t test under 0.01; and low 
significant difference when the ratio was between 0.76 and 1.24 but the statistical p-value 
was under 0.05.  
Proteins expressed with high significant differences are presented as a comparative 
histogram in Figure II.1. Interestingly, among this proteins, we found that the protein 
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Calreticulin was overexpressed in all JAK2(+) Ph- MPNs compared with Mut0: ET vs Mut0 
(ratio 1.28, p-value<0.001), PV vs Mut0 (ratio 1.29, p-value<0.001) and PMF vs Mut0 (ratio 
1.22, p-value<0.001). The list of all deregulated proteins is accessible in Supplemental Data 
II-1). 
Among the proteins expressed with low significant differences we found some Rho 
GTPase proteins that we had previously observed in erythrocytes, such as Rho-related GTP-
binding protein RhoG (ratio 0.88, p-value 0.001 in PMF vs Mut0); Rho GDP-dissociation 
inhibitor 1 (ratio 0.95, p-value 0.01 in PMF vs Mut0); and Rho GDP-dissociation inhibitor 2 
(ratio 0.93, p-value 0.001 in PMF vs Mut0). These two last proteins were also upregulated in 
our proteomic study of MPN RBCs. The Rho GDP-dissociation inhibitor 1 was twofold more 
expressed in RBCs of ET patients than in controls and 1.7 times in PV than in non-mutated 
patients. The Rho GDP-dissociation inhibitor 2 was 2.7 times more expressed in RBCs of ET 
patients than in controls and 2.5 times more than in non-mutated patients.  
The Ras GTPase-activating-like protein IQGAP1, which was overexpressed in MPN 
RBCs, was surprisingly found lightly down-regulated when comparing ET vs PMF patients 
(ratio 0.95, p-value<0.01) and PV vs PMF patients (ratio 0.93, p-value<0.001). We also 
highlighted that the IQGAP1 regulatory protein calmodulin was highly downregulated in 
ET vs PMF patients (ratio 0.76, p-value<0.01) and in PV vs PMF patients (ratio 0.80, p-
value<0.01). 
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Figure II.1. Proteins expressed with high significant differences between A) PV and Mut0, B) 
ET and Mut0, C) PMF and Mut0, D) PV and ET, E) PV and PMF, F) ET and PMF. Names of 
proteins: A1AG1: Alpha-1-acid glycoprotein 1, A8K4K0: cDNA FLJ75006, highly similar to Homo 
sapiens CD177, ACTG: Actin cytoplasmic-2, B3AT: Band 3 anion transport protein, B4DVJ0: 
Glucose-6-phosphate isomerase, B4E3B6: Heat shock 70 kDa protein, BLVRB: Flavin reductase, 
C5HZ13: Galectin-10, CAH1: carbonic anhydrase 1, CAH2: carbonic anhydrase 2, CALM2: 
calmodulin 2, CALR: calreticulin, CAMP: cathelicidin antimicrobial peptide, CAN1: Calpain-1 
catalytic subunit, CAP7: azurocidin, CATD: Cathepsin D, CATG: cathepsin G, CD44: CD44 antigen, 
ECP: Eosinophil cationic protein, F189B: protein FAM189B, FCG3B: Low affinity immunoglobulin 
gamma Fc region receptor II-B, FCN1: Ficolin-1, FOLR3: folate receptor gamma, HXK3: Hexokinase-
3, ITAM: Integrin alpha-M - CD11b, LEG1: Galectin-1, LOX15: arachidonate 15-lipoxygenase, 
MARCS: Myristoylated alanine-rich C-kinase substrate, MCEM: Mast cell-expressed membrane 
protein 1, MMP9: matrix metalloproteinase-9, MVP: Major vault protein, NIBAN: Protein Niban, 
OLFM4: olfactomedin 4, PERE: eosinophil peroxidase, PRDX2: peroxiredoxin 2, PRG3: proteoglycan 
3, Q4VAK1: integrin, alpha M, Q86SR2: AZU1 protein, RETN: Resistin, TPM1: tropomyosin alpha-
1chain. P-values: **p<0.01, ***p<0.001. 
 
 
Looking at these deregulated proteins, we noticed that some of them appeared in more 
than one comparison, meaning that they were commonly altered in at less two subgroups of 
patients (Table II.3).   
0,54 
0,57 
0,66 
0,66 
0,72 
0,73 
0,74 
0,76 
1,27 
1,28 
1,31 
1,39 
1,41 
1,41 
1,44 
1,5 
1,52 
1,6 
0 0,5 1 1,5 2
Q4VAK1***
FOLR3***
C5HZ13***
LOX15***
OLFM4***
B4DVJ0***
FCN1**
CALM2**
CAH2**
CAMP***
ITAM**
B4E3B6***
Q86SR2***
B3AT**
CAH1***
PRDX2***
A8K4K0**
F189B***
Ratio 
ET vs PMF 
0,71 
0,74 
1,25 
1,25 
1,25 
1,25 
1,25 
1,64 
2,82 
0 1 2 3
F189B***
PRDX2***
CAN1***
PERE***
CATG***
HXK3**
CATD***
Q4VAK1**
FOLR3***
Ratio 
PV vs ET 
E F 
CHAPTER II - Proteomic study of granulocytes in Ph-negative MPNs 
103 
 
 
PV vs 
Mut0 
ET vs 
Mut0 
PMF vs 
Mut0 
PV vs PMF ET vs PMF PV vs ET 
B4DVJ0  ↓   ↓  
C5HZ13 ↑   ↓ ↓  
CAH1 ↑ ↑   ↑  
CAH2  ↑   ↑  
CALR ↑ ↑     
CAP7 ↓  ↓    
CATG   ↓ ↑  ↑ 
F189B  ↑   ↑ ↓ 
FOLR3  ↓ ↓ ↑ ↓ ↑ 
LOX15   ↑ ↓ ↓  
MMP9 ↑ ↑     
OLFM4   ↑  ↓  
PRDX2  ↑   ↑ ↓ 
PRG3  ↑ ↑ ↓   
Q4VAK1  ↓   ↓ ↑ 
TPM1 ↓ ↓     
 
Table II.3. Common proteins between the different comparisons and their status of expression 
either over-expressed (↑) or under-expressed (↓).Names of proteins: B4DVJ0: Glucose-6-phosphate 
isomerase; C5HZ13: Galectin-10, CAH1: carbonic anhydrase 1, CAH2: carbonic anhydrase 2, CALR: 
calreticulin, CAP7: azurocidin, CATG: cathepsin G, F189B: protein FAM189B, FOLR3: folate 
receptor gamma, LOX15: arachidonate 15-lipoxygenase, MMP9: matrix metalloproteinase-9, OLFM4: 
olfactomedin 4, PRDX2: peroxiredoxin 2, PRG3: proteoglycan 3, Q4VAK1: integrin, alpha M, TPM1: 
tropomyosin alpha-1chain. 
 
 
Moreover, as shown in Figure II.2, when comparing JAK2(+) patients (PV, ET and 
PMF) versus the JAK2(-) (ET and PMF patients), we could identify several proteins that 
were selectively different between mutated and non-mutated patients. Interestingly, when 
we compared the spectrum of these proteins, we highlighted that there were four proteins 
commonly overexpressed in PV and ET JAK2(+) (vs JAK2(-)), two common in both mutated 
ET and PMF and one in both PV and PMF patients. However, we failed to found any protein 
significantly modified in all subtypes of JAK2(+) MPNs. 
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Figure II.2. Venn diagram of high differently expressed proteins in JAK2(+) vs JAK2(-) (Mut0) 
MPNs. 
 
Regarding proteins expressed with low significant differences, Figure II.3 shows the 
number of them that rose when comparing two subgroups. 
 
Figure II.3. Number of proteins expressed with low-significant differences between the 
different subgroups. 
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2-Impact of JAK2V617F allele burden in granulocyte protein expression 
 
The level of JAK2V617F expression in PV has been shown to be directly associated 
with hemoglobin concentration, leukocytosis, splenomegaly, age-adjusted bone marrow 
cellularity but inversely to platelet count. Moreover, patients with the highest amounts of 
JAK2V617F were more likely to develop myelofibrotic evolution (26). In addition, a link 
between the allele burden and thrombotic complications has also been suggested but 
remains controversial. 
Taking into account that JAK2V617F allele burden is assessed on purified neutrophils 
from peripheral blood, we aimed to study the influence of JAK2V617F allele burden in 
granulocyte protein expression. Therefore, we performed another comparative analysis of 
proteome between subgroups of patients classified according to their levels of JAK2V617F. 
We hence compared the ratios of the proteins expressed with significant differences in ET vs 
Mut0 patients (allele burden <50%) and PV vs Mut0 patients (allele burden >88% (88-93%)), 
(Table II.4).  
 
 
JAK2 
<50% 
JAK2 
>88% 
No of proteins 111 83 
Ratio>1 48 32 
Ratio<1 63 51 
 
Table II.4. Impact of JAK2V617F allele burden in protein expression. No: Number of proteins 
significantly altered. 
 
As shown in Table II.4, the number of deregulated proteins was higher at low allele 
burden than at higher ranges of allele burden (over 88%). Table II.5 shows the particular 
influence of mutated JAK2 allele burden in some proteins. Interestingly, the expression of 
some proteins rose in parallel with mutated JAK2 allele burden. It is the case of the mast 
cell-expressed membrane protein 1, the major vault protein, the protein Niban or the 
resisitin. On the contrary, even though the Flavin reductase and the carbonic anhydrase 1 
are overexpressed in JAK2V617F granulocytes, their overexpression decreased when the 
JAK2V617F allele burden rose. Furthermore, the protein Peroxiredoxin 2, that was highly 
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expressed in low-JAK2(-)allele-burden granulocytes (ratio=1.42), hugely decreased its 
expression when the allele burden increased (ratio=0.94). It is remarkable that the folate 
receptor gamma is strongly under-expressed at low ranges of allele burden and, even being 
always highly under-expressed, its expression increases at higher charges of JAK2V617F. 
 
Protein group Description 
JAK2 
<50% 
JAK2 
38-94% 
JAK2 
>88% 
A8K9E4_HUMAN 
cDNA FLJ76459, highly similar to Homo sapiens 
matrix metallopeptidase 8 (neutrophil 
collagenase) (MMP8) 
1.13 1.10 1.24 
ANXA1_HUMAN Annexin A1 1.09 1.05 
 
B4DV10_HUMAN 
cDNA FLJ59142, highly similar to Epididymal 
secretory protein E1 
0,79 
 
0.84 
BLVRB_HUMAN Flavin reductase 1.31 
 
1.18 
BPI_HUMAN Bactericidal permeability-increasing protein  0.81 0.94 0.84 
C5HZ13_HUMAN Galectin-10 0.78 1.21 0.77 
CAH1_HUMAN Carbonic anhydrase 1 1.47 
 
1.22 
CALR_HUMAN Calreticulin 1.28 1.22 1.29 
CAP7_HUMAN Azurocidin 0.86 0.65 0.77 
CATG_HUMAN Cathepsin G 0.81 0.74 
 
FLNA_HUMAN Filamin-A 0.94 0.94 0.94 
FOLR3_HUMAN Folate receptor gamma 0.36 0.63 
 
HPT_HUMAN Haptoglobin 1.14 
 
1.17 
MCEM1_HUMAN Mast cell-expressed membrane protein 1  
 
1.19 1.33 
MMP9_HUMAN Matrix metalloproteinase-9 1.27 1.14 1.26 
MVP_HUMAN Major vault protein  
 
1.22 1.38 
NIBAN_HUMAN Protein Niban 
 
1.15 1.34 
PRDX2_HUMAN Peroxiredoxin-2 1.42 0.94 
 
RETN_HUMAN Resistin 1.07 
 
1.22 
 
Table II.5. Impact of JAK2V617F allele burden in protein expression. 
 
 
CALR protein keeps its presence significantly increased in all MPN granulocytes but 
independently of JAK2V617F allele burden suggesting that only the presence of the 
mutation but not the amount of mutation present any influence on CALR regulation.  
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3-Pathway alterations in Ph-MPN granulocytes 
 
In order to discover the pathways that could be altered due to the deregulation of 
many proteins, we used the Reactome. It is an online site that analyzes data and compares 
them to their pathway database. Thanks to this software, we remarked an important 
deregulation of the Rho GTPase pathways among the most deregulated pathways in 
JAK2V617F MPN granulocytes as well as pathways in relation with ROS detoxification 
(highly deregulated in PMF vs Mut0 comparison), MAPK-ERK pathways or mTOR among 
others. (Lists of all altered pathways are accessible in Supplemental Data II-2).  
 
4-Rho GTPase deregulations in Ph-MPN granulocytes 
 
We have previously reported important alterations of the Rho family of GTPases in 
red blood cells. More specifically, we highlighted an upregulation of the Ras GTPase-
activating-like protein IQGAP1 in RBCs of MPNs compared with controls. This protein also 
appeared in our proteomic study of granulocytes. Interestingly, we observed variations on 
its levels of expression among MPN patients in these cells. More concretely, IQGAP1 was 
lightly down-regulated in ET and PV vs PMF patients thus overexpressed in PMF patients. 
However, we cannot certify its overexpression in MPN granulocytes since iTRAQ analysis 
did not include non-MPN controls. Similarly to what we had observed in erythrocytes, 
JAK2(-) patients harbored higher levels of IQGAP1 as compared with JAK2(+) ones. Indeed, 
in the comparison between PV vs Mut0 patients in granulocytes we found a weak but highly 
significant decrease (ratio 0.96, p-value<0.01). 
We also remarked that the IQGAP1 regulatory protein calmodulin was highly 
downregulated in ET vs PMF patients (ratio 0.76, p-value<0.01) and in PV vs PMF patients 
(ratio 0.80, p-value<0.01). Calmodulin is thus upregulated in PMF patients compared with 
PV and ET ones providing an explanation for IQGAP1 levels modification at least in ET 
patients. Altogether, these data suggest that alterations of IQGAP1 regulation are 
dependent, at least partially, of JAK2 mutation and take place in both granulocytes and 
erythrocytes and could be considered as a hallmark of MPNs. 
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Interestingly, among the deregulated proteins in granulocytes we also found some Rho 
GTPases as well as some of the big family of RAS GTPases. Table II.6 summarizes RAS 
GTPase protein deregulations in granulocytes.  
 
Protein description Comparison Ratio p-value 
GDI2 protein 
 
PMF vs Mut0 0.94 0.0063    
PV vs Mut0 0.92 0.0172    
GTP-binding nuclear protein Ran ET vs Mut0 0.92 2.21E-04 
Rab GDP dissociation inhibitor alpha ET vs PMF 1.09 0.0192    
Ras-related C3 botulinum toxin substrate 2, 
(RAC2) 
PMF vs Mut0 0.85 0.0386    
ET vs Mut0 0.74 0.0147    
Ras-related protein Rab-11B PV vs Mut0 0.88 5.96E-04 
Ras-related protein Rab-31 PMF vs Mut0 0.93 0.0043    
Ras-related protein Rab-35 PMF vs Mut0 0.95 0.0041    
Rho GDP-dissociation inhibitor 1 PMF vs Mut0 0.95 0.0017    
Rho GDP-dissociation inhibitor 2 
PMF vs Mut0 0.93 0.0007    
PV vs Mut0 0.86 2.99E-06 
PV vs PMF 0.94 0.0180    
Rho-related GTP-binding protein RhoG 
PMF vs Mut0 0.88 9.30E-05 
ET vs Mut0 0.85 0.0080    
Transforming protein RhoA PV vs PMF 0.95 0.0059    
 
Table II.6. RAS GTPase protein deregulations in granulocytes. 
 
Rho GDP-dissociation inhibitors 1 and 2 were also upregulated in our proteomic study 
of MPN RBCs. The first one was twofold more expressed in RBCs of ET patients than in 
controls and 1.7 times in PV than in non-mutated patients. The second one was 2.7 times 
more expressed in RBCs of ET patients than in controls and 2.5 times more than in non-
mutated patients. On the contrary, both proteins were under-expressed in JAK2(+) MPN 
granulocytes compared with JAK2(-) ones. In addition, the protein Rab-11B that was also 
under-expressed in PV RBCs when compared with ET (ratio 0.3) was also under-expressed 
in PV vs Mut0 granulocytes.  
Altogether these results show a deregulation of the RAS family of GTPases and, more 
concretely, the Rho family of GTPases in MPN granulocytes that reinforce similar results 
observed in erythrocytes. 
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5-Oxidative stress in granulocytes 
 
Neutrophils are well-known cells to produce high levels of free radicals, the reactive 
oxygen species (ROS). These ions can cause significant damages in the environment. 
Fortunately, cells are gifted with machinery that helps them to battle this harmful oxidative 
stress. Many of these proteins that control ROS were found deregulated in our proteomic 
analysis, (Table II.7). 
 
Description Comparison Ratio p-value 
Flavin reductase PMF vs Mut0 1.09 1.97E-02 
ET vs Mut0 1.31 2.68E-06 
PV vs Mut0 1.18 1.49E-04 
PV vs PMF 1.09 8.27E-03 
ET vs PMF 1.21 1.28E-05 
Catalase PV vs ET 0.93 7.55E-04 
PMF vs Mut0 0.94 1.55E-06 
ET vs Mut0 0.97 1.63E-01 
PV vs Mut0 0.90 1.91E-08 
Superoxide dismutase [Cu-Zn] ET vs PMF 1.09 8.73E-03 
PMF vs Mut0 0.97 1.97E-02 
Glutathione reductase, mitochondrial PMF vs Mut0 1.04 2.42E-02 
Glutathione S-transferase omega-1  PMF vs Mut0 0.93 4.37E-05 
PV vs Mut0 1.09 2.37E-03 
PV vs PMF 1.17 2.99E-05 
ET vs PMF 1.10 1.02E-02 
Glutathione S-transferase P PMF vs Mut0 0.91 1.04E-07 
ET vs Mut0 0.94 9.37E-04 
PV vs PMF 1.00 1.35E-02 
Protein disulfide-isomerase ET vs Mut0 0.99 2.11E-01 
Eosinophil peroxidase ET vs PMF 0.88 7.90E-04 
Myeloperoxidase PMF vs Mut0 0.80 2.53E-15 
ET vs Mut0 0.96 8.32E-03 
PV vs Mut0 0.94 1.69E-03 
PV vs PMF 1.21 1.69E-09 
ET vs PMF 1.22 1.82E-09 
Peroxiredoxin-2  PMF vs Mut0 0.94 9.70E-03 
ET vs Mut0 1.42 7.53E-08 
ET vs PMF 1.50 3.38E-09 
PV vs ET 0.74 2.24E-05 
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Description Comparison Ratio p-value 
Thioredoxin-dependent peroxide reductase, 
mitochondrial 
PMF vs Mut0 0.92 2.18E-02 
NAD(P)H dehydrogenase, quinone 2 ET vs Mut0 1.23 1.84E-02 
Sulfhydryl oxidase 1 ET vs Mut0 1.17 4.96E-03 
Thioredoxin PMF vs Mut0 0.97 8.32E-03 
Glutaredoxin PMF vs Mut0 1.08 1.24E-02 
PV vs PMF 0.91 9.49E-03 
ET vs PMF 0.89 5.82E-03 
 
Table II.7. Oxidative stress protein deregulations in granulocytes. 
 
6-Transcriptomic analysis 
 
The transcriptomic analysis of CD34+ cells and granulocytes is detailed on the 
published article of Čokić et al. (175) (Supplemental Data II-3). They showed that in CD34+ 
cells, the number of differently expressed genes was twofold larger compared with 
granulocytes. Thirty-six genes were persistently highly expressed in both CD34+ cells and 
granulocytes and forty-two genes persistently highly down-regulated. Interestingly, they 
showed that, among upregulated genes, there were genes that control myeloid 
differentiation such as runt-related transcription factor 1 (RUNX1) or hematopoietic cell-
specific Lyn substrate 1 (HCLS1); as well as genes that stimulate cell proliferation as signal 
transducer and activator of transcription 1 (STAT1), MAS1 oncogene (MAS1) or the ras-
related C3 botulinum toxin substrate 2 (RAC2). There were also upregulated some genes 
that control cell proliferation such as retinoic acid receptor responder 3 (RARRES3) and 
transducer of ERBB2 1 (TOB1); and apoptotic genes such as S100 calcium binding protein 
A8 (S100A8) and tumor necrosis factor receptor superfamily 19 (TNFRSF19). Apoptotic 
inhibitor genes such as NLR family apoptosis inhibitory protein (NAIP, absent in PMF) and 
tumor necrosis factor alpha-induced protein 3 (TNFAIP3) were also upregulated. 
Interestingly, it was shown that some of the upregulated genes belonged to the 
PI3K/AKT/mTOR pathway such as ribosomal protein S6 kinase, 90kDa, polypeptide 1 
(RPS6KA1), Ras-related GTP binding A (RRAGA) or the phosphatase and tensin homolog 
(PTEN) and the protein kinase C β (PRKCB). Phosphoinositide-3-kinase, catalytic, α 
polypeptide (PIK3CA), regulatory subunit 1 (PIK3R1) and MAPK1 were only overexpressed 
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in PV subjects while hypoxia inducible factor α (HIF1α) was significantly more expressed in 
JAK2 positive ET and PMF subjects. It was also reported that some of the upregulated 
genes could activate this apoptotic pathway (the PI35/AKT pathway) such as the coiled-coil 
domain containing 88A (CCDC88A) and coronin 1A (CORO1A) genes, while it could be 
inhibited by up-regulated Kruppel-like factor 13 (KLF13). Similarly, MAPK pathway could 
be activated by up-regulated chemokine (C-X-C motif) receptor 4 (CXCR4), growth arrest 
and DNA-damage-inducible, beta (GADD45B) and MAPK10 gene expression. This pathway 
plays a critical role in regulation of cell proliferation. In addition, it could be inhibited by up-
regulated dual specificity phosphatase 1 (DUSP1) and protein tyrosine phosphatase, 
receptor type J (PTPRJ) genes. Altogether these data showed an important deregulation on 
the genome of MPN granulocytes and CD34+ cells. 
 
7-Comparison between transcriptomic and proteomic analysis 
 
We took in advantage that for some patients we had both, transcriptome and proteome 
results to link genetic deregulations with protein alterations in granulocytes. Indeed, in the 
literature, data about any correlation between transcripts and proteins stressed out that all 
cases were possible. Čokić et al. (175), in their report, found that the upregulation of certain 
genes resulted in an augmentation of some protein expression and the opposite. For 
instance, they reported an upregulation in JAK2 positive MPN subjects of the following 
genes and proteins: annexin A1 (ANXA1) in ET and PMF; carbonic anhydrase 1 (CAI), 
ficolin 1 (FCN1), major vault protein (MVP) in PV; formin binding protein 1 (FNBP1) and 
S100A4 in PMF; as well as in JAK2 negative MPN subjects: tropomyosin 3 (TPM3), actin 
related protein 2/3 complex subunit 2 (ACTR2), leukotriene A4 hydrolase (LTA4H) and 
oxidative stress related catalase (CAT). Finally, the proteins Ras-related C3 botulinum 
toxin substrate 2 (RAC2), myeloid cell nuclear differentiation antigen (MNDA), S100A8/9, 
coronin 1A (CORO1A) and the guanine nucleotide binding protein α inhibiting activity 
polypeptide (GNAI2) were deregulated in both analysis (transcriptomic and proteomic). 
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DISCUSSION 
 
The LC-MS/MS analysis allowed us to identify more than 1000 proteins expressed by 
granulocytes. Quantification of these proteins allows establishing the picture of the relative 
variations (expressed as protein ratios between two conditions) of the granulocyte proteome 
according to clinical and JAK2V617F presence. Globally, we found that a small part of the 
proteome varied among the different subtypes of MPNs. The variation ranged from 4.4% 
(PV vs ET) to 9.6% (ET vs PMF). A significant number of proteins were also altered in 
mutated JAK2 MPN granulocytes compared with non-mutated (76 in PV, 97 in ET and 146 
in PMF). This represents the variation of the proteome from 7.3% (JAK2(+) PV vs JAK2 WT 
MPNs) to 13.9 % (JAK2(+) PMF vs JAK2 WT MPNs). Several conclusions raise from these 
data: i) MPNs are associated with significant variations of the proteome of mature blood 
cells originated from clonal progenitors; ii) alterations of protein levels could participate to 
phenotypic differences observed among Ph- MPNs; II) mutations could induce proteome 
variations; iv) the number of proteins found differently expressed among MPNs or according 
to JAK2 mutation is quite low. This last point is of importance because it suggests that 
probably, a relatively low number of pathways play a critical role in MPN physiopathology.  
The approach presented in the first part of the manuscript about the erythrocyte 
proteome reinforces these data since when comparing with non-MPN controls, we observed 
variations of the erythrocyte proteome of PV and ET ranging from 6.5 to 13.4% respectively. 
 
Another interesting issue that allows the proteome analysis is the variation of the 
proteins directly targeted by driver mutations. Indeed, molecular analysis of DNA doesn’t 
inform about the levels of JAK2 or CALR and their variations according to the presence of 
the mutation. Interestingly, in this study we were able to analyze CALR expression and 
variation in different subgroups of patients. We showed that Calreticulin was effectively 
present in granulocytes as previously reported, but that it was overexpressed in 
JAK2V617F/CALR(-) granulocytes compared with JAK2(-)/CALR(-) ones (ET vs Mut0 ratio 
1.28, p-value<0.001, PV vs Mut0 ratio 1.29, p-value<0.001 and PMF vs Mut0 ratio 1.22, p-
value<0.001). The fact that this protein is upregulated in these cells even though they are 
non-CALR(-)mutated, may suggest that CALR could play a role in the MPN pathogenesis 
due to its upregulation (in non- CALR(-)mutated patients) or to its molecular alteration 
(mutated CALR ones). The higher values observed in JAK2(+) patients suggest that CALR 
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levels could be impacted by JAK2 mutation in granulocytes. We did not observe a similar 
impact of JAK2V617F in red blood cells; however, in the absence of gene activity in 
erythrocytes, it is quite logical that JAK2V617F did not play a significant role.  
 The fact that calreticulin is overexpressed in MPNs, and particularly in granulocytes 
from JAK2 mutated patients without CALR mutation, raised the hypothesis that normal 
CALR protein by itself could have an oncogenic role potentially dependent of JAK2V617F. 
In fact, CALR has already been suggested to take part in pancreatic cancer development 
and progression through MEK/ERK signaling pathway and independently of p53 (176). On 
the contrary, calreticulin overexpression has been related to increase apoptosis sensitivity 
to some drugs in calreticulin-inducible HeLa cells (177), as well as in human MCF-7 breast 
cancer cells (178). 
Unfortunately, our LC MS/MS analysis failed to quantify JAK2 protein so we were not 
able to analyze the impact of JAK2 protein levels. In addition, the transcriptomic analysis 
didn’t highlight any up-regulation of JAK2 in granulocytes. Nonetheless, the mRNA 
analysis of CD34+ cells showed an important up-regulation of JAK2 transcription in PV 
(4.02 times), ET (3.54 times) and PMF (3.01 times). 
 
Calreticulin is also well-known to be a regulator of calcium homeostasis. Thus its 
deregulation linked to the deregulation of calcium binding proteins S100 also observed in 
MPNs (see Supplemental Data II-1) could imply possible calcium alterations in MPN 
granulocytes that influence their homeostasis. In fact, S100 alterations have already been 
described in other cancers such as breast, melanoma, head and neck or colorectal tumors 
(179). In addition, the protein S100A8 was identified as a marker of poor prognosis in AML 
patients (180). Moreover, IQGAP1 functions are known to be modified by Ca2+ regulation via 
calmodulin (131, 155) thus these Ca2+ alterations could also influence IQGAP1 state. 
 
As seen in the first part of this manuscript, we found that the Ras GTPase-activating-
like protein IQGAP1 and the Rho family of GTPases were deregulated in MPN erythrocytes. 
Regarding granulocyte deregulations, IQGAP1 was found lightly upregulated in PMF 
patients compared with ET ones and in PV compared with non-mutated ET and PMF. 
Moreover, calmodulin, an IQGAP1 regulatory protein, was highly upregulated in PMF. 
Generally, calmodulin causes a conformational change in IQGAP1 that avoids its bound to 
the Rho GTPases (159). Therefore, we could hypothesize that alteration of the activation of 
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some Rho GTPases could occur in PMF granulocytes. In the same sense, we also found that 
the expression of the RhoGDI-dissociation inhibitors 1 and 2 was reduced in JAK2V617F 
PMF and PV compared with JAK2 WT. Altogether these data suggested that the specific 
alteration of IQGAP1 and some of its effector proteins could take place in the clinical 
diversity of MPNs. In particular, PMF patients seemed characterized by a moderate 
increase of IQGAP1 levels together with calmodulin overexpression and decreased levels of 
RhoGDI that were globally decreased in all JAK2(+) patients compared with JAK2 WT.  
 
Thanks to pathway analysis software, we could confirm the deregulation of the Rho 
GTPases, also observed in RBCs, in JAK2V617F granulocytes. In RBCs, this alteration was 
related to both PV and ET patients compared with controls. Therefore, we could relate Rho 
GTPase deregulations to JAK2V617F MPNs. Furthermore, the fact that Rho GTPase 
pathways are deregulated in both JAK2V617F MPN granulocytes and erythrocytes suggests 
a deregulation on this family that could take place on a common myeloid progenitor and 
affect to the entire myeloid lineage. Rho GTPases are principally involved in actin 
cytoskeleton remodeling, cellular movement, cell cycle progression and gene expression 
(142). The fact that these functions are altered in granulocytes could explain that leukocyte 
levels above 15x109/L were associated with an increased risk of major thrombosis as 
myocardial infarction in PV patients (181) as well as in ET (182, 183) Moreover, leukocytes 
can contribute to the pathogenesis of thrombosis in ET and PV through their interaction 
with platelets, endothelial cells, and coagulation factors. They can also participate in 
inflammatory processes in atherosclerotic plaques increasing thrombotic risk. In addition, 
neutrophil activation involves ROS production, proteolytic enzymes such as elastase and 
cathepsin G and higher expression of CD11b on their cell surface. All of these molecules can 
alter the hemostasis and induce a prothrombotic condition (61). Interestingly, we 
highlighted that CD11b was deregulated in our proteomic results. It was significantly 
overexpressed in JAK2V617F ET granulocytes compared with non-mutated ones (ratio 1.15, 
p-value<0.01); in ET vs PMF (ratio 1.31, p-value<0.001); in PV vs PMF (ratio 1.16, p-
value<0.01), in PV vs ET (ratio 1.68, p-value<0.01) and PMF vs Mut0 (ratio 0.90, p-
value<0.05) thus overexpressed principally in JAK2V617F PV and ET granulocytes and 
down-expressed in PMF ones. These data agree with Arellano-Rodrigo et al. (105) that 
related this molecule to JAK2V617F ET neutrophils but not to thrombotic risk. 
Nevertheless, CD11b expression in monocytes was indeed associated with thrombosis. 
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We also remarked some deregulations of the MAPK, ERK and mTOR pathways (see 
Supplemental Data II-2). Interestingly, Čokić et al. (175) had already described that some of 
the upregulated genes belonged to the PI3K/AKT/mTOR pathway such as ribosomal protein 
S6 kinase, 90kDa, polypeptide 1 (RPS6KA1), Ras-related GTP binding A (RRAGA) or the 
phosphatase and tensin homolog (PTEN) and the protein kinase C β (PRKCB). The 
PI3K/Akt pathway plays a crucial role in cancer progression due to its capacity of regulating 
apoptotic processes. In fact, Akt has already been shown to be activated in many types of 
cancer (184) inhibiting apoptosis and promoting cell cycle progression and differentiation. 
Grimwade et al. (185) showed how Akt as well as STAT-5 were highly activated in 
JAK2V617F megakaryocytes of ET and PV patients compared with healthy donors and 
JAK2(-) ones. Interestingly, there was no such difference in JAK2 exon 12 patients. 
Furthermore, the PI3K/Akt effector: the mammalian target of rapamycin (mTOR) has been 
shown to be activated by the thrombopoietin receptor in human megakaryocytes. This 
protein is present in two different complexes: mTORC1 and mTORC2. The mTOR pathway 
is necessary for proliferation of primary human megakaryocyte progenitors and MO7E cells 
(a human magakaryoblastic cell line) (186). In addition, Vicari et al. (187) showed that 
mTOR phosphorylation was higher in ET and PMF megakaryocyte cells, derived from 
CD34+ progenitors, compared with healthy donors. Finally, Khan et al. (188) confirmed that 
the PI3K/Akt pathway is activated in both JAK2V617F and MPLW515L MPN cells. 
 
These investigations suggested this pathway as a new target for new therapy 
strategies in Ph- MPNs. Some studies have already tested the effects of mTOR inhibitors 
alone and in combination with JAK2 inhibitors. Bogani et al. (189) showed that both the 
RAD001, also known as Everolimus, (an allosteric mTOR inhibitor of mTORC1) and the 
PP242 (an ATP mTOR inhibitor that targets both mTORC1 and 2) were able to inhibit cell 
proliferation in a dose-dependent manner as well as the inhibition of CD34+ cells and the 
formation of hematopoietic colonies from MPN patients. They also proved the synergic effect 
of using mTOR and JAK2 inhibitors together in cell proliferation and colony formation 
inhibition in Ba/F3 cell lines. Bartalucci et al. (190) studied the effects of a dual mTOR/PI3K 
inhibitor, BEZ235 in mouse and human cells expressing JAK2V617F. They showed that this 
molecule caused cell cycle arrest, proliferation inhibition, apoptosis induction (at higher 
concentrations) and inhibited cytokine-induced clonogenic growth of MPN progenitors as 
well as endogenous erythroid colony formation. They also evidenced the enhanced effect 
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when combining mTOR inhibitors with Ruxolitinib (JAK inhibitor). This synergy provided 
more survival, reduced splenomegaly and cell production in JAK2V617F mouse models. 
Similar results were obtained by Fiskus et al. (191) combining the BEZ235 with the JAK 
inhibitors TG101209 and SAR302503 in Ba/F3 cells presenting JAK2V617F mutation. 
Another strategy to block this pathway is the one taken by Khan et al. (188) that 
investigated the effects of an Akt inhibitor, the MK-2206. They showed that this drug 
hugely reduced megakaryocyte colony formation from PMF CD34+ cells (and also from 
healthy donors unfortunately). Nonetheless, using an MPLW515L murine model with 
myelofibrosis, they could show that the MK-2206 reduced extramedullary hematopoiesis, 
megakaryocyte expansion and reticulin fibrosis in the bone marrow without peripheral 
cytopenias and without any effect on the hematopoiesis of healthy mice. 
 
In addition, the protein IQGAP1, which appeared to have a crucial role in MPN RBCs, 
is tightly linked to this pathway as it interacts with the mTOR protein through is N-
terminus domain enhancing cell size and division. The phosphorylated form of IQGAP1 
could be implicated in these alterations as it was shown to directly activate the mTOR/Akt 
signaling pathway (144, 161). We could hypothesized that mutated JAK2 could also 
phosphorylate IQGAP1 and then activate the mTOR/Akt signaling pathway amplifying the 
PI3K/Akt/mTOR signal. 
 
High levels of oxidative stress have already been associated with thrombosis in PV 
and ET patients (192) and with myelofibrotic evolution in PV patients (193). Furthermore, 
Hurtado-Nedelec et al. (194) described an increased production of reactive oxygen species in 
MPN neutrophils in JAK2V617F patients compared with non-mutated ones together with 
an increased phosphorylation of p47phox and ERK1/2. In agreement with those results, 
Marty et al. (170) reported increased ROS production in PV and PMF CD34+ cells and 
Ba/F3-EpoR-JAK2V617F cells that lead to an increase of DNA oxidative damage (8-oxo-
guanines and DNA double-strand-breaks). In our proteomic research, we also found a big 
deregulation of ROS related proteins that involved an alteration of oxygen detoxification 
pathways (see Table II.7). For instance, the protein myeloperoxidase (MPO) was 
overexpressed in non-JAK2 mutated granulocytes compared with mutated ones and 
particularly we observed an increased under-expression in mutated PMF granulocytes 
compared with JAK2V617F PV, ET and JAK2(-) ones. Peroxiredoxin 2 was highly 
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upregulated in JAK2V617F ET granulocytes compared with JAK2V617F PV, PMF and non-
mutated ones. Moreover, the analysis of genomic analysis confirmed the implication of 
oxidative stress in the pathophysiology of MPNs. We highlighted that the oxidative stress 
related catalase (CAT) was under-regulated due to a decreased on the expression of the CAT 
gene in JAK2V617F MPN subjects.  
In addition, catalase gene expression was also reduced in PV and PMF CD34+ cells. 
Concerning the catalase protein, unfortunately, we couldn’t confirm a decrease expression 
in granulocytes of patients compared with normal ones since we did not explore control 
granulocytes. However, we observed a significant variation of the catalase expression among 
MPN subtypes and particularly lower levels were found in JAK2(+) MPNs vs JAK2 WT. 
This latter observation could suggest that JAK2V617F induces a decrease of catalase 
expression participating to the oncogenic role of this mutation. Indeed, Marty et al. (170) 
had already reported a decreased of the catalase expression in mouse models that showed 
that the PI3K/Akt activation via JAK2V617F negatively regulated the Forkhead O 
transcription factor leading to a reduced expression of anti-oxidant enzymes such as the 
catalase in bone marrow cells of knock-in mice. Moreover, the protein RAC2, which was 
under-regulated in JAK2V617F ET and PMF patients compared with non-mutated ones, is 
directly linked to the NADPH complex. It has been related to ROS production as it is 
capable of altering the mitochondrial membrane potential and electron flow producing high 
levels of ROS in CML in chronic phase cells and primitive leukemia stem cells (195). 
Altogether, our data confirmed, in clinical samples, the prominent role of ROS balance in 
MPN physiopathology. 
 
Apart clinical aspects associated with JAK2V617F expression in PV granulocytes such 
as hemoglobin concentration, leukocytosis or splenomegaly, as well as JAK2V617F value as 
poor prognostic factor (myelofibrotic evolution) (26), JAK2V617F allele burden has also been 
correlated with high expression of CD11b in ET neutrophils (105). In our proteomic 
analysis, we reported (Table II.5) that some proteins could be directly impacted by the 
amount of mutated JAK2. The protein Galectin-10 (C5HZ13) was more overexpressed in ET 
granulocytes than in PMF and in these ones more than in PV ones and those ones more 
than in non-mutated granulocytes suggesting a positive JAK2V617F allele burden impact. 
Conversely, the protein azurocidin (CAP7), an antibacterial granule of neutrophils with a 
cytotoxic action against Gram-negative bacteria and tropomyosin alpha-1 chain (TPM1) a 
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protein with a central role on the stabilization of cytoskeleton actin filaments, appeared 
overexpressed in non-mutated granulocytes alluding a negative impact of the JAK2V617F 
allele burden. Finally, some proteins like folate receptor gamma (FOLR3), cathepsin G 
(CATG) and proteoglycan 3 (PRG3) were equally expressed in PV and non-mutated 
granulocytes and their expression was higher than in PMF and ET suggesting that JAK2 
allele burden did not influence their levels of expression.   
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CONCLUSION AND PERSPECTIVES 
 
The collaboration with the Institute of Medical Research in Belgrade, (Serbia), let us 
perform a proteomic and transcriptomic study of granulocytes in Ph- MPNs. The cDNA 
microarray analysis was done by the research group of Alan N. Schechter and their results 
can be found in their article (Supplemental Data II-3). In this paper, it is principally 
developed the genomic deregulations in granulocytes and CD34+ cells in MPNs. To complete 
this analysis, the proteomic study of granulocytes allowed us to identify important protein 
alterations associated with transcriptomic data (see the article). 
Our data showed that important proteomic deregulations existed between JAK2V617F 
MPNs and non-mutated ones as well as between PV, ET and PMF mutated patients. 
Moreover, some of these proteins seemed to be impacted by the JAK2V617F allele burden. 
Moreover, it was remarkable that the protein CALR, whose gene is mutated in some cases 
of Ph- MPNs, was up-regulated in JAK2V617F MPN granulocytes independently of this 
mutation allele burden. 
Our results also showed an important deregulation of the RAS GTPase pathways that 
had also been found altered in MPN RBCs suggesting a myeloid alteration of this family of 
proteins. Moreover, the mTOR pathways, linked to cell growth, were also deregulated in 
MPN granulocytes. 
Finally, the stress conditions to which JAK2V617F cells are exposed could be the 
reason that brings to Ca2+ as well as ROS deregulation presented in MPN granulocytes.  
Altogether these data showed that, apart from genetic well-known alterations such as 
JAK2V617F and CALR exon 9, proteome alterations play a critical role in MPNs.  
Considering this common alterations in granulocytes and RBCs, it could be useful to 
perform a proteomic analysis of progenitors to better understand proteome alterations that 
take place in HSC and their link with the main genotypes.  
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RESUME DU CHAPITRE II 
 
L’analyse quantitative et qualitative par LC-MS/MS couplée au LTQ Orbitrap des 
granulocytes des patients atteintes des syndromes myéloprolifératifs Philadelphia négatifs 
nous a permis de montrer des dérégulations importantes des protéines selon le statut 
moléculaire des patients (JAK2V617F vs JAK2 WT), leur diagnostic (JAK2V617F PV, ET ou 
PMF)  voir pour certaines protéines comme la Peroxiredoxine 2 selon la charge allélique en 
JAK2V617F.  
 
En plus, nous avons retrouvé dans les polynucléaires des dérégulations de la famille 
des Rho GTPases qui étaient aussi altérées chez les globules rouges des SMP (cf part I), 
confirmant l’importance des dérégulations de cette voie dans la physiopathologie des SMP 
Ph-. Outre les protéines GTPases, nous avons retrouvé des dérégulations de la signalisation 
mTOR, de protéines de régulation de l’homéostasie du calcium, et d’importante dérégulation 
de protéines régulatrices du stress oxydatif, pouvant altérer à la fois les mécanismes de 
protection contre le stress oxydatif (i.e. diminution de la catalase) ou au contraire favoriser 
la production d’espèces réactives de l’oxygène comme la MPO. Ces dérégulations de l’activité 
peroxydasique renforcent l’hypothèse du possible rôle de l’activation des PNN sur des 
complications thrombotiques si fréquentes chez les patients SMP. Enfin, nous avons montré 
que la protéine Calréticuline, connue pour son potentiel myéloprolifératif quand elle est 
mutée, se trouve hyper-exprimée chez les granulocytes des patients SMP JAK2V617F en 
comparaison avec les JAK2 WT de façon indépendant à la charge allélique de JAK2V617F. 
Ce résultat suggère un potetiel oncogénique de la protéine CALR native en dehors de ses 
formes mutées. 
 
En conclusion, ces résultats mettent en évidence la présence de dérégulations 
protéiques dans les granulocytes, certaines communes avec les érythrocytes des patients 
SMP suggérant qu’elles prennent leur origine dans un d’un progéniteur clonale commun. En 
outre, ces altérations protéiques différentes selon le diagnostic des patients pourraient 
expliquer les différences phénotypiques trouvées chez les sous-groupes des SMP Ph-. 
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BACKGROUND 
 
Our results on RBC proteome highlighted the implication of Rho GTPases in protein 
alterations. At this point, two questions arise: i) Are these Rho GTPase deregulations 
specific of RBCs or do they occur in other MPN cell lineages? ii) Is there a link between 
JAK2V617F and these deregulations?  
To answer these questions, Ba/F3 EpoR, Ba/F3 EpoR JAK2 wild-type (WT), Ba/F3 
EpoR JAK2V617F and HEL cells were selected as MPN cell models. Hence, the objective of 
this third chapter was to validate in these cell models the previous reported deregulations of 
Rho GTPases and to evaluate the influence that JAK2 inhibitors and hydroxyurea may have 
on them.  
 
Ba/F3 cell lines are interleukin 3 (IL-3) dependent hematopoietic cells. They are very 
used in the study of cytokines; mutations, downstream signaling pathways and inhibitors. 
The fact that they are used for kinase-related drug discovery lets researchers evaluate drug 
potential; effects and the screening of possible resistant mutations to these kinase 
inhibitors. Their high utilization emerges because these Ba/F3 are suspension cells that 
grow very quickly facilitating rapid experimental procedures. Secondly, they are easily 
transfected by electroporation and susceptible to infection by retro and lentiviral expression 
systems. Finally, they can proliferate independently from IL-3 when they express 
constitutively active tyrosine kinases or other growth oncogenes. They have already been 
proved for the study of multiple kinases such as NPM-Alk, Flt3 mutants and JAK2 (196).  
First studies of JAK2 mutations in Ba/F3 cells by James et al. (17) showed that 
JAK2V617F EpoR increased cell sensitivity to erythropoietin stimulation compared with 
Ba/F3 wild type EpoR. In addition, mutated JAK2 Ba/F3 presented growth-factor 
independent growth and increased STAT5 signaling as well as PI3K and ERK pathways. 
Similar experiences in Ba/F3 cells were carried out in other JAK2 cytokine receptors such 
as thrombopoietin and granulocyte-colony stimulating factor receptors with analogous 
results (197). 
In addition, another human cell line also presents the JAK2V617F mutation: the 
leukemia cell line HEL (19). It expresses constitutively tyrosine-phosphorylated JAK2 as 
well as its downstream effectors STAT5 and ERK. When treated with JAK2 inhibitors, 
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these cells showed a dose-dependent inhibition of proliferation due to reduced JAK2 
phosphorylation as wells as apoptosis. Therefore, Ba/F3 EpoR cell lines: normal EpoR, EpoR 
JAK2 wild-type (overexpressing JAK2) and EpoR mutated JAK2 (JAK2V617F) are well 
stablished cell lines in MPN researches.  
 
In this study, I used the three Ba/F3 cell lines as well as the leukemia cell line HEL to 
go on with my investigations of MPN protein deregulations and to evaluate the possible 
effects of JAK2 inhibitors on the IQGAP1/Rho GTPase signaling. 
 
Nowadays, the only approved JAK2 inhibitor for MPN treatment is Ruxolitinib; 
(approved by the U.S. Food and Drug Administration in 2011 and the European 
Commission in 2012) for its use in intermediate-2 and low risk PMF and secondary 
myelofibrosis post-PV or ET. It can also be given in PV treatment as third line when 
hydroxyurea and IFNα have already been discarded (43). In my research, I used Ruxolitinib 
(INCB018424), which inhibits JAK1 and JAK2; as well as AZD1480 that inhibits JAK2. 
Both are Adenosine Tri-Phosphate (ATP) mimetic JAK inhibitors that bind to the active 
form of JAKs. 
I also selected hydroxyurea, a first line chemotherapy of high risk MPN to test its 
possible effects on the Rho family of GTPases in my cell models. HU blocks the 
dihydrophosphate reductase, an enzyme needed for nucleotide reduction inhibiting DNA 
synthesis and inducing cell death in S-phase. It is used for treating both ET and PV patients 
as first choice in high risk patients (83). 
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MATERIAL AND METHODS 
Cell Lines 
Ba/F3 EpoR, Ba/F3 EpoR JAK2 wild-type (WT) and Ba/F3 EpoR JAK2V617F were 
provided by Dr Isabelle Plo from (INSERM U1009 “Hématopoïèse et cellules souches,” 
“Institut Gustave Roussy” Villejuif, Pr Solary E). They were cultured in DMEM culture with 
1% penicillin/streptomycin, 1% glutamine, 10% fetal bovine serum (FBS) and 1UI 
Erythropoietin (EPO).  
HEL cells were cultured in RPMI culture with 1% penicillin/streptomycin, 1% 
glutamine, 10% FBS at 37°C with 5% CO2. 
All cell lines (Ba/F3 and HEL) were washed three times in cold 1x PBS, lysed with 
lysis buffer (20 µL/million de cellules) (1% NP-40, 10 mM KCl, 10 mM HEPES, 0.1 mM 
EDTA + protease (cOmplete, EDTA-free, Roche) and phosphatase inhibitors (phospho-
STOP, Roche)) during 20 minutes vortexing vigorously each five minutes at 4°C and 
quantified by BIORAD DCTM protein assay. Cell viability was measured using trypan blue 
as cell death marker. 
Western-Blotting 
(See Material and Methods of Chapter I) 
Immunoprecipitation 
(See Material and Methods of Chapter I) 
Antibodies 
(See Material and Methods of Chapter I) 
Inhibitors 
Ruxolitinib (INCB018424) a JAK1 and JAK2 inhibitor was provided by Novartis. 
AZD1480 an ATP-competitive JAK2 inhibitor was from Selleckchem®. Both drugs were 
diluted in dimethyl sulfoxide (DMSO).  
Hydroxyurea (HU) was purchased at Sigma-Aldrich® and diluted in water.  
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Cell cycle analysis by Flow Cytometry 
Flow cytometry was used to measure cell cycles of HEL cells under the influence of the 
different inhibitors. To explore cell cycleS we chose propidium iodide (PI) which is a DNA 
intercalant agent that will let us quantify the quantity of DNA in each cell. How cell cycle is 
shown by flow cytometry is explain in Figure III.1. 
One million cells were washed twice in cold 1x PBS and resuspended in 300 µL of PBS. 
Then, 700 µL of cold ethanol (70%) was drop-wise and left at 4°C overnight. Next, cells were 
washed twice in cold PBS and resuspended in 250 µL of PBS. 5 µL of 10 mg/mL RNAse A 
were carefully added and samples were incubated at 37°C for 1 hour. Finally, 10 µL of 1 
mg/mL of propidium iodide stain were added and samples were analyzed on Fluorescence-
activated cell sorting, (FACS) on cytometer at 488 nm. We measured a minimum of 30,000 
cells if possible. 
 
 
Figure III.1. A) Cell cycle of normal cells. B) Image of cell cycle analyzed by flow cytometry. 
To read the cryptogram, if we go from left to right the amount of DNA increases and from down to up 
the number of cells rises. When cells are in G0/G1 phase they have a quantity of DNA. If they pass to 
S phase they start replicating their DNA so the quantity of DNA increases and finally, cells in G2/M 
phase have the biggest quantity of DNA (they have doubled it) just before they split in two. In this 
case we can see that most of the cells are in G0/G1 phase followed by G2/M phase and there are fewer 
cells in S phase. Cells that appear on the left represent death cells (Sub-G1).  
 
  
A B 
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RESULTS 
HEL CELLS 
1-Effects of JAK2 inhibitors and hydroxyurea on cell concentration and 
cell viability 
 
The objective of this part was to determine HEL cell sensibility to some inhibitors 
(Ruxolitinib, AZD1480 and Hydroxyurea) to select an ideal concentration balanced between 
toxicity and no effect. These concentrations would be used to study the effects of these 
inhibitors on protein expression, specifically on the Rho family of GTPases. 
In order to fulfil this objective, HEL cells were cultured for 24, 48 and 72 hours with 
inhibitors at different concentrations. A control with DMSO was used to measure cell death 
caused by this toxic agent as Ruxolitinib and AZD1480 are diluted on it. DMSO final 
concentration was always ≤ 1%.  
 
As seen in Figure III.2, cell death was correlated with increased concentrations of 
hydroxyurea. We could observe that concentrations above 250 µM of HU completely blocked 
cell growth and induced apoptosis. Both Ruxolitinib and AZD1480 also inhibited cell growth 
when comparing with controls but less markedly than HU. 
After 24h of incubation, cell viability hardly changed in all cases; however, it 
decreased together with time and rising inhibitor concentrations. We observed that HU 
caused more apoptosis than Ruxolitinib or AZD1480 at the concentrations tested. 
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Figure III.2. Effects of Hydroxyurea (A), Ruxolitinib (B) and AZD1480 (C) on HEL cells. 
Graphics on the left show cell concentration after 24, 48 and 72 hours of incubation at different 
inhibitor concentrations. Those on the right represent cell viability after 24, 48 and 72 hours of 
incubation at different inhibitor concentrations.  
 
2-Cell cycle analysis 
 
Cell cycle analysis by flow cytometry was determined at 24 and 48 hours after 
treatment with HU, Ruxolitinib or AZD1480 at different concentrations (Figure III.3 to III.8 
and Tables III.1 to III.6). Results show that after 24 hours of drug incubation, hydroxyurea 
blocked cells on the S phase and cells on the G0/G1 and G2/M phases decreased dose-
dependently. Ruxolitinib effects were similar at all conentrations. However, AZD1480 
caused a light decreased of cells on the G0/G1 phase while the proportion of cells on S and 
G2/M phases raised blocking cells on the S phase. After 48 hours of drug incubation, we saw 
that the number of cells decreased on S phase and increased on G2/M phase under HU 
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treatment. AZD1480 turned cells into apoptosis and Ruxolitinib decreased number of cells 
on S and G2/M phases as the number of cells on G0/G1 phase was more or less stable. 
 
 
 
Figure III.3. DNA fluorescence profiles of HEL cells with +/- Hydroxyurea. The x axis shows 
PI intensity and y axis number of cells. More than 30,000 cells were measured apart from those 
where it is noted. 
 
Hydroxyurea 24h Control 50 µM 100 µM 150 µM 250 µM 
G0/G1 Phase 44.9 42.6 30.7 26.3 20.3 
S Phase 18.1 20.4 18.2 33.2 30.8 
G2/M Phase 17.3 16.5 9.7 17.6 6.5 
Apoptotic cells 16.2 17.8 39.7 19.3 40.3 
Double cells 3.5 2.6 1.7 3.5 2.2 
Total population 100 100 100 100 100 
  
Table III.1. Cell cycle analysis by flow cytometry. It shows the percentage of cells in each 
phase at different concentrations of HU after 24 hours.  
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Hydroxyurea 48h Control 50 µM 100 µM 150 µM 250 µM 
G0/G1 Phase 37.7 36.7 27.4 26.4 19.7 
S Phase 21.6 13.8 18.9 19.5 11.5 
G2/M Phase 22 20.9 18.5 15.9 21.3 
Apoptotic cells 10.3 15.5 21.2 19.5 34.8 
Double cells 8.4 13 14 18.7 12.6 
Total population 100 100 100 100 100 
 
Table III.2. Cell cycle analysis by flow cytometry. It shows the percentage of cells in each 
phase at different concentrations of HU after 48 hours.  
 
 
 
 
 
Figure III.4. Analysis of cell cycle of HEL cells with +/- hydroxyurea. Graphics show 
the percentage of cells in each phase at different hydroxyurea concentrations after 24 (A) or 
48 hours (B) of drug incubation. 
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Figure III.5. DNA fluorescence profiles of HEL cells with +/- Ruxolitinib. The x axis shows PI 
intensity and y axis number of cells. More than 30,000 cells were measured each time. 
 
 
Ruxolitinib 24h Control 50 nM 100 nM 200 nM 400 nM 
G0/G1 Phase 52.5 45.9 46.6 51.6 52.2 
S Phase 6.5 6 7.7 5.9 5.8 
G2/M Phase 16.6 20.7 24.7 22.7 23 
Apoptotic cells 22.1 24.5 17.8 17.7 17.3 
Double cells 2.3 3 3.3 2.1 1.7 
Total population 100 100 100 100 100 
 
Table III.3. Cell cycle analysis by flow cytometry. It shows the percentage of cells in 
each phase at different concentrations of Ruxolitinib after 24 hours.  
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Ruxolitinib 48h Control 50 nM 100 nM 200 nM 400 nM 
G0/G1 Phase 38.7 41.5 39.1 43.9 39.3 
S Phase 22.9 23.6 20.6 18.2 17.3 
G2/M Phase 19.8 16.9 17 15.5 15.5 
Apoptotic cells 9.7 12.6 11.8 13.3 13.6 
Double cells 8.8 5.4 11.5 9 14.3 
Total population 100 100 100 100 100 
 
Table III.4. Cell cycle analysis by flow cytometry. It shows the percentage of cells in each 
phase at different concentrations of Ruxolitinib after 48 hours.  
 
 
 
 
Figure III.6. Analysis of cell cycle of HEL cells with +/- Ruxolitinib. Graphics show the 
percentage of cells in each phase at different inhibitor concentrations after 24 (A) or 48 hours (B) of 
drug incubation. 
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Figure III.7. DNA fluorescence profiles of HEL cells with +/- AZD1480. The x axis shows PI 
intensity and y axis number of cells. More than 30,000 cells were measured apart from those where it 
is noted. 
 
 
AZD1480 24h Control 50 nM 100 nM 200 nM 400 nM 
G0/G1 Phase 52.5 46.7 38.9 42.1 36.7 
S Phase 6.5 19.5 18.9 19.7 18.6 
G2/M Phase 16.6 18.3 20.7 21 22.7 
Apoptotic cells 22.1 12.6 16.6 13.4 15.4 
Double cells 2.3 2.9 5 3,9 6.8 
Total population 100 100 100 100 100 
 
Table III.5. Cell cycle analysis by flow cytometry. It shows the percentage of cells in each 
phase at different concentrations of AZD1480 after 24 hours.  
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AZD1480 48h Control 50 nM 100 nM 200 nM 400 nM 
G0/G1 Phase 38.7 30.1 42.7 37.2 39.5 
S Phase 22.9 22 19 21.4 7.6 
G2/M Phase 19.8 20.9 17.6 20.9 1.6 
Apoptotic cells 9.7 10.2 9.6 11.1 50.8 
Double cells 8.8 16.8 11.1 9.3 0.5 
Total population 100 100 100 100 100 
 
Table III.6. Cell cycle analysis by flow cytometry. It shows the percentage of cells in each 
phase at different concentrations of AZD1480 after 48 hours.  
 
 
 
Figure III.8. Analysis of cell cycle of HEL cells with +/- AZD1480. Graphics show the 
percentage of cells in each phase at different AZD1480 concentrations after 24 (A) or 48 hours (B) of 
drug incubation. 
 
 
3-IQGAP1 and Rho GTPases expression in HEL cells 
 
We first verified by western blotting the expression of the following proteins: IQGAP1, 
PAK1, P-PAK1, Rac1, Cdcd42, RhoA and RhoGDI in HEL lysates. As seen in Figure III.9 all 
the proteins tested except for phosphorylated PAK-1 were present in HEL lysates. 
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Figure III.9. Western blot analysis of HEL lysates. 20 µg of HEL lysates were loaded on SDS-
PAGE gels and transferred to nitrocellulose membranes to be revealed with suitable antibodies: 
IQGAP1, PAK1, P-PAK1, Rac1, Cdc42, RhoA, RhoGDI and β-actin. Red arrows point to the 
correspondent proteins. Blue arrows point to β-actin. Molecular weights of targeted proteins: 
IQGAP1: 189 kDa, PAK1 and P-PAK1: 61 kDa, Rac1 21 kDa, Cdc42 21 kDa, RhoA 22 kDa, RhoGDI: 
22 kDa, β-actin: 42 kDa. 
 
 
Secondly, we measured inhibitor effects on protein expression in HEL cells. Equal 
amounts of protein were loaded to be analyzed by western blotting using the specific 
antibodies (Figures III.10 to III.15).  
 
 
 
Figure III.10. IQGAP1 expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate IQGAP1/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: IQGAP1: 189 kDa, β-actin: 42 kDa. 
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Figure III.11. Rac1 expression in HEL cells. Western blots of HEL lysates under hydroxyurea, 
Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading control. 
Numbers indicate Rac1/β-actin ratios relative to Control ratios. Ct: Control. Molecular weights: Rac1; 
21 kDa, β-actin: 42 kDa. 
 
 
 
Figure III.12. Cdc42 expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate Cdc42/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: Cdc42: 21 kDa, β-actin: 42 kDa. 
 
 
 
Figure III.13. RhoA expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate RhoA/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: RhoA: 22 kDa, β-actin: 42 kDa. 
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Figure III.14. RhoGDI expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate RhoGDI/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: RhoGDI: 22 kDa, β-actin: 42 kDa. 
 
 
 
 
Figure III.15. PAK1 expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate PAK1/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: PAK1: 61 kDa, β-actin: 42 kDa. 
 
 
As shown in Figures III.10 to III.15, and as resumed in Table III.7, IQGAP1 
expression was reduced by increasing concentrations of HU at both 24h and 48h of 
incubation and after 48h with Ruxolitinib and AZD1480. On the opposite, IQGAP1 
expression was increased after 24h of AZD1480 and Ruxolitinib treatment. Rac1 decreased 
it expression under hydroxyurea and AZD1480 influence but not with Ruxolitinib (increased 
expression). Surprisingly, RhoA expression decreased at higher concentrations of the three 
inhibitors after 24h and it increased its expression after 48h. Similar results were obtained 
for PAK1 expression under the effects of Ruxolitinib and AZD1480. Nevertheless, PAK1 
expression was increased after 24h under rising concentrations of hydroxyurea. The signals 
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for Cdc42 were light but it tended to increased it expression under inhibiting conditions. We 
remarked that RhoGDI wasn’t perturbed by hydroxyurea. 
 
  
Hydroxyurea Ruxolitinib AZD1480 
  
Ct 50 100 150 250   Ct 50 100 200 400   Ct 50 100 200 400   
IQGAP1 
24h 1 0,6 0,5 0,1 0,4 ↓ 1 5,0 6,0 4,6 1,4 ↑ 1 0,7 2,4 4,8 3,9 ↑ 
48h 1 0,3 0,6 1,2 0,4 ↓ 1 0,6 0,8 0,9 0,3 ↓ 1 1,7 0,5 0,6 0,3 ↓ 
Rac1 
24h 1 1,0 0,4 0,2 0,2 ↓ 1 0,8 1,2 1,2 0,5 ≈ 1 0,4 0,2 1,1 0,5 ↓ 
48h 1 0,1 0,1 0,2 0,5 ↓ 1 9,6 4,3 3,4 1,3 ↑ 1 0,4 0,2 0,1 0,1 ↓ 
Cdc42 
24h 1 1,0 1,5 1,4 1,8 ↑ 1 2,3 2,2 2,3 0,7 ↑ 1 1,2 1,2 0,7 0,8 ≈ 
48h 1 5,5 12,0 5,2 3,1 ↑ 1 1,2 2,1 1,2 1,0 ↑ 1 0,9 0,9 0,8 1,3 ≈ 
RhoA 
24h 1 x 0,6 0,1 0,4 ↓ 1 0,9 0,5 0,5 0,7 ↓ 1 0,7 0,5 0,5 0,4 ↓ 
48h 1 0,2 0,8 1,7 2,1 ↑ 1 1,0 2,3 2,4 1,9 ↑ 1 1,1 1,8 1,3 1,9 ↑ 
RhoGDI 
24h 1 x 1,0 1,0 1,0 ≈ 1 1,6 1,2 1,3 0,7 ↑ 1 2,8 11,0 11,5 1,9 ↑ 
48h 1 0,9 0,8 0,9 0,9 ≈ 1 1,0 0,6 0,2 0,1 ↓ 0 0 0 0 1 ↑ 
PAK1 
24h 1 5,9 6,6 7,3 4,3 ↑ 1 0,6 0,5 0,3 0,2 ↓ 1 0,7 0,4 0,2 0,1 ↓ 
48h 1 2,8 9,0 1,0 0,2 ↑ 1 1,0 2,0 2,3 1,8 ↑ 1 1,5 0,7 0,5 1,2 ≈ 
 
Table III.7. Protein/β-actin ratios. This table shows the different protein/β-actin ratios under 
the influence of the diverse inhibitors from western blot results (Figures III.10 to III.15). 
Abbreviations: Ct: Control (DMSO or water). 
 
 
4-Both Rac1 and Cdc42 are activated in HEL cells 
 
We pulled-down HEL lysates with GST-PAK-PBD beads and found that both Rac1 and 
Cdc42 were activated in HEL lysates. On the contrary, pulled-down essays with GST-
Rhotekin-RBD beads did not show any activation for RhoA. (Figure III.16) 
 
 
 
Figure III.16. Rho activated proteins in HEL cells. HEL lysates were pulled-down with GST-
PAK-RBD and GST-Rhotekin-RBD beads followed by WB developed by Rac1, Cdc42 and RhoA. 
Molecular weights: Rac1: 21 kDa, Cdc42: 21 kDa, RhoA: 22 kDa. 
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5-JAK2 and Calreticulin expression in HEL cells 
 
Concurrently, we also studied JAK2 and CALR expressions in HEL cells as they are 
important actors on MPNs. Figure III.17 shows that JAK2, P-JAK2 and CALR are 
expressed in normal HEL lysates. 
 
 
 
 
Figure III.17. Western blot analysis of HEL lysates. 20 µg of HEL lysates were loaded on 
SDS-PAGE gels and transferred to nitrocellulose membranes to be revealed with suitable antibodies: 
JAK2, P-JAK2, CALR and β-actin. Red arrows point to the correspondent proteins. Blue arrows point 
to β-actin. Molecular weights of targeted proteins: JAK2 and P-JAK2: 131 kDa, CALR: 48 kDa, β-
actin: 42 kDa. 
 
 
The effects of Hydroxyurea, Ruxolitinib and AZD1480 on CALR and JAK2 protein 
expression were also measured as shown in Figures III.18 to III.20 and as resumed in Table 
III.8. In general, JAK2 and P-JAK2 signals were so light that it was difficult to observe any 
variation. Nonetheless, β-actin ratios suggest that JAK2 tended to increase its expression 
under the influence of JAK2 inhibitors. On the opposite, P-JAK2 seemed to decrease under 
the effects of both JAK2 inhibitors. The levels of CALR expression didn’t present any huge 
variation.  
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Figure III.18. JAK2 expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate JAK2/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: JAK2: 131 kDa, β-actin: 42 kDa. 
 
 
 
Figure III.19. Phosphorylated JAK2 expression in HEL cells. Western blots of HEL lysates 
under hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as 
loading control. Numbers indicate P-JAK2/β-actin ratios relative to Control ratios. Ct: Control. 
Molecular weights: P-JAK2: 131 kDa, β-actin: 42 kDa. 
 
 
 
Figure III.20. Calreticulin expression in HEL cells. Western blots of HEL lysates under 
hydroxyurea, Ruxolitinib or AZD1480 conditions and at 24 or 48 hours. β-actin was used as loading 
control. Numbers indicate CALR/β-actin ratios relative to Control ratios. Ct: Control. Molecular 
weights: CALR: 48 kDa, β-actin: 42 kDa. 
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Hydroxyurea Ruxolitinib AZD1480 
  
Ct 50 100 150 250 µM Ct 50 100 200 400 nM Ct 50 100 200 400 nM 
JAK2 
24h 1 0.3 0.7 0.8 1.0 ↓ 1 4.9 2.6 8.4 2.7 ↑ 1 0.9 2.6 8.4 4.6 ↑ 
48h 1 6.2 1.7 5.8 1.5 ↑ 1 45 15 21 7.4 ↑ 1 5.3 2.4 5.6 1.2 ↑ 
P-JAK2 
24h 0 x 0 0 0 ≈ 1 1.1 0.8 0.8 1.1 ≈ 1 1.0 1.3 0.9 0.6 ≈ 
48h 0 0 0 0 0 ≈ 1 2.6 0.7 3.0 2.0 ↑ 1 2.2 0.5 0.6 2.0 ≈ 
CALR 
24h 1 1.2 1.0 0.8 0.6 ≈ 1 0.1 0.5 0.8 0.2 ↓ 1 0.7 0.5 0.1 1.0 ↓ 
48h 1 1.2 1.1 0.8 0.6 ≈ 1 2.1 2.4 3.5 2.0 ↑ 1 1.0 2.0 0.4 2.4 ↑ 
 
Table III.8. Protein/β-actin ratios. This table shows the different protein/β-actin ratios under 
the influence of the diverse inhibitors from western blot results (Figures III.18 to III.20). 
Abbreviations: Ct: Control (DMSO or water). 
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Ba/F3 CELLS 
1-Effects of inhibitors on cell concentration and cell viability 
 
Similarly to HEL cells, the objective was to determine the sensibility to Ruxolitinib 
and AZD1480 of the three Ba/F3 cell lines to select an ideal concentration balanced between 
toxicity and no effect so as to study the effects on protein expression, specifically on the Rho 
family of GTPases. 
 The three types of Ba/F3 cells: Ba/F3 EpoR, Ba/F3 EpoR JAK2 WT and Ba/F3 EpoR 
JAK2V617F were cultured for 24 and 48 hours with JAK2 inhibitors at different 
concentrations. A control with DMSO was used to measure its toxicity (DMSO concentration 
≤ 1%).  
As seen in Figures III.21 to III.23, JAK2 inhibitors hampered cell proliferation after 
24 hours and they induced cell death after 48 hours of incubation in the three cell lines.  
 
 
 
Figure III.21. Effects of Ruxolitinib (A) and AZD1480 (B) on cell concentration and cell 
viability of Ba/F3 EpoR cells. Graphics on the left show cell concentration after 24 and 48 hours of 
incubation at different inhibitor concentrations. Those on the right represent cell viability after 24 
and 48 hours of incubation at different inhibitor concentrations.  
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Figure III.22. Effects of Ruxolitinib (A) and AZD1480 (B) on cell concentration and cell 
viability of Ba/F3 EpoR JAK2 WT cells. Graphics on the left show cell concentration after 24 and 48 
hours of incubation at different inhibitor concentrations. Those on the right represent cell viability 
after 24 and 48 hours of incubation at different inhibitor concentrations.  
 
 
 
Figure III.23. Effects of Ruxolitinib (A) and AZD1480 (B) on cell concentration and cell 
viability of Ba/F3 EpoR JAK2V617F cells. Graphics on the left show cell concentration after 24 and 
48 hours of incubation at different inhibitor concentrations. Those on the right represent cell viability 
after 24 and 48 hours of incubation at different inhibitor concentrations.  
 
 CHAPTER III - Ba/F3 and HEL cells as models on the study of MPN deregulations 
146 
 
2-Rho GTPase family expression in Ba/F3 cells 
 
The expressions of IQGAP1, Rac1, RhoA and phosphorylated PAK1 were measured 
under different conditions. First culture conditions, (referred to as “Control”), consisted of 
DMEM medium with 1% penicillin/streptomycin, 1% glutamine, 10% FBS and 1UI EPO. 
Second one consisted of deprivation conditions without either FBS or EPO in order to see 
the effects of environmental distress on our protein expressions. Finally, cells were cultured 
under deprivation conditions with JAK2 inhibitors (500 nM Ruxolitinib and AZD1480). All 
cells were cultured during 6 hours and lysed for western blotting. (Figure III.24). 
 
 
 
 
Figure III.24. Protein expression in Ba/F3 cells. Cells were cultured under different conditions; After 6h, 
cells were lysed, run on SDS-PAGE gels followed by western blotting incubated with suitable antibodies. A) 
IQGAP1 expression, B) Rac1 expression, C) RhoA expression and D) P-PAK1 expression. Β-actin was used as 
loading control. Abbreviations: Ct: Control, D: Deprivation of FBS and EPO, R: Ruxolitinib 500 nM, A: AZD1480 
500 nM. Molecular weights of targeted proteins: IQGAP1: 189 kDa, P-PAK1: 61 kDa, Rac1 21 kDa, RhoA 22 
kDa, β-actin: 42 kDa. 
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  EpoR WT V617F 
IQGAP1 
Control 0.57 1.50 0.28 
Deprivation 0.61 1.58 5.87 
D + Ruxolitinib 0.79 2.14 0.37 
D + AZD1480 0.41 2.50 0.83 
Rac1 
Control 0.76 0.04 0.55 
Deprivation 0.70 0.04 3.10 
D + Ruxolitinib 0.42 0.20 0.31 
D + AZD1480 0.86 0.50 0.29 
RhoA 
Control 0.04 0.04 0.43 
Deprivation 0.03 0.05 0.66 
D + Ruxolitinib 0.04 0.05 0.34 
D + AZD1480 0.02 0.03 0.02 
P-PAK1 
Control 0.07 0.07 0.02 
Deprivation 0.13 0.09 0.64 
D + Ruxolitinib 0.09 0.05 0.03 
D + AZD1480 0.10 0.06 0.05 
 
  EpoR WT V617F 
Control 
conditions 
IQGAP1 0.57 1.50 0.28 
Rac1 0.76 0.04 0.55 
RhoA 0.04 0.04 0.43 
P-PAK1 0.07 0.07 0.02 
Deprivation 
(FBS-, EPO-) 
IQGAP1 0.61 1.58 5.87 
Rac1 0.70 0.04 3.10 
RhoA 0.03 0.05 0.66 
P-PAK1 0.13 0.09 0.64 
Deprivation + 
Ruxolitinib 
(500nM) 
IQGAP1 0.79 2.14 0.37 
Rac1 0.42 0.20 0.31 
RhoA 0.04 0.05 0.34 
P-PAK1 0.09 0.05 0.03 
Deprivation + 
AZD1480 
(500nM) 
IQGAP1 0.41 2.50 0.83 
Rac1 0.86 0.50 0.29 
RhoA 0.02 0.03 0.02 
P-PAK1 0.10 0.06 0.05 
 
Table III.9 and III.10. Protein/β-actin ratios. These tables show the different protein/β-actin 
ratios on the diverse conditions and cell lines from western blot results (Figure III.24). First arrow 
indicates ratio variations comparing WT with EpoR and second one V617F with EpoR. Abbreviations: 
D: Deprivation; EpoR: Ba/F3 EpoR; WT: Ba/F3 EpoR JAK2 WT; V617F: Ba/F3 EpoR JAK2V617F. 
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As shown in Tables III.9 and III.10, we first compared protein expressions under 
control conditions (presence of serum and EPO). Interestingly, over-expression in Ba/F3 
cells of JAK2 WT was associated with an upregulation of IQGAP1 expression comparatively 
with EpoR cells which do not overexpress JAK2. In contrast, JAK2V617F cells showed a net 
decrease (x2) of IQGAP1 levels at steady state, (control cell culture conditions). IQGAP1 
expression was the lowest in mutated JAK2 cells compared with JAK2 WT and EpoR. 
 
Concerning other proteins at steady state, Rac1 and RhoA were expressed at variable 
amounts in the different types of Ba/F3 cells. Both proteins were overexpressed in 
JAK2V617F cells in comparison with JAK2 WT cells, even though their levels in non-
transfected cells varied. P-PAK1 levels seemed to be non-affected by overexpression of JAK2 
either WT or V617F compared with control. 
 
Dynamic evolution of IQGAP1 and Rho GTPase members was also studied using 
serum deprivation which allows studying the impact of JAK2V617F. Firstly, we observed 
that under these distress conditions the expression of all proteins showed a markedly 
increase in Ba/F3 EpoR JAK2V617F cells; x9.7; 4.4; 22 and 4.9 for IQGAP1, Rac1, RhoA and 
P-PAK1 respectively (compared with EpoR cells) and x3.7; 77.5; 13.2 and 7.1 compared with 
JAK2 WT ones. It is noteworthy that these four proteins displayed less or none significant 
variations in Ba/F3 EpoR and JAK2 WT when these cells were cultivated under deprivation. 
We also noticed that IQGAP1, which was upregulated in JAK2 WT (vs controls), did not 
display variation in these stress conditions. 
 
When we combined JAK2 inhibitors with deprivation, levels of all upregulated 
proteins in JAK2V617F cells under distress conditions, were decreased to levels very closed 
to or under their steady state levels unlike RhoA which seemed less sensitive to Ruxolitinib.  
Interestingly, the impact of these inhibitors on JAK2 WT cells was quite negative 
since we observed no decrease, even a slight increase of proteins (mainly IQGAP1). 
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3-Rac1 and Cdc42 are activated in Ba/F3 EpoR JAK2 V617F cells 
 
GST-Rhotekin-RBD and GST-PAK-PBD agarose beads were used to establish if Rho 
proteins were activated in Ba/F3 cells. As shown in Figure III.25, Rac1 and Cdc42 were 
activated in all 3 cell lines but not RhoA. In order to normalize the amount of protein 
loaded, we calculated Rac1/GST and Cdc42/GST ratios. We observed that Rac1 presented 
variations on its activation as it was more active in Ba/F3 EpoR cells than in those 
overexpressing JAK2 WT and in those ones more than in mutated ones. The effects of JAK2 
inhibitors increased its activation. Similarly, Cdc42 was more active in Ba/F3 EpoR cells 
than in mutated ones were it was almost non-active.  
 
 
 
 
 
Figure III.25. Pull-down assays of activated proteins of the Rho family. 500 µg of protein were 
pulled-down with GST-PAK-PBD (A, B and D) and GST-Rhotekin-RBD (C) agarose beads. Elution 
was made with 60 µL of 2x Sample Buffer with β-mercaptoethanol (5 min at 95°C) followed by 
western blotting revealed with anti Rac1 (A), Cdc42 (B), RhoA (C) or GST (D) antibodies. The ratios 
between Rac1 and Cdc42/GST are under the images. Abbreviations: Ct: control; R: 500 nM 
Ruxolitinib; A: 500 nM AZD1480. Molecular weights: Rac1: 21 kDa, Cdc42: 21 kDa, RhoA: 22 kDa, 
GST: 26 kDa. 
 
 
4-JAK2 and Calreticulin expression in Ba/F3 cells 
 
In similarity as performed for the Rho GTPase family, we also inquired into the 
expression of CALR and JAK2 proteins in the same conditions as seen before (Figure III.26). 
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Figure III.26. Protein expression in Ba/F3 cells with inhibitors. Cells were cultured under 
different conditions; Ct: Control, D: Deprivation of FBS and EPO, R: Ruxolitinib 500nM, A: AZD1480 
500nM. After 6h, cells were lysed and run on SDS-PAGE gels for western blotting. A) JAK2 
expression and B) CALR expression. Β-actin was used as loading control. Molecular weights of 
targeted proteins: JAK2: 131 kDa, CALR: 48 kDa, β-actin: 42 kDa0. 
 
  EpoR WT V617F 
JAK2 
Control 0.16 0.24 1.63 
Deprivation 0.19 0.01 0.44 
D + Ruxolitinib 0.16 0.19 0.52 
D + AZD1480 0.10 0.22 0.41 
CALR 
Control 0.45 0.16 0.19 
Deprivation 0.42 0.16 8.1 
D + Ruxolitinib 0.39 0.24 0.21 
D + AZD1480 0.37 0.15 0.32 
 
  EpoR WT V617F 
Control 
conditions 
JAK2 0.16 0.24 1.63 
CALR 0.45 0.16 0.19 
Deprivation 
(FBS-, EPO-) 
JAK2 0.19 0.01 0.44 
CALR 0.42 0.16 8.1 
D + Ruxolitinib 
(500nM) 
JAK2 0.16 0.19 0.52 
CALR 0.39 0.24 0.21 
D + AZD1480 
(500nM) 
JAK2 0.10 0.22 0.41 
CALR 0.37 0.15 0.32 
 
Table III.11 and III.12. Protein/β-actin ratios. These tables show the different protein/β-actin 
ratios on the diverse conditions and cell lines from the western blot results (Figure III.26). 
Abbreviations: D: Deprivation; EpoR: Ba/F3 EpoR; WT: Ba/F3 EpoR JAK2 WT; V617F: Ba/F3 EpoR 
JAK2V617F. 
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As expected, JAK2 expression in control culture conditions was increased in 
JAK2V617F cells and at a lesser degree in Ba/F3 EpoR JAK2 WT compared with non-
transfected ones. Under deprivation conditions, we observed a significant decrease of both 
JAK2 WT and JAK2V617F compared with control conditions. The addition of inhibitors in 
deprivation conditions corrected JAK2 expression in WT cells, reaching levels closed to 
those observed in control culture. However, in JAK2V617F cells, inhibitors partially 
corrected the decreased induced by deprivation.  
The protein Calreticulin was globally expressed at similar levels in JAK2 WT and 
JAK2V617F cells but slightly lower in those JAK2 transfected cells compared with control 
cells (Ba/F3 EpoR cells). However, when cells were deprived of serum, we observed, in 
comparison with normal conditions, a very significant increase (x42) of CALR in 
JAK2V617F cells. In contrast, CALR levels in JAK2 WT or EpoR cells in the same 
deprivation conditions were not altered. As observed for Rho proteins, P-PAK1 and IQGAP1 
when using JAK2 inhibitors this up-regulation was annihilated.  
Unfortunately, western blot assays for phosphorylated JAK2 didn’t work. 
 
5-IQGAP1 effectors in Ba/F3 cells  
 
In order to detect IQGAP1 effectors, we immunoprecipitate Ba/F3 cell lysates with 
IQGAP1 followed by western blotting. Figure III.27 shows that when we revealed with anti-
mouse antibodies, plenty of lines appeared on the membranes. Theoretically, Rac1 and 
Cdc42 should be the bands present around the band marker of 25-26 kDa. Nevertheless, 
after dehybridization and incubation with first antibodies followed by protein A, membranes 
didn’t present any signal even though the protein A should emphasize heavy chains 
suggesting that IQGAP1 didn’t immunoprecipitate with Rac1 or Cdc42. 
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Figure III.27. IQGAP1 effectors. 1000 mg of protein were lysed an immunoprecipitated with 
rabbit polyclonal anti-IQGAP1 antibodies followed by western blotting. A) Western blots revealed 
with anti-mouse antibodies. B) Western blots revealed with protein A. Molecular weights of targeted 
proteins: Rac1: 21 kDa, Cdc42: 21 kDa. 
 
 
 
Furthermore, we immunoprecipitated Ba/F3 cell lysates with JAK2 antibodies and 
revealed it with IQGAP1 antibodies to see if there could be a link between these two 
proteins. As shown in Figure III.28, IQGAP1 co-immunoprecipitated with JAK2 in all cell 
lysates independently of JAK2 inhibitors. We remarked that a band appeared around 100 
kDa that could correspond to IQGAP1 degradation. Nonetheless, PAK1 didn’t co-
immunoprecipitate with JAK2. 
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Figure III.28. JAK2 effectors. 1000 mg of protein were lysed an immunoprecipitated with 
JAK2 antibodies followed by western blotting. A) Ba/F3 EpoR, Ba/F3 EpoR JAK2 WT and Ba/F3 
EpoR JAK2V617F cell lysates revealed with IQGAP1 antibodies under inhibiting conditions: Ct: 
Control; Ruxo: Ruxolitinib 600nM; AZD: AZD1480 600nM. B) Ba/F3 EpoR JAK2V617F cell lysates 
revealed with PAK1 antibodies under inhibiting conditions: Ct: Control; Ruxo: Ruxolitinib 600nM; 
AZD: AZD1480 600nM. Molecular weights: IQGAP1: 189 kDa, PAK1: 61 kDa. 
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DISCUSSION 
1-Effects of inhibitors on cell concentration and cell viability 
 
In HEL cells, as shown in results, hydroxyurea’s capacity for blocking cell proliferation 
is stronger than Ruxolitinib’s or AZD1480’s at concentrations tested. We should have tried 
higher concentrations of Ruxolitinib and AZD1480 to see more effects. In fact, Bogani et al. 
(189) reported that the IC50 of Ruxolitinib and AZD1480 in HEL cells after 24 hours were 
0.79±0.15 µM and 0.86±0.02 µM respectively. Contrarily, Barrio et al. (198) also measured 
IC50 of Ruxolitinib in HEL cells being 274 nM. Therefore, we just used concentrations up to 
600 nM and as we couldn’t observe the apoptotic effects of these drugs; our results may 
agree with those of Bogani et al. (189) and we should have used higher concentrations to see 
the apoptotic induction of these inhibitors. To sum up, at tested concentration ranges, 
hydroxyurea was more effective providing apoptosis and preventing cell division and 
proliferation than JAK2 inhibitors in HEL cells. 
 
The effects of JAK2 inhibitors in Ba/F3 cells were higher than in HEL cells. As seen in 
Figures II.21 to II.23, in all types of Ba/F3 cells, at 48 hours of incubation, cell proliferation 
decreased markedly as cells were induced into apoptosis. Bogani et al. (189) also measured 
the effects of these JAK2 inhibitors on Ba/F3 cells. They obtained less viability than us after 
48 hours of incubation. However, they did not incubate cells with EPO as we did. They 
showed that the addition of EPO to cell culture protected cells from the inhibitory effects of 
JAK2 inhibitors increasing their IC50: 313±23 nM for AZD1480 in Ba/F3 JAK2V617F cells 
vs 707±11 nM with EPO and 220±20 vs 521±45 nM for Ruxolitinib in Ba/F3 JAK2 V617F 
cells without and with EPO respectively. Barrio et al. (198) also measured the IC50 of 
Ruxolitinib in Ba/F3 cells obtaining 157.5 nM for JAK2V617F cells and 137.4 for the wild 
type. Differences in IC50 values may be due to the fact that Barrio et al. (198) supplemented 
cell media with IL-3 and Bogani et al. (189) used ±EPO. 
Therefore, these results suggested that Ba/F3 cells are more sensitive to Ruxolitinib 
and AZD1480 than HEL cells and that these drugs are capable of inducing apoptosis and 
inhibiting proliferation. The fact that Ba/F3 cells are supplemented with EPO reduces JAK2 
effects but not when supplemented with IL-3. 
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2-Cell cycle analysis 
 
Cell cycle disturbances of HEL cells under drug incubation were measured by flow 
cytometry. After 24 hours of drug incubation, we saw how hydroxyurea blocked cells on the 
S phase in a dose-dependent manner whereas cells on the G0/G1 and G2/M phases 
decreased similarly. For Ruxolitinib, we observed similar but less marked effects. When 
treated with AZD1480 we remarked a huge fall of cells on the G0/G1 phase while the 
proportion of cells on S and G2/M phases rose; thus cell cycle was blocked on the S phase 
after 24 hours.  
Nevertheless, after 48 hours of drug incubation, we saw that cells treated with high 
doses of hydroxyurea tried to repair drug effects and to continue normal cell cycles (number 
of cells on S phase decreased and number of cells on G2/M phase went up) but reparation 
mechanisms didn’t work and cells turned to apoptosis, (increased proportion of death cells). 
These results agreed with the ones got by Gui et al. (199) who demonstrated how HEL cells 
turned to apoptosis when treated with HU. For AZD1480, at the highest dose after 48 
hours, cells also turned into apoptosis as we saw a big amount of cells on the left part of the 
graphic and the number of cells in replication phases almost decreased to zero. Cells were 
blocked at G0/G1 phase with subsequent reduction of the S and G2/M phases. The effects of 
Ruxolitinib after 48 hours of incubation didn’t vary among the different concentrations. We 
just observed that the amount of cells on S and G2/M phases decreased as the number of 
cells on G0/G1 phase was more or less stable as long as we increased drug concentrations 
suggesting that cells were blocked on G0/G1 phase. 
 
3-Protein expression in Ba/F3 EpoR, Ba/F3 JAK2 WT, Ba/F3 EpoR 
JAK2V617F and HEL cells 
 
This model of cell lines brought out some teaching about the link between JAK2V617F 
and IQGAP1/Rho GTPase signaling. 
 
First, we had observed in erythrocytes different levels of IQGAP1 according to JAK2 
status; JAK2 WT patients expressed higher levels than JAK2V617F ones. In Ba/F3 cells, we 
clearly observed that Ba/F3 EpoR JAK2 WT cells also expressed higher levels of IQGAP1 
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than Ba/F3 EpoR JAK2V617F. In HEL cells, we indirectly confirmed this JAK2(-) 
dependent regulation of the amount of IQGAP1 protein. Indeed, levels of IQGAP1 increased 
in HEL cells, which are JAK2V617F, when using JAK2 inhibitors which down-regulate the 
levels of JAK2V617F activity. Up-regulation of IQGAP1 levels did not seem to correlate with 
the amount of JAK2 protein itself (including JAK2 WT and JAK2V617F) since in our 
experience, higher levels of JAK2 protein were found in Ba/F3 EpoR JAK2V617F cells 
contrasting with the lowest levels of IQGAP1. Moreover, JAK2 inhibitors but not 
hydroxyurea increased JAK2 levels in HEL cells similarly to IQGAP1. We could hypothesize 
that in presence of JAK2 inhibitors, cells could promote JAK2 (and IQGAP1) transcription 
to counteract their effect. 
 
We also underscore a particular link between JAK2 and IQGAP1 by our 
immunoprecipitation results. We inquired into JAK2 possible links with IQGAP1 and saw 
that these two proteins co-immunoprecipitated together in the three types of Ba/F3 
suggesting that this co-precipitation was not affected by the mutation of the pseudo kinase 
domain of JAK2 protein (JH2). Liu et al. (172) studied IQGAP1 new binding partners 
through the “sequence repeats” of this protein but did not propose JAK2 as one of them. 
Nevertheless, JAK2 could potentially bind IQGAP1 as it presents a FERM domain 
comprised between JH4 and JH7 domains. Thus, our results confirmed in cellulo the 
potential link between these two proteins. The fact that this interaction was not perturbed 
by the addition of JAK2 inhibitors confirmed that JAK2(-) IQGAP1 relationship is not 
influenced by JAK2 mutation. Moreover, we noticed that a band appeared around 100 kDa 
in JAK2 immunoprecipitations. IQGAP1 antibody recognizes the sequence comprised 
between 314 and 422 amino acids on the N-terminal part that corresponds to the WW 
domain (see Figure I.13 on the chapter I of the manuscript) present next to the “sequence 
repeats” domain proposed to link JAK2. Therefore, even if IQGAP1 cleavage took place next 
to the C-terminal resulting in a ~100 kDa peptide, IQGAP1 could precipitate with JAK2. 
 
The analysis of Ba/F3 cells demonstrated a direct link between JAK2V617F presence 
and the deregulation of the IQGAP1/Rho GTPase signaling. JAK2V617F is well known to 
induce a cytokine independent proliferation mediated by constitutive activation of the JAK-
STAT pathway. This impact is better evidenced in culture conditions deprived of growth 
factors and serum which induce, in normal cells, a stress that could lead to apoptosis. We 
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therefore evaluated the impact of such conditions (referred to as deprivation in our study) 
on IQGAP1/Rho GTPase signaling. We hence highlighted that all tested partners of this 
pathway could be clearly up-regulated in such metabolic stress but only in cells expressing 
JAK2V617F. This effect was confirmed to be JAK2V617F dependent since using JAK2 
inhibitors we were able to impede this up-regulation in JAK2V617F cells, (without any 
effect on JAK2 WT cells). These data strongly suggest a direct link between JAK2V617F 
and Rho signaling alteration. On the other hand, they propose that, in parallel to 
constitutive activation of JAK-STAT pathway, activation of IQGAP1/Rho GTPase signaling 
could be implicated in autonomous growth induced by JAK2V617F. The fact that P-PAK1 is 
similarly influenced by deprivation and JAK2 inhibitors is in favor of a potential role of 
these inhibitors on membrane homeostasis via regulation of PAK1 recruitment and 
activation. This highlights a potential impact of JAK2 inhibitors in thrombotic 
complications via P-PAK1 regulation. 
 
The results on Rac1 and Cdc42 activation showed that both are more or less activated 
in all types of Ba/F3 and HEL cells in normal culture conditions. This suggests that either 
their activation is not dependent on JAK2 mutation or that Ba/F3 cells have developed an 
internal mechanism of activation linked to EpoR expression that could activate Rac1 and 
Cdc42 probably linked with the protein JAK2 itself.  
 
Results on CALR protein expression are also informative of new relationships between 
CALR and JAK2V617F. Indeed, in similar deprivation conditions that revealed JAK2V617F 
effects, we observed a very significant increase of CALR expression sensitive to JAK2 
inhibitors. Of note, in granulocytes we showed that CALR amount was significantly higher 
in JAK2V617F granulocytes compared with JAK2 WT. We can therefore hypothesize that 
JAK2V617F mutation could induce up-regulation of CALR, at least in some cells, and 
thereby induce modification of cellular pathways regulated by its global chaperone activity. 
This hypothesis would suggest that new mechanisms complementary to JAK-STAT 
pathway could be deregulated via JAK2V617F. Finally, these data underscore a dual 
oncogenic potential of CALR in MPNs via its mutated form (as previously published) but 
also through the up-regulation of the native protein. 
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CONCLUSION AND PERSPECTIVES 
 
In this third part we confirmed, in the cell model of Ba/F3 cell lines overexpressing 
JAK2V617F, that there was indeed a special connection between the presence of JAK2 
mutation and IQGAP1/Rho GTPases signaling alterations and emphasized a potential 
oncogenic role of unmutated JAK2 and CALR proteins. HEL and Ba/F3 cell models let us 
confirm that hydroxyurea and JAK2 inhibitors have a cell growth potential as they blocked 
cell proliferation leading cells to turn into apoptosis.  
 
Altogether, these data raise some new issues: 
1-Does JAK2V617F have any influence on the IQGAP1/Rho GTPase 
complexes? 
The role of JAK2 mutation on IQGAP1/Rho GTPase signaling is remarkable as the 
tested members of this signaling increased their levels of expression under distress 
conditions in JAK2V617F cells. To confirm the implication of IQGAP1/Rho GTPases 
activation in the autonomous cell growth, it would be interesting to investigate the impact 
of blocking this signaling on Ba/F3 cell proliferation under deprivation conditions. 
Moreover, IQGAP1 links with its Rho GTPase effectors, which we have actually 
demonstrated in RBCs, remains to be explored in this model of Ba/F3 cells as well as the 
possible effects that distress conditions and JAK2 inhibitors may have on the formation of 
IQGAP1/Rho GTPases complexes especially in mutated JAK2 cells. 
 
2-Is there any link between STAT5/3 and IQGAP1/Rho GTPase 
signaling? 
JAK2V617F is well known to induce autonomous cell growth through activation of 
STAT proteins. As our results demonstrated a direct link between IQGAP1/Rho GTPase 
signaling and the presence of JAK2V617F, it is licit to ask whether STAT5/3 are implicated 
in IQGAP1/Rho GTPases deregulation. Phosphorylated STAT5 has been demonstrated to 
induce NADPH oxidase ROS production via its binding to Rac1, which is part of NADPH 
oxidase complex. In contrast, inactivated STAT5 has a protective effect due to the fact that 
it reduces Rac1 binding and ROS production (200). In addition, Rac1 was shown to 
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indirectly activate STAT3 by phosphorylation promoting nuclear translocation and gene 
expression in HeLa cells (201). It is proposed that active Rac1 leads to NF-kB activation and 
thus IL-6 gene induction. Then, IL-6 binds its receptor activating JAKs and subsequently 
tyrosine phosphorylation and activation of STAT3. Moreover, Debidda et al. (202) found that 
apart from active Rac1, active Cdc42 and RhoA could also promote tyrosine and serine 
phosphorylation of STAT3 independently from IL-6. However, Rho GTPases activate STAT3 
in and indirect way. This activation implies nuclear translocation and regulation of cellular 
functions such as actin cytoskeleton reorganization, cell migration, gene activation and 
proliferation. Kanda et al. (203) showed that Rac was activated via phosphorylation of 
JAK2(-) EpoR in hematopoietic cells promoting cell adhesion.  
Altogether these data from the literature strongly imply a link between IQGAP1/Rac1 
and the STATs activation that remains to be explored. 
 
3-Does CALR mutations induce deregulation of IQGAP1/Rho GTPase 
signaling? 
Our results in erythrocytes underscored differences between CALR(+) and JAK2 
mutated patients in the nature of IQGAP1/Rho GTPase interactions particularly concerning 
RhoGDI recruitment. Moreover, we observed that CALR protein displayed functional 
alterations in MPN erythrocytes (independently of CALR mutation). However, we lack of 
confirmation of these observations in a cellular model. The use of Ba/F3 cells expressing 
CALR mutation should answer these issues. 
 
4-Does up-regulation of CALR protein participate to autonomous 
growth of cells? 
Our results stressed out an up-regulation of the CALR protein in JAK2V617F Ba/F3 
cells cultured without serum nor growth factor. These unexpected data suggest that CALR 
up-regulation could participate to mechanisms implicated in autonomous growth. Hence, it 
would be informative to study the potential impact of CALR up-regulation in a cell model 
expressing high levels of CALR (mutated or not). 
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RESUME DU CHAPITRE III 
 
L’utilisation des lignées cellulaires HEL (qui possède JAK2V617F de façon 
constitutive) et des lignées Ba/F3 EpoR, surexprimant JAK2 dans sa forme native (Ba/F3 
EpoR JAK2 WT) ou dans sa forme mutée (Ba/F3 EpoR JAK2V617F) nous a permis d’évaluer 
les liens entre la mutation JAK2 et les protéines de la voie de signalisation IQGAP1/ Rho 
GTPases.  
L’évaluation des inhibiteurs sur ces cellules a montré que l’hydroxyurée était plus 
effective sur les cellules HEL en favorisant l’apoptose et en empêchant la division et la 
prolifération cellulaires que les inhibiteurs de JAK2. Par contre, l’impact des inhibiteurs a 
été plus marqué sur les Ba/F3.  
Dans le modèle Ba/F3 nous avons pu confirmer l’observation faite dans les globules 
rouges que les niveaux d’IQGAP1 se rattachent à la présence de JAK2 WT et non à la 
présence de JAK2V617F ni à sa quantité d’allèle muté. En outre, les inhibiteurs de JAK2 
font augmenter les niveaux d’IQGAP1 ce qui supporte ces résultats. 
La culture des lignées cellulaires Ba/F3 sous des conditions de stress, c’est à dire, 
privées de sérum et d’érythropoïétine, en comparaison avec les conditions normales, montre 
une augmentation très significative des protéines de la voie IQGAP1/Rho GTPases qui 
retournent à leurs niveaux de base quand on ajoute les inhibiteurs de JAK2. Ces résultats 
confirment donc  une grosse influence de JAK2V617F dans la régulation de cette voie de 
signalisation. En plus, nous avons montré par co-précipitation un lien entre IQGAP1 et 
JAK2 qui ne dépend pas du domaine muté de JAK2. 
Finalement, nos résultats mettent en lueur l’effet direct de JAK2V617F, sensible à 
l’action des inhibiteurs de JAK2, sur les niveaux d’expression de la protéine calréticuline en 
conditions de culture sans facteur de croissance. Tenant compte de nos observations sur les 
polynucléaires, ces résultats soulignent un nouveau mode d’action de la calréticuline dans la 
pathogenèse des SMP via la régulation de son niveau d’expression qui pourrait modifier les 
nombreuses voies au niveau desquelles elle intervient comme protéine chaperonne. 
En conclusion, ces modèles cellulaires nous ont permis de montrer les liens 
particuliers entre la mutation JAK2V617F  et la voie IQGAP1/Rho GTPases et de mettre à 
jour un role original de la calréticuline. 
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The aim of my work was to characterize proteomic deregulations in Ph- MPNs that 
would help us better understand the mechanisms in myeloid cells that brought to 
uncontrolled proliferation as well as pathways implicated in some complications such as 
thrombotic complications. 
 
The proteomic approach of Ph- MPN erythrocytes and granulocytes revealed more 
than 1000 proteins in each type of cell. Among them, we highlighted significant protein 
deregulations that varied not only according to the genetic status JAK2(+) vs JAK2(-) or 
JAK2(+) vs CALR(+) but also among JAK2(+) MPNs or depending on the JAK2V617F allele 
burden. Among this landscape of proteome alterations in MPNs, we stressed out 5 
functional pathways that seem particularly implicated in MPN pathogenesis. 
 
Firstly, we were able to reveal and decipher the particular role of the alterations of the 
IQGAP1/Rho GTPase signaling in MPNs. We highlighted that IQGAP1 was up regulated in 
RBCs according to JAK2 and CALR status, in Ba/F3 JAK2V617F under stress conditions 
and in granulocytes when comparing PMF with PV and ET. Subsequently, we showed that 
the recruitment of the Rho GTPases by IQGAP1 in RBCs depended on JAK2(+) and 
CALR(+) status. We also showed the up-regulation of these proteins in Ba/F3 JAK2V617F 
cells under stress conditions. Altogether, these data imply a particular role of IQGAP1/Rho 
GTPase signaling in the autonomous growth of MPNs additionally to JAK-STAT pathway 
activation. The concordance and the complementarity of our data in erythrocytes, 
granulocytes and Ba/F3 cell line models reinforced by the impact of JAK2 inhibitors and the 
connection between IQGAP1 and JAK2 proteins, plead for a critical oncogenic role of this 
pathway in JAK2V617F MPNs. 
 
We also found a big deregulation of ROS related proteins, in particular the 
myeloperoxidase and those involved in detoxification pathways. The Transcriptomic 
analysis confirmed the implication of oxidative stress in the pathophysiology of MPNs. We 
highlighted that the oxidative stress related catalase (CAT) was under-regulated due to a 
decreased on the expression of the CAT gene in JAK2V617F MPN subjects. Moreover, we 
observed a significant variation of the catalase protein expression among MPN subtypes 
and particularly lower levels were found in JAK2(+) MPNs vs JAK2 WT. This latter 
observation could suggest that JAK2V617F induces a decrease of catalase expression 
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participating in the oncogenic role of this mutation. Altogether, our data confirmed, in 
clinical samples, the prominent role of ROS balance in MPN physiopathology. 
 
Besides, we were able to underline a significant deregulation of proteins implicated in 
the membrane cytoskeleton and actin signaling closed to IQGAP1/Rho GTPase signaling. In 
particular, we demonstrated that PAK1 alteration was associated with IQGAP1 up-
regulation in RBCs and in Ba/F3 JAK2V617F cells. Focal Adhesion Kinase (FAK) pathways, 
which are activated by RhoA, also appeared deregulated in ET vs Controls in RBCs. 
Altogether, these deregulations may play an important role on the membrane integrity of 
RBCs or other cell types and therefore induce alterations of cell adhesion that could be 
connected with thrombotic events so frequent in these patients. 
 
Finally our data highlighted mTOR pathway deregulation in JAK2V617F 
granulocytes, which was not surprising taking into account knowledge about the implication 
of this pathway in oncogenesis but also in the light of promising results obtained with 
therapies targeting this pathway in MPNs. CALR up-regulation linked to S100 protein 
alterations observed in granulocytes could be the cause of Ca2+ deregulations in JAK2V617F 
granulocytes that could play a role in MPNs even though currently no data from the 
literature have confirmed this hypothesis. 
 
Regarding CALR protein expression, our data allow hypothesizing additional roles of 
CALR in MPN oncogenesis through its up-regulation. It must be stressed that Calreticulin 
appeared over-expressed in JAK2V617F granulocytes compared with non-mutated ones 
independently of JAK2V617F allele burden even if its expression didn’t present any 
variation in RBCs. Moreover, when we looked for CALR expression in our cell model, we 
underlined that CALR levels were also positively influenced by JAK2V617F under stress 
conditions suggesting that this mutation could increase CALR expression in some MPN 
cells. Hence, CALR could have a dual oncogenic role through its up-regulation in 
JAK2V617F MPN or though the alteration of its function in CALR mutated patients. 
 
Altogether, these data showed that proteomic deregulations in Ph- MPN cells play an 
important oncogenic role in uncontrolled cell proliferation and could be implicated in 
complication as thrombotic accidents. Differences on the proteome among genetic status, 
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(JAK2(+), JAK2(-) or CALR(+)), and diagnosis (PV, ET or PMF), could explain some 
phenotypical differences found among these patients. Nevertheless, the number of 
deregulated proteins, compared with the total number of quantified proteins, remains quite 
low. Indeed, globally just 5 to 15% of the proteome displayed significant variations in MPNs. 
The study of the functional role of these deregulated proteins showed that a limited number 
of pathways were found commonly deregulated in MPNs by these proteome variations. This 
confirms that a little number of pathways is mandatory to maintain the control of myeloid 
cell proliferation, and consequently, that proteins of these pathways could play a critical 
role on MPN pathogenesis. This dependence on proteins may be closed to the concept of 
oncogene addiction and, by analogy, this protein dependence could lead to new therapeutic 
targets. 
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SUPPLEMENTAL DATA I 
Supplemental Data I-1 
 
Lists of deregulated proteins in erythrocytes between the different subgroups: JAK2V617F 
PV, JAK2V617F ET, JAK2(-) ET and controls. 
List of most upregulated proteins in JAK2V617F PV vs control patients  
Protein name p-value Ratio 
C8orf62 Phosphoserine aminotransferase 0.022 Infinite 
RABGGTA Geranylgeranyl transferase type-2 subunit alpha 0.005 Infinite 
PHKB Isoform 1 of Phosphorylase b kinase regulatory subunit beta 0.009 Infinite 
IGHG4 Putative uncharacterized protein DKFZp686M24218 0.021 Infinite 
SMS Isoform 1 of Spermine synthase 0.025 18.483 
MYH10 Isoform 3 of Myosin-10 0.009 13.055 
TRIM58 Tripartite motif-containing protein 58 0.038 11.327 
PSMB8 Isoform 2 of Proteasome subunit beta type-8 0.017 8.289 
CASP8 Isoform 4 of Caspase-8 0.015 8.236 
CYB5A Isoform 1 of Cytochrome b5 0.027 7.021 
TNPO1 Isoform 2 of Transportin-1 0.017 6.670 
IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 0.020 5.571 
ANXA3 Annexin A3 0.044 5.528 
MYH9 Isoform 1 of Myosin-9 0.003 5.427 
APOA1 Apolipoprotein A-I 0.027 5.401 
MYL4 Myosin light chain 4 0.003 5.083 
MYL12B Myosin regulatory light chain 12B 0.009 4.947 
PRIC285 Isoform 2 of Peroxisomal proliferator-activated receptor A-
interacting complex 285 kDa protein 
0.024 4.841 
IFI35 Isoform 2 of Interferon-induced 35 kDa protein 0.011 4.229 
DNM1L cDNA FLJ55044, highly similar to Dynamin-1-like protein 0.011 4.218 
TSG101 Isoform 2 of Tumor susceptibility gene 101 protein 0.027 3.508 
S100A9 Protein S100-A9 0.029 3.448 
DPCD Protein DPCD 0.024 3.431 
TTC38 Tetratricopeptide repeat protein 38 0.017 3.405 
ARPC5 Isoform 1 of Actin-related protein 2/3 complex subunit 5 0.038 3.378 
EEF1A1 Elongation factor 1-alpha 1 0.013 3.338 
ARPC1B cDNA FLJ57124, highly similar to Actin-related protein 2/3 
complex subunit 1A 
0.038 3.321 
LAP3 Isoform 1 of Cytosol aminopeptidase 0.045 3.185 
YARS Tyrosyl-tRNA synthetase, cytoplasmic 0.015 3.058 
MYL6B 16 kDa protein 0.006 2.854 
DCTN5 Dynactin subunit 5 0.026 2.824 
RPSAP15;RPSA 40S ribosomal protein SA 0.048 2.727 
GCA 22 kDa protein 0.047 2.621 
ACTN1 Alpha-actinin-1 0.003 2.543 
SUPPLEMENTAL DATA I 
 
184 
 
DCTN3 Isoform 3 of Dynactin subunit 3 0.038 2.365 
KPNA1 Importin subunit alpha-1 0.010 2.311 
ACTN4 cDNA FLJ58087, highly similar to Alpha-actinin-4 0.045 2.311 
NIT1 Isoform 5 of Nitrilase homolog 1 0.006 2.295 
DHRS11 Isoform 1 of Dehydrogenase/reductase SDR family member 11 0.007 2.226 
AARS cDNA FLJ61339, highly similar to Alanyl-tRNA synthetase 0.004 2.211 
GNPDA1 Glucosamine-6-phosphate isomerase 1 0.013 2.203 
TPT1 Tumor protein, translationally-controlled 1 0.003 2.160 
TSTA3 GDP-L-fucose synthetase 0.001 2.156 
TLN2 Talin-2 0.012 2.129 
DCTN2 dynactin 2 0.026 2.081 
PCBP1 Poly(rC)-binding protein 1 0.032 2.077 
ANXA7 Isoform 1 of Annexin A7 0.004 2.057 
PPCS Phosphopantothenate--cysteine ligase 0.014 2.048 
VPS35 Vacuolar protein sorting-associated protein 35 0.012 2.033 
CLIC2 Chloride intracellular channel protein 2 0.006 2.033 
ACTR3 Actin-related protein 3 0.025 2.030 
List of most downregulated proteins in JAK2V617F PV vs Controls  
Protein name p-value Ratio 
LDHA Isoform 1 of L-lactate dehydrogenase A chain 0.002 0.497 
DAK Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP 
lyase (cyclizing) 
0.003 0.495 
AK1 Adenylate kinase 1 0.005 0.494 
PGD 6-phosphogluconate dehydrogenase, decarboxylating 0.021 0.491 
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic 0.027 0.468 
BAG1 Isoform 3 of BAG family molecular chaperone regulator 1 0.007 0.464 
HBB Hemoglobin subunit beta 0.015 0.400 
EIF4G3 Isoform 1 of Eukaryotic translation initiation factor 4 gamma 3 0.015 0.399 
ATP7A Isoform 4 of Copper-transporting ATPase 1 0.034 0.390 
- Similar to L-lactate dehydrogenase 0.013 0.376 
BCL2L1 Isoform Bcl-X(L) of Bcl-2-like protein 1 0.011 0.354 
HBD Hemoglobin subunit delta 0.002 0.311 
CA3 Carbonic anhydrase 3 0.042 0.280 
RRM1 Ribonucleoside-diphosphate reductase large subunit 0.005 0.268 
HBG2 Hemoglobin subunit gamma-2 0.0003 0.174 
List of most upregulated proteins in JAK2V617F ET vs Controls  
Protein name p-value Ratio 
RABGGTA Geranylgeranyl transferase type-2 subunit alpha 0.016 Infinite 
PHKB Isoform 1 of Phosphorylase b kinase regulatory subunit beta 0.036 Infinite 
IGHG2 Putative uncharacterized protein DKFZp686I04196 (Fragment) 0.040 Infinite 
IGHG4 Putative uncharacterized protein DKFZp686M24218 0.036 Infinite 
CP cDNA FLJ58075, highly similar to Ceruloplasmin 0.045 Infinite 
A2M Alpha-2-macroglobulin 0.040 36.777 
SERPINA1 Isoform 1 of Alpha-1-antitrypsin 0.035 33.341 
LMNB1 LMNB1 protein 0.008 15.805 
ALB Isoform 1 of Serum albumin 0.014 12.057 
IPO4 Isoform 2 of Importin-4 0.029 11.437 
APOA1 Apolipoprotein A-I 0.027 10.672 
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ISOC1 CGI-111 protein 0.043 10.363 
GYG1 cDNA FLJ57427, highly similar to Glycogenin-1 0.008 8.543 
FGG Putative uncharacterized protein FGG 0.007 7.892 
FGA Isoform 2 of Fibrinogen alpha chain 0.012 7.523 
PYGB Glycogen phosphorylase, brain form 0.037 7.077 
PYGL Glycogen phosphorylase, liver form 0.021 6.924 
CLU CLU 0.015 6.889 
LOC653888 similar to actin related protein 2/3 complex subunit 1B 0.019 6.835 
CORO1A 40 kDa protein 0.005 6.607 
ANXA3 Annexin A3 0.010 6.538 
GYS1 glycogen synthase 1 (muscle) isoform 2 0.002 6.276 
HDDC3 7 kDa protein 0.001 5.315 
F13A1 Coagulation factor XIII A chain 0.009 5.045 
FGB Fibrinogen beta chain 0.006 5.035 
RABEP1 Isoform 2 of Rab GTPase-binding effector protein 1 0.005 5.021 
MYH10 Isoform 3 of Myosin-10 0.024 4.871 
ARPC5 Isoform 1 of Actin-related protein 2/3 complex subunit 5 0.011 4.711 
DPCD Protein DPCD 0.0003 4.596 
TTC38 Tetratricopeptide repeat protein 38 0.009 4.486 
CAB39 Calcium-binding protein 39 0.018 4.458 
TNPO1 Isoform 2 of Transportin-1 0.002 3.844 
CBX3 Chromobox protein homolog 3 0.044 3.758 
LOC646214;PAK2 Serine/threonine-protein kinase PAK 2 0.012 3.755 
SHPK Sedoheptulokinase 0.005 3.751 
RTCD1 Isoform 2 of RNA 3'-terminal phosphate cyclase 0.003 3.711 
IQGAP1 Ras GTPase-activating-like protein IQGAP1 0.005 3.684 
FLNA Isoform 2 of Filamin-A 0.001 3.530 
CYB5A Isoform 1 of Cytochrome b5 0.012 3.357 
MYH9 Isoform 1 of Myosin-9 0.008 3.307 
PDIA6 Isoform 2 of Protein disulfide-isomerase A6 0.005 3.273 
TSG101 Isoform 2 of Tumor susceptibility gene 101 protein 0.025 3.246 
TLN2 Talin-2 0.001 3.243 
PLEK Pleckstrin 0.002 3.215 
ACTN1 Alpha-actinin-1 0.004 3.195 
CASP3 Caspase-3 0.023 2.899 
THBS1 Thrombospondin-1 0.045 2.886 
NIT1 Isoform 5 of Nitrilase homolog 1 0.011 2.840 
ARHGDIB Rho GDP-dissociation inhibitor 2 0.009 2.730 
COPB2 Coatomer subunit beta' 0.044 2.719 
TPT1 Tumor protein, translationally-controlled 1 0.002 2.707 
PARVB parvin, beta isoform a 0.021 2.685 
TLN1 Talin-1 0.001 2.622 
ZNF595 Zinc finger protein 595 0.002 2.568 
YARS Tyrosyl-tRNA synthetase, cytoplasmic 0.035 2.542 
NUDCD1 Isoform 1 of NudC domain-containing protein 1 0.003 2.528 
PCBP1 Poly(rC)-binding protein 1 0.015 2.474 
MYL12B Myosin regulatory light chain 12B 0.029 2.471 
TNPO2 Isoform 2 of Transportin-2 0.051 2.469 
MYL4 Myosin light chain 4 0.051 2.465 
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 0.002 2.455 
RPSAP15;RPSA 40S ribosomal protein SA 0.026 2.437 
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ATP6V1C1 V-type proton ATPase subunit C 1 0.021 2.423 
FLNB Isoform 1 of Filamin-B 0.023 2.381 
ACTR3 Actin-related protein 3 0.006 2.362 
CAP1 Isoform 1 of Adenylyl cyclase-associated protein 1 0.00001 2.345 
ANXA11 cDNA FLJ55482, highly similar to Annexin A11 0.035 2.324 
KPNA3 Importin subunit alpha-3 0.007 2.261 
MYL6B 16 kDa protein 0.011 2.241 
OSTF1 Osteoclast-stimulating factor 1 0.031 2.230 
CCDC150 Isoform 1 of Coiled-coil domain-containing protein 150 0.002 2.210 
MDP1 Isoform 2 of Magnesium-dependent phosphatase 1 0.010 2.206 
CLIC2 Chloride intracellular channel protein 2 0.0001 2.177 
RGS10 Isoform 3 of Regulator of G-protein signaling 10 0.018 2.158 
ACTN4 Alpha-actinin-4 0.009 2.155 
GNPDA2 Isoform 1 of Glucosamine-6-phosphate isomerase 2 0.011 2.145 
CAP1 Adenylyl cyclase-associated protein 0.00001 2.131 
UCHL5 Isoform 3 of Ubiquitin carboxyl-terminal hydrolase isozyme L5 0.006 2.107 
DHRS11 Isoform 1 of Dehydrogenase/reductase SDR family member 11 0.0002 2.099 
CARS Isoform 2 of Cysteinyl-tRNA synthetase, cytoplasmic 0.005 2.092 
PPCS Phosphopantothenate--cysteine ligase 0.001 2.091 
PRKACA Isoform 2 of cAMP-dependent protein kinase catalytic subunit 
alpha 
0.026 2.083 
HBQ1 Hemoglobin subunit theta-1 0.005 2.081 
PABPC1 cDNA FLJ37875 fis, clone BRSSN2018771, highly similar to 
Poly(A)-binding protein 1 
0.040 2.024 
EEF1A1 Elongation factor 1-alpha 1 0.015 2.023 
List of most downregulated proteins in JAK2V617F ET vs Controls  
Protein name p-value Ratio 
UBB;UBC;RPS27A 16 kDa protein 0.021 0.481 
PRKAG1 cDNA FLJ40287 fis, clone TESTI2027909, highly similar to 5'-
AMP-ACTIVATED PROTEIN KINASE, GAMMA-1 SUBUNIT 
0.047 0.466 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.018 0.464 
NEDD8 Putative uncharacterized protein NEDD8 (Fragment) 0.005 0.461 
WDR1 Isoform 1 of WD repeat-containing protein 1 0.003 0.457 
GAPDH 9 kDa protein 0.009 0.450 
PPA1 Inorganic pyrophosphatase 0.010 0.448 
GRHPR Glyoxylate reductase/hydroxypyruvate reductase 0.023 0.444 
FAM114A2 Isoform 1 of Protein FAM114A2 0.012 0.433 
LTA4H Isoform 1 of Leukotriene A-4 hydrolase 0.000 0.430 
FAM114A2 cDNA FLJ54229 0.014 0.422 
CFL1 Cofilin-1 0.0005 0.422 
LDHB L-lactate dehydrogenase B chain 0.0001 0.414 
SELENBP1 Selenium binding protein 1 0.002 0.414 
CMBL Carboxymethylenebutenolidase homolog 0.032 0.403 
AP2S1 Isoform 1 of AP-2 complex subunit sigma 0.041 0.401 
RAB3GAP2 Isoform 2 of Rab3 GTPase-activating protein non-catalytic 
subunit 
0.011 0.400 
BCL2L1 Isoform Bcl-X(L) of Bcl-2-like protein 1 0.014 0.399 
PARK7 Protein DJ-1 0.006 0.390 
ADA Adenosine deaminase 0.001 0.390 
ABHD14B Isoform 1 of Abhydrolase domain-containing protein 14B 0.016 0.383 
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AK1 Adenylate kinase 1 0.001 0.364 
ACP1 Isoform 1 of Low molecular weight phosphotyrosine protein 
phosphatase 
0.0002 0.346 
LDHC L-lactate dehydrogenase C chain 0.015 0.341 
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic 0.008 0.335 
LDHA Isoform 1 of L-lactate dehydrogenase A chain 0.0001 0.335 
ALDOA Fructose-bisphosphate aldolase A 0.001 0.323 
6 KDA PROTEIN 0.034 0.320 
GLOD4 Uncharacterized protein C17orf25 0.014 0.317 
- Similar to L-lactate dehydrogenase 0.005 0.316 
ALDOC Fructose-bisphosphate aldolase 0.005 0.309 
CA3 Carbonic anhydrase 3 0.040 0.307 
HBA2;HBA1 Hemoglobin subunit alpha 0.012 0.297 
GSTO1 Glutathione S-transferase omega-1 0.001 0.274 
MDH1 Malate dehydrogenase 0.001 0.267 
MDH1 Putative uncharacterized protein MDH1 0.004 0.251 
CBR1 Carbonyl reductase 1, isoform CRA_c 0.002 0.250 
HBA2;HBA1 Hemoglobin alpha-2 0.00001 0.232 
PGD 6-phosphogluconate dehydrogenase, decarboxylating 0.000002 0.228 
HBB Hemoglobin subunit beta 0.001 0.225 
PGD 6-phosphogluconate dehydrogenase, decarboxylating 0.000003 0.215 
CA1 Carbonic anhydrase 1 0.002 0.213 
CA3 cDNA FLJ52895, highly similar to Carbonic anhydrase 3 0.005 0.212 
HBD Hemoglobin subunit delta 0.001 0.195 
HBG2 Hemoglobin subunit gamma-2 0.0005 0.180 
PAFAH1B1 Putative uncharacterized protein PAFAH1B1 (Fragment) 0.021 0.122 
ESD S-formylglutathione hydrolase 0.004 0.116 
PGM2 Phosphoglucomutase-2 0.015 0.108 
FSCN1 Fascin 0.015 0.101 
PGK1 Phosphoglycerate kinase 1 0.001 0.080 
List of most deregulated proteins in JAK2V617F PV vs JAK2V617F ET 
Protein name p-value Ratio 
IFI35 Isoform 2 of Interferon-induced 35 kDa protein 0.007 4.983 
PSMB8 Isoform 2 of Proteasome subunit beta type-8 0.028 4.884 
FLNA Isoform 2 of Filamin-A 0.008 0.500 
IQGAP2 Isoform 1 of Ras GTPase-activating-like protein IQGAP2 0.006 0.483 
BAG5 Isoform 2 of BAG family molecular chaperone regulator 5 0.003 0.447 
HDHD2 Isoform 1 of Haloacid dehalogenase-like hydrolase domain-
containing protein 2 
0.011 0.427 
DAZAP1 Isoform 2 of DAZ-associated protein 1 0.023 0.425 
FLNB Isoform 1 of Filamin-B 0.014 0.408 
FGG Putative uncharacterized protein FGG 0.047 0.379 
THBS1 Thrombospondin-1 0.026 0.368 
GYG1 cDNA FLJ57427, highly similar to Glycogenin-1 0.033 0.336 
RRM1 Ribonucleoside-diphosphate reductase large subunit 0.004 0.333 
RAB11B Ras-related protein Rab-11B 0.003 0.296 
PARVB parvin, beta isoform a 0.007 0.283 
F13A1 Coagulation factor XIII A chain 0.012 0.252 
PLEK Pleckstrin 0.0004 0.247 
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List of most deregulated proteins in JAK2V617F PV vs JAK2(-) ET 
Protein name p-value Ratio 
PRIC285 Isoform 2 of Peroxisomal proliferator-activated receptor A-
interacting complex 285 kDa protein 
0.008 26.445 
TRIM58 Tripartite motif-containing protein 58 0.039 11.182 
PSMB8 Isoform 2 of Proteasome subunit beta type-8 0.020 6.873 
IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 0.022 5.713 
IFI35 Isoform 2 of Interferon-induced 35 kDa protein 0.007 5.320 
RABGGTA Geranylgeranyl transferase type-2 subunit alpha 0.017 5.305 
TARS Threonyl-tRNA synthetase, cytoplasmic 0.019 3.861 
MYH10 Isoform 3 of Myosin-10 0.049 3.359 
PPP2R2B Isoform 4 of Serine/threonine-protein phosphatase 2A  0.020 3.157 
MYL12B Myosin regulatory light chain 12B 0.033 2.635 
MYL4 Myosin light chain 4 0.053 2.384 
PSMA1 Isoform Short of Proteasome subunit alpha type-1 0.043 2.334 
CUTA Isoform B of Protein CutA 0.040 2.258 
PFDN2 Prefoldin subunit 2 0.035 2.232 
EEF1A1 Elongation factor 1-alpha 1 0.048 2.171 
MYH9 Isoform 1 of Myosin-9 0.034 2.143 
DCTN3 Isoform 3 of Dynactin subunit 3 0.049 2.112 
PRPS2 Isoform 2 of Ribose-phosphate pyrophosphokinase 2 0.026 0.485 
KRT1 Keratin, type II cytoskeletal 1 0.029 0.483 
RGS10 Isoform 3 of Regulator of G-protein signaling 10 0.025 0.475 
ATG4B Putative uncharacterized protein ATG4B 0.043 0.466 
ATG4A Isoform 1 of Cysteine protease ATG4A 0.014 0.465 
SEPT2 Putative uncharacterized protein SEPT2 0.027 0.446 
TMOD1 Tropomodulin-1 0.036 0.400 
GAK Cyclin G-associated kinase 0.032 0.394 
BAG5 Isoform 2 of BAG family molecular chaperone regulator 5 0.012 0.380 
TBCB Tubulin-folding cofactor B 0.020 0.350 
PRKAR2B cAMP-dependent protein kinase type II-beta regulatory subunit 0.037 0.170 
List of most deregulated proteins in JAK2V617F ET vs JAK2(-) ET 
Protein name p-value Ratio 
PDCD5 Programmed cell death protein 5 0.042 6.463 
RABGGTA Geranylgeranyl transferase type-2 subunit alpha 0.036 6.037 
ISYNA1 cDNA FLJ57998, highly similar to Homo sapiens myo-inositol 1-
phosphate synthase A1 (ISYNA1), mRNA 
0.042 3.485 
IGBP1 Immunoglobulin-binding protein 1 0.004 2.770 
CASP3 Caspase-3 0.024 2.640 
FADD Protein FADD 0.017 2.524 
ARHGDIB Rho GDP-dissociation inhibitor 2 0.009 2.452 
IQGAP2 Isoform 1 of Ras GTPase-activating-like protein IQGAP2 0.015 2.158 
ARHGDIA Rho GDP-dissociation inhibitor 1 0.010 2.024 
PRPS2 Isoform 2 of Ribose-phosphate pyrophosphokinase 2 0.027 0.493 
PARK7 Protein DJ-1 0.037 0.443 
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Supplemental Data I-2 
Deregulated pathways in MPN erytrhocytes. 
Deregulated pathways in JAK2V617F PV vs Controls 
List of the significantly deregulated pathways in PV vs controls (p-value < 0.01) ordered in 
decreasing –log p-value according to IPA results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Ingenuity Canonical Pathways -log(p-value) Ratio 
RAN Signaling 8.62 0.25 
Actin Cytoskeleton Signaling 8.35 0.05 
Integrin Signaling 7.87 0.06 
Clathrin-mediated Endocytosis Signaling 5.07 0.05 
Regulation of Actin-based Motility by Rho 4.63 0.07 
Protein Ubiquitination Pathway 4.50 0.04 
Ephrin Receptor Signaling 4.40 0.04 
VEGF Signaling 4.23 0.06 
Rac Signaling 3.95 0.05 
RhoA Signaling 3.95 0.05 
Axonal Guidance Signaling 3.84 0.03 
fMLP Signaling in Neutrophils 3.75 0.05 
Signaling by Rho Family GTPases 3.68 0.03 
CD28 Signaling in T Helper Cells 3.63 0.05 
Corticotropin Releasing Hormone Signaling 3.57 0.04 
Synaptic Long Term Potentiation 3.49 0.05 
Apoptosis Signaling 3.37 0.05 
Cdc42 Signaling 3.37 0.03 
ERK/MAPK Signaling 3.36 0.03 
Protein Kinase A Signaling 3.30 0.02 
CD27 Signaling in Lymphocytes 3.27 0.07 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 3.19 0.05 
Actin Nucleation by ARP-WASP Complex 3.18 0.06 
PRPP Biosynthesis I 3.10 0.29 
Pyruvate Fermentation to Lactate 2.96 0.20 
NGF Signaling 2.85 0.04 
RhoGDI Signaling 2.85 0.03 
Phospholipase C Signaling 2.79 0.03 
Renal Cell Carcinoma Signaling 2.73 0.05 
Calcium Signaling 2.65 0.03 
Cellular Effects of Sildenafil (Viagra) 2.45 0.03 
Role of IL-17F in Allergic Inflammatory Airway Diseases 2.44 0.06 
Melanocyte Development and Pigmentation Signaling 2.43 0.04 
PAK Signaling 2.38 0.04 
α-Adrenergic Signaling 2.28 0.04 
CNTF Signaling 2.28 0.05 
Cardiac Hypertrophy Signaling 2.17 0.02 
HGF Signaling 2.17 0.04 
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Role of IL-17A in Arthritis 2.09 0.05 
PPARα/RXRα Activation 2.05 0.03 
Sertoli Cell-Sertoli Cell Junction Signaling 2.05 0.03 
Gα12/13 Signaling 2.01 0.03 
 
Deregulated pathways in JAK2V617F ET vs Controls 
List of the significantly deregulated pathways in ET vs controls (p-value < 0.01) ordered in 
decreasing –log p-value according to IPA results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Ingenuity Canonical Pathways -log(p-value) Ratio 
Actin Cytoskeleton Signaling 15.80 0.10 
Integrin Signaling 9.41 0.08 
VEGF Signaling 8.17 0.11 
Regulation of Actin-based Motility by Rho 7.77 0.11 
ILK Signaling 7.67 0.07 
RhoA Signaling 7.65 0.10 
RAN Signaling 7.50 0.25 
Sertoli Cell-Sertoli Cell Junction Signaling 7.12 0.07 
Signaling by Rho Family GTPases 6.74 0.06 
Germ Cell-Sertoli Cell Junction Signaling 6.70 0.07 
Rac Signaling 6.61 0.08 
RhoGDI Signaling 6.40 0.06 
Tight Junction Signaling 6.18 0.07 
Clathrin-mediated Endocytosis Signaling 5.92 0.06 
α-Adrenergic Signaling 5.91 0.09 
Protein Kinase A Signaling 5.83 0.04 
Coagulation System 5.71 0.16 
Cellular Effects of Sildenafil (Viagra) 5.43 0.07 
Mechanisms of Viral Exit from Host Cells 5.28 0.13 
FAK Signaling 5.21 0.08 
NRF2-mediated Oxidative Stress Response 5.20 0.06 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 4.96 0.08 
Paxillin Signaling 4.83 0.07 
Caveolar-mediated Endocytosis Signaling 4.67 0.08 
Acute Phase Response Signaling 4.66 0.06 
Extrinsic Prothrombin Activation Pathway 4.59 0.20 
Pyruvate Fermentation to Lactate 4.32 0.30 
Virus Entry via Endocytic Pathways 4.00 0.07 
Gap Junction Signaling 3.93 0.05 
Cdc42 Signaling 3.90 0.05 
Gluconeogenesis I 3.83 0.10 
Intrinsic Prothrombin Activation Pathway 3.59 0.11 
Crosstalk between Dendritic Cells and Natural Killer Cells 3.35 0.06 
Axonal Guidance Signaling 3.30 0.03 
PAK Signaling 3.29 0.06 
Glycogen Degradation II 3.24 0.19 
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Ephrin Receptor Signaling 3.12 0.04 
Glucocorticoid Receptor Signaling 3.09 0.03 
Protein Ubiquitination Pathway 3.09 0.04 
Glycogen Degradation III 3.07 0.17 
Leukocyte Extravasation Signaling 2.98 0.04 
Regulation of eIF4 and p70S6K Signaling 2.98 0.04 
AMPK Signaling 2.91 0.04 
Glycolysis I 2.90 0.09 
BMP signaling pathway 2.88 0.06 
Role of Tissue Factor in Cancer 2.85 0.05 
Breast Cancer Regulation by Stathmin1 2.79 0.04 
D-myo-inositol-5-phosphate Metabolism 2.79 0.08 
Melatonin Signaling 2.78 0.06 
Neuroprotective Role of THOP1 in Alzheimer's Disease 2.75 0.07 
Leptin Signaling in Obesity 2.73 0.06 
PRPP Biosynthesis I 2.73 0.29 
EIF2 Signaling 2.63 0.03 
Corticotropin Releasing Hormone Signaling 2.60 0.04 
CD27 Signaling in Lymphocytes 2.59 0.07 
Thioredoxin Pathway 2.59 0.25 
Melanocyte Development and Pigmentation Signaling 2.54 0.05 
Actin Nucleation by ARP-WASP Complex 2.50 0.06 
PPARα/RXRα Activation 2.47 0.04 
CDK5 Signaling 2.43 0.05 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 2.38 0.09 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 2.38 0.09 
Sonic Hedgehog Signaling 2.38 0.09 
Insulin Receptor Signaling 2.37 0.04 
Cardiac Hypertrophy Signaling 2.36 0.03 
Calcium Signaling 2.33 0.03 
ERK/MAPK Signaling 2.30 0.03 
IGF-1 Signaling 2.30 0.05 
3-phosphoinositide Biosynthesis 2.28 0.06 
Colorectal Cancer Metastasis Signaling 2.22 0.03 
Glycogen Biosynthesis II (from UDP-D-Glucose) 2.11 0.17 
fMLP Signaling in Neutrophils 2.06 0.04 
Gα12/13 Signaling 2.04 0.04 
Chemokine Signaling 2.03 0.05 
Ephrin B Signaling 2.01 0.05 
 
Deregulated pathways in JAK2V617F PV vs JAK2V617F ET 
List of the significantly deregulated pathways in PV vs ET (p-value < 0.01) ordered in 
decreasing –log p-value according to IPA results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
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Ingenuity Canonical Pathways -log(p-value) Ratio 
Actin Cytoskeleton Signaling 15.50 0.09 
RhoGDI Signaling 9.74 0.08 
RhoA Signaling 9.17 0.11 
Signaling by Rho Family GTPases 9.01 0.06 
Integrin Signaling 8.98 0.07 
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 8.47 0.11 
Rac Signaling 8.04 0.09 
RAN Signaling 7.73 0.25 
Regulation of Actin-based Motility by Rho 6.97 0.10 
Protein Ubiquitination Pathway 6.39 0.05 
VEGF Signaling 6.34 0.09 
FAK Signaling 5.49 0.08 
ILK Signaling 5.47 0.06 
Germ Cell-Sertoli Cell Junction Signaling 5.29 0.06 
Paxillin Signaling 5.10 0.07 
Sertoli Cell-Sertoli Cell Junction Signaling 4.92 0.05 
Tight Junction Signaling 4.75 0.06 
NRF2-mediated Oxidative Stress Response 4.74 0.05 
Leukocyte Extravasation Signaling 4.72 0.05 
Clathrin-mediated Endocytosis Signaling 4.66 0.05 
Pyruvate Fermentation to Lactate 4.43 0.30 
Mechanisms of Viral Exit from Host Cells 4.26 0.11 
Virus Entry via Endocytic Pathways 4.24 0.07 
Cdc42 Signaling 4.16 0.05 
Ephrin Receptor Signaling 4.12 0.05 
Regulation of eIF4 and p70S6K Signaling 3.98 0.05 
Breast Cancer Regulation by Stathmin1 3.72 0.04 
Actin Nucleation by ARP-WASP Complex 3.63 0.08 
Gap Junction Signaling 3.46 0.05 
α-Adrenergic Signaling 3.34 0.06 
Ephrin B Signaling 3.00 0.06 
Caveolar-mediated Endocytosis Signaling 2.97 0.06 
fMLP Signaling in Neutrophils 2.96 0.05 
D-myo-inositol-5-phosphate Metabolism 2.93 0.08 
CD28 Signaling in T Helper Cells 2.85 0.05 
EIF2 Signaling 2.84 0.03 
PRPP Biosynthesis I 2.81 0.29 
Adenosine Nucleotides Degradation II 2.78 0.12 
CD27 Signaling in Lymphocytes 2.72 0.07 
Protein Kinase A Signaling 2.69 0.03 
Crosstalk between Dendritic Cells and Natural Killer Cells 2.68 0.05 
Thioredoxin Pathway 2.67 0.25 
PAK Signaling 2.64 0.05 
Axonal Guidance Signaling 2.60 0.03 
CDK5 Signaling 2.60 0.05 
ERK/MAPK Signaling 2.50 0.03 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 2.49 0.09 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 2.49 0.09 
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3-phosphoinositide Biosynthesis 2.41 0.06 
AMPK Signaling 2.41 0.04 
Role of Tissue Factor in Cancer 2.28 0.04 
Agrin Interactions at Neuromuscular Junction 2.25 0.06 
Glucocorticoid Receptor Signaling 2.21 0.03 
BMP signaling pathway 2.18 0.05 
Glycogen Biosynthesis II (from UDP-D-Glucose) 2.18 0.17 
Chemokine Signaling 2.16 0.05 
PTEN Signaling 2.13 0.04 
Adenine and Adenosine Salvage III 2.11 0.13 
Melatonin Signaling 2.10 0.05 
Corticotropin Releasing Hormone Signaling 2.07 0.04 
Leptin Signaling in Obesity 2.06 0.05 
Purine Ribonucleosides Degradation to Ribose-1-phosphate 2.05 0.12 
PI3K/AKT Signaling 2.00 0.03 
 
Deregulated pathways in JAK2V617F PV vs JAK2(-) ET 
List of the significantly deregulated pathways in PV vs Mut0 (p-value < 0.01) ordered in 
decreasing –log p-value according to IPA results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Ingenuity Canonical Pathways -log(p-value) Ratio 
RAN Signaling 9.33 0.29 
Actin Cytoskeleton Signaling 8.94 0.07 
Protein Ubiquitination Pathway 7.81 0.06 
Rac Signaling 5.73 0.07 
Regulation of Actin-based Motility by Rho 5.68 0.09 
ILK Signaling 5.25 0.06 
RhoGDI Signaling 4.85 0.05 
RhoA Signaling 4.78 0.07 
Protein Kinase A Signaling 4.74 0.04 
Tight Junction Signaling 4.57 0.06 
Signaling by Rho Family GTPases 4.56 0.04 
Pyruvate Fermentation to Lactate 4.36 0.30 
PAK Signaling 4.28 0.07 
Breast Cancer Regulation by Stathmin1 4.27 0.05 
α-Adrenergic Signaling 4.10 0.07 
Regulation of eIF4 and p70S6K Signaling 3.82 0.05 
AMPK Signaling 3.74 0.05 
Integrin Signaling 3.65 0.04 
CDK5 Signaling 3.32 0.06 
Sertoli Cell-Sertoli Cell Junction Signaling 3.22 0.04 
Cdc42 Signaling 3.21 0.04 
IGF-1 Signaling 3.15 0.06 
Cellular Effects of Sildenafil (Viagra) 3.10 0.05 
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Mechanisms of Viral Exit from Host Cells 3.04 0.09 
ERK/MAPK Signaling 3.01 0.04 
BMP signaling pathway 2.95 0.06 
Axonal Guidance Signaling 2.91 0.03 
Ephrin B Signaling 2.89 0.06 
D-myo-inositol-5-phosphate Metabolism 2.84 0.08 
Melatonin Signaling 2.84 0.06 
Gα12/13 Signaling 2.83 0.05 
Neuroprotective Role of THOP1 in Alzheimer's Disease 2.81 0.07 
Germ Cell-Sertoli Cell Junction Signaling 2.79 0.04 
Leptin Signaling in Obesity 2.79 0.06 
PRPP Biosynthesis I 2.76 0.29 
EIF2 Signaling 2.71 0.03 
Corticotropin Releasing Hormone Signaling 2.68 0.04 
CD27 Signaling in Lymphocytes 2.64 0.07 
Thioredoxin Pathway 2.62 0.25 
Melanocyte Development and Pigmentation Signaling 2.60 0.05 
Ephrin Receptor Signaling 2.55 0.04 
PPARα/RXRα Activation 2.55 0.04 
GNRH Signaling 2.50 0.04 
VEGF Signaling 2.48 0.05 
Cardiac Hypertrophy Signaling 2.45 0.03 
Insulin Receptor Signaling 2.44 0.04 
NRF2-mediated Oxidative Stress Response 2.44 0.04 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 2.42 0.09 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 2.42 0.09 
Sonic Hedgehog Signaling 2.42 0.09 
Virus Entry via Endocytic Pathways 2.42 0.05 
Clathrin-mediated Endocytosis Signaling 2.39 0.04 
3-phosphoinositide Biosynthesis 2.33 0.06 
Colorectal Cancer Metastasis Signaling 2.30 0.03 
Chemokine Signaling 2.08 0.05 
PTEN Signaling 2.04 0.04 
Renin-Angiotensin Signaling 2.04 0.04 
Gap Junction Signaling 2.00 0.03 
 
Deregulated pathways in JAK2V617F ET vs JAK2(-) ET 
List of the significantly deregulated pathways in ET vs Mut0 (p-value < 0.01) ordered in 
decreasing –log p-value according to IPA results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Ingenuity Canonical Pathways -log(p-value) Ratio 
PRPP Biosynthesis I 4.09 0.29 
Role of PKR in Interferon Induction and Antiviral Response 3.94 0.07 
Parkinson's Signaling 3.19 0.13 
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Endoplasmic Reticulum Stress Pathway 3.09 0.11 
Tumoricidal Function of Hepatic Natural Killer Cells 2.84 0.08 
TWEAK Signaling 2.56 0.05 
TNFR1 Signaling 2.26 0.04 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells 2.16 0.02 
Death Receptor Signaling 2.08 0.03 
Myc Mediated Apoptosis Signaling 2.08 0.03 
Induction of Apoptosis by HIV1 2.07 0.03 
Retinoic acid Mediated Apoptosis Signaling 2.03 0.03 
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Supplemental Data I-3 
 
A IQGAP1/ 
actin 
means 
Standard 
Deviation 
N 
 
T-test analysis p-value  
PV 48.07 39.92 15 
 
PV vs ET 0.3030  
ET 33.35 33.95 14 
 
PV vs control set 0.0032 * 
Control 
set 
5.76 4.70 10 
 
ET vs control set 0.0188 * 
    
 
ET+PV vs control set 0.0057 * 
     
Retrospective (PV+ET) 
vs control set 
0.0313 * 
     
Prospective (PV+ET) vs 
control set 
0.0012 * 
 
B IQGAP1/ 
actin 
means 
Standard 
Deviation 
N 
 
T-test analysis p-value  
JAK2+ 32.69 30.26 25 
 
JAK2+ vs JAK2- 0.0310 * 
JAK2- 88.78 42.35 4 
 
JAK2+ vs Control set 0.0091 * 
Control 
set 
5.76 4.70 10 
 
JAK2- vs Control set 0.0001 * 
 
 
Supplemental Data I-3. IQGAP1/β-actin ratios, means and T-test assays. A) It shows 
IQGAP1/ β-actin ratios derived from western blot assays in MPNs and control patients which 
correspond to figure 1. First table contains information about IQGAP1/β-actin ratio means. standard 
deviations and number of subjects (N). Second table shows the p-value of student’s t test analysis. B) 
IQGAP1/β-actin ratio means and T-test assays according to patients’ genotype. First table contains 
information about IQGAP1/β-actin ratio means. standard deviations and number of subjects (N). 
Second table shows the p-value of student’s t test analysis.  Patients: Retrospective set: PV1. PV2. 
PV3. PV4. PV5. PV6 and ET1. ET2. ET3. ET5. ET6 and ET7. Prospective set: JAK2+: PV8. PV9. 
PV10. PV11. PV12. PV13. PV14. ET9. ET10. ET12. ET13. JAK2-: ET8. ET11. ET14 and PV15. 
Control set: C1. C2. C3. C4. C5. C6. C7. C8. C9. and C10. 
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Supplemental Data I-4 
 
 
Calreticulin/ 
actin 
means 
Standard 
Deviation 
N 
 
T-test analysis p-value  
PV 15.07 23.32 8 
 
Calreticulin+ vs Control set 0.4053  
ET 4.15 4.57 7 
 
Calreticulin+ vs JAK2+  0.7005  
MPNs 
(PV+ET) 
9.97 17.68 15 
 
Calreticulin+ vs JAK2- 0.0782  
Calreticulin+ 
set 
16.77 14.93 6 
 
Control vs JAK2- 0.0655  
Control set 11.51 9.75 10 
 
Control vs JAK2+ 0.8215  
JAK2+ 13.10 19.93 11 
 
JAK2+ vs JAK2- 0.2709  
JAK2- 1.37 1.04 4 
 
PV vs ET 0.2469  
    
 
MPNs (PV+ET) vs control 0.8051  
    
 
Calreticulin+ vs PV 0.8790  
    
 
Calreticulin+ vs ET  0.0560  
    
 
Calreticulin+ vs MPNs 0.4184  
 
Supplemental Data I-4. Calreticulin/β-actin ratios, means and T-test assays. First 
table contains information about Calreticulin/β-actin ratio means. standard deviations and 
number of subjects (N). Second table shows the p-value of student’s t test analysis. Patients: 
JAK2+: Prospective set: PV8. PV9. PV10. PV11. PV12. PV13. PV14. ET9. ET10. ET12. 
ET13. JAK2-: Prospective set: ET8. ET11. ET14 and PV15. Calreticulin+ set: Calr1. Calr2. 
Calr3. Calr4. Calr5 and Calr6. Control set: C1. C2. C3. C4. C5. C6. C7. C8. C9. and C10.  
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Supplemental Data I-5 
 
 
 
Supplemental Data I-5. Pull-down assays of activated proteins of the Rho family. RBC 
lysates were pulled-down with GST-PAK-PBD or GST-Rhotekin-RBD agarose beads. WBs were 
developed with Rac1 (A). Cdc42 (B) and RhoA (C) antibodies. Rac1 and RhoA act as positive 
controls. Patients: Calreticulin set: Calr3 and Calr4. Molecular weights of targeted proteins: Rac1 21 
kDa. Cdc42 21 kDa and RhoA 22kDa. 
 
 
Supplemental Data I-6 
 
 
Supplemental Data I-6. GTP-Rac1 complexes. Rac1Q61L-GST coupled to Sepharose beads 
were used to pull-down proteins in CALR mutated RBC lysates. A) IQGAP1-Rac1 complex was 
present in all samples. B) Calreticulin doesn’t form a complex with Rac1-GTP in calreticulin set 
patients. Patients: Calreticulin+ samples Calr1. Calr2. Calr3. Molecular weights of targeted proteins: 
IQGAP1 189 kDa. Calreticulin 52 kDa. KG1 was used as positive control.  
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SUPPLEMENTAL DATA II 
Supplemental Data II-1 
Lists of deregulated proteins in granulocytes among the different subgroups PV, ET, PMF 
(all JAK2(+)) and Mut0 (JAK2(-) ET and PMF). 
PV vs Mut0 (JAK2(-) ET and PMF) comparison 
Protein group Protein description Ratio p-value 
REEP5_HUMAN Receptor expression-enhancing protein 5 0.74 3.20E-02 
LEG10_HUMAN Galectin-10  0.77 3.67E-13 
ANXA2_HUMAN Annexin A2  0.77 3.83E-02 
CAP7_HUMAN Azurocidin  0.77 9.38E-06 
EVI2B_HUMAN Protein EVI2B (CD antigen CD361) 0.79 8.33E-03 
LEG1_HUMAN Galectin-1  0.80 3.58E-03 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1  0.83 3.78E-07 
B4DV10_HUMAN 
cDNA FLJ59142. highly similar to Epididymal secretory 
protein E1 
0.84 2.75E-03 
D3DPU2_HUMAN Adenylyl cyclase-associated protein 0.84 1.13E-02 
BPI_HUMAN Bactericidal permeability-increasing protein  0.84 1.75E-18 
PYGL_HUMAN Glycogen phosphorylase. liver form  0.84 1.21E-13 
COTL1_HUMAN Coactosin-like protein 0.84 6.85E-03 
S10A4_HUMAN Protein S100-A4 (Calvasculin) 0.84 6.63E-04 
B4DVJ0_HUMAN Glucose-6-phosphate isomerase  0.85 1.35E-02 
H2B1O_HUMAN Histone H2B type 1-O  0.85 2.82E-02 
OSTF1_HUMAN Osteoclast-stimulating factor 1 0.85 1.46E-02 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2  0.86 2.99E-06 
MYH9_HUMAN Myosin-9  0.87 1.25E-23 
ARC1B_HUMAN Actin-related protein 2/3 complex subunit 1B  0.87 1.44E-02 
RB11B_HUMAN Ras-related protein Rab-11B  0.88 5.96E-04 
B2RDE1_HUMAN 
cDNA. FLJ96568. highly similar to Homo sapiens 
tropomyosin 3  
0.89 2.18E-03 
TYPH_HUMAN Thymidine phosphorylase  0.89 2.44E-02 
ENOB_HUMAN Beta-enolase  0.89 1.27E-07 
1433B_HUMAN 14-3-3 protein beta/alpha  0.89 1.36E-03 
COF1_HUMAN Cofilin-1  0.90 1.91E-05 
S10AC_HUMAN Protein S100-A12  0.90 1.24E-07 
Q5U077_HUMAN L-lactate dehydrogenase  0.90 4.38E-02 
CATA_HUMAN Catalase  0.90 1.91E-08 
TALDO_HUMAN Transaldolase 0.91 1.92E-11 
Q6IAT1_HUMAN 
Epididymis secretory sperm binding protein Li 46e  
(GDP dissociation inhibitor 2 isoform 1) 
0.92 1.72E-02 
ECP_HUMAN Eosinophil cationic protein  0.92 1.43E-02 
B2RDW1_HUMAN Epididymis luminal protein 112  0.93 1.87E-02 
MNDA_HUMAN Myeloid cell nuclear differentiation antigen 0.93 4.19E-03 
PROF1_HUMAN Profilin-1  0.93 5.95E-14 
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ELNE_HUMAN Neutrophil elastase  0.93 2.23E-02 
Q53EM5_HUMAN Transketolase  0.93 4.46E-04 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  0.94 4.80E-07 
ARP2_HUMAN Actin-related protein 2  0.94 4.28E-03 
FLNA_HUMAN Filamin-A  0.94 5.60E-09 
PERM_HUMAN Myeloperoxidase  0.94 1.69E-03 
LKHA4_HUMAN Leukotriene A-4 hydrolase  0.94 4.92E-04 
RHOA_HUMAN Transforming protein Rhoa 0.94 1.55E-03 
A4QPB0_HUMAN IQ motif containing GTPase activating protein 1 0.96 6.60E-03 
GELS_HUMAN Gelsolin  0.96 8.57E-03 
COR1A_HUMAN Coronin-1A (Coronin-like protein A)  0.97 2.48E-02 
TPIS_HUMAN Triosephosphate isomerase  0.97 2.24E-02 
ANXA3_HUMAN Annexin A3  1.04 8.40E-03 
S10A8_HUMAN Protein S100-A8 (Calgranulin-A)  1.05 1.27E-05 
CAMP_HUMAN Cathelicidin antimicrobial peptide  1.08 1.91E-05 
NAMPT_HUMAN Nicotinamide phosphoribosyltransferase  1.08 1.90E-02 
GSTO1_HUMAN Glutathione S-transferase omega-1 (GSTO-1) 1.09 2.37E-03 
EFHD2_HUMAN EF-hand domain-containing protein D2  1.10 1.85E-02 
PRG3_HUMAN Proteoglycan 3  1.11 2.41E-04 
PRTN3_HUMAN Myeloblastin  1.12 2.52E-06 
HXK3_HUMAN Hexokinase-3  1.12 3.77E-03 
PNCB_HUMAN Nicotinate phosphoribosyltransferase (NAPRTase)  1.12 2.19E-02 
CATD_HUMAN Cathepsin D  1.13 5.53E-03 
HS71A_HUMAN Heat shock 70 kDa protein 1A  1.13 3.13E-03 
CH3L1_HUMAN Chitinase-3-like protein 1  1.14 1.09E-03 
B3KSM6_HUMAN 
cDNA FLJ36606 fis. clone TRACH2015654. highly 
similar to HEAT SHOCK 70 kDa PROTEIN 6 
1.14 1.40E-02 
ACSL1_HUMAN Long-chain-fatty-acid--CoA ligase 1  1.15 2.72E-03 
Q5CAQ5_HUMAN Tumor rejection antigen (Gp96) 1 1.16 5.75E-03 
BLVRB_HUMAN Flavin reductase (NADPH) 1.18 1.49E-04 
OLFM4_HUMAN Olfactomedin-4  1.21 1.11E-05 
GRP78_HUMAN 78 kDa glucose-regulated protein  1.22 1.09E-15 
RETN_HUMAN Resistin  1.22 6.79E-12 
CAH1_HUMAN Carbonic anhydrase 1  1.22 1.75E-05 
A8K9E4_HUMAN 
cDNA FLJ76459. highly similar to Homo sapiens matrix 
metallopeptidase 8 (neutrophil collagenase)  
1.24 7.09E-20 
MMP9_HUMAN Matrix metalloproteinase-9] 1.26 4.75E-13 
CALR_HUMAN Calreticulin (CRP55) (Calregulin) 1.29 4.12E-07 
CD44_HUMAN CD44 antigen (CD antigen CD44) 1.30 1.95E-02 
MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate  1.32 1.12E-02 
MCEM1_HUMAN Mast cell-expressed membrane protein 1 1.33 1.20E-03 
NIBAN_HUMAN Protein Niban 1.34 5.31E-04 
MVP_HUMAN Major vault protein  1.38 5.02E-04 
VAMP8_HUMAN Vesicle-associated membrane protein 8  1.56 4.01E-02 
ET vs Mut0 (JAK2(-) ET and PMF) comparison 
Protein group Protein description Ratio p-value 
FOLR3_HUMAN Folate receptor gamma  0.36 2.66E-05 
ITAM_HUMAN Integrin. alpha M  0.62 1.68E-03 
TPM1_HUMAN Tropomyosin alpha-1 chain  0.73 7.97E-04 
RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2  0.74 1.47E-02 
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B4DVJ0_HUMAN Glucose-6-phosphate isomerase  0.76 1.37E-02 
FCN1_HUMAN Ficolin-1  0.77 8.07E-03 
LEG10_HUMAN Galectin-10  0.78 1.76E-15 
B4DV10_HUMAN 
cDNA FLJ59142. highly similar to Epididymal secretory 
protein E1 
0.79 1.33E-03 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1  0.80 2.53E-05 
ARC1B_HUMAN Actin-related protein 2/3 complex subunit 1B  0.80 7.04E-04 
EVI2B_HUMAN Protein EVI2B  (CD antigen CD361) 0.81 4.41E-03 
CATG_HUMAN Cathepsin G  0.81 4.14E-12 
BPI_HUMAN Bactericidal permeability-increasing protein  0.81 4.34E-13 
PERE_HUMAN Eosinophil peroxidase (EPO)  0.83 2.92E-05 
RHOG_HUMAN Rho-related GTP-binding protein RhoG 0.85 7.95E-03 
TCPB_HUMAN T-complex protein 1 subunit beta  0.86 1.47E-04 
B2RDE1_HUMAN 
cDNA. FLJ96568. highly similar to Homo sapiens 
tropomyosin 3  
0.87 3.78E-04 
Q53GC7_HUMAN Capping protein  0.87 6.38E-03 
LOX15_HUMAN Arachidonate 15-lipoxygenase  0.88 1.80E-03 
CAP7_HUMAN Azurocidin  0.88 8.23E-05 
B2RDW0_HUMAN 
cDNA. FLJ96792. highly similar to Homo sapiens 
calmodulin 2  
0.88 3.89E-04 
CBX3_HUMAN Chromobox protein homolog 3  0.88 2.75E-02 
ARPC2_HUMAN Actin-related protein 2/3 complex subunit 2  0.89 1.14E-03 
CATD_HUMAN Cathepsin D  0.89 3.59E-03 
TCPE_HUMAN T-complex protein 1 subunit epsilon  0.89 3.06E-02 
PRS8_HUMAN 26S protease regulatory subunit 8 0.90 5.00E-02 
HXK3_HUMAN Hexokinase-3 ( 0.90 2.68E-07 
ARP2_HUMAN Actin-related protein 2  0.91 1.98E-07 
S10AC_HUMAN Protein S100-A12  0.91 5.61E-06 
1433B_HUMAN 14-3-3 protein beta/alpha  0.91 1.83E-02 
B2RBR9_HUMAN 
cDNA. FLJ95650. highly similar to Homo sapiens 
karyopherin (importin) beta 1  
0.91 7.65E-04 
CAN1_HUMAN Calpain-1 catalytic subunit  0.91 2.74E-03 
ILEU_HUMAN Leukocyte elastase inhibitor  0.92 7.49E-03 
ARP3_HUMAN Actin-related protein 3  0.92 3.88E-04 
RAN_HUMAN GTP-binding nuclear protein Ran  0.92 2.21E-04 
HS90A_HUMAN Heat shock protein HSP 90-alpha ( 0.92 3.93E-04 
URP2_HUMAN Fermitin family homolog 3  0.92 2.44E-02 
ATPB_HUMAN ATP synthase subunit beta 0.92 7.66E-04 
PYGL_HUMAN Glycogen phosphorylase. liver form  0.92 3.03E-03 
ATPA_HUMAN ATP synthase subunit alpha. mitochondrial 0.92 1.50E-02 
Q53EM5_HUMAN Transketolase  0.92 6.35E-04 
B4DMA2_HUMAN 
cDNA FLJ54023. highly similar to Heat shock protein 
HSP 90-beta 
0.93 8.29E-04 
MYO1F_HUMAN Unconventional myosin-If  0.93 3.91E-04 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2  0.93 4.90E-03 
B4DZT3_HUMAN cDNA FLJ50934. highly similar to Lamin-B1 0.93 1.94E-01 
GSTP1_HUMAN Glutathione S-transferase P  0.94 9.37E-04 
COF1_HUMAN Cofilin-1 0.94 6.92E-03 
CALX_HUMAN Calnexin  0.94 9.13E-03 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  0.94 6.15E-07 
FLNA_HUMAN Filamin-A  0.94 7.10E-09 
EF1D_HUMAN Elongation factor 1-delta  0.95 1.31E-01 
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PGK1_HUMAN Phosphoglycerate kinase 1  0.95 1.15E-06 
PERM_HUMAN Myeloperoxidase  0.96 8.32E-03 
PLSL_HUMAN Plastin-2  0.96 5.21E-06 
RNAS2_HUMAN Non-secretory ribonuclease  0.96 9.37E-03 
CATA_HUMAN Catalase  0.97 1.63E-01 
PDIA1_HUMAN Protein disulfide-isomerase ( 0.99 2.11E-01 
DOPD_HUMAN D-dopachrome decarboxylase  1.00 4.55E-03 
TLN1_HUMAN Talin-1 1.06 2.55E-02 
MOES_HUMAN Moesin  1.06 5.21E-03 
ITB2_HUMAN Integrin beta-2  (CD antigen CD18) 1.06 7.19E-04 
RETN_HUMAN Resistin  1.07 1.75E-04 
H15_HUMAN Histone H1.5  1.08 4.80E-05 
GRP78_HUMAN 78 kDa glucose-regulated protein (GRP-78)  1.09 1.69E-06 
ANXA1_HUMAN Annexin A1  1.09 4.43E-09 
B2R4C5_HUMAN Lysozyme  1.10 6.45E-03 
APOBR_HUMAN Apolipoprotein B receptor (Apolipoprotein B-100 ) 1.12 1.17E-01 
ANXA3_HUMAN Annexin A3  1.13 1.35E-05 
A8K9E4_HUMAN 
cDNA FLJ76459. highly similar to Homo sapiens matrix 
metallopeptidase 8  
1.13 6.84E-08 
Q5NKU1_HUMAN Intercellular adhesion molecule 3  1.13 3.71E-03 
BST1_HUMAN 
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (CD 
antigen CD157) 
1.13 3.92E-02 
S10A9_HUMAN Protein S100-A9 (Calgranulin-B)  1.13 1.45E-02 
TERA_HUMAN Transitional endoplasmic reticulum ATPase  1.14 5.00E-03 
6PGL_HUMAN 6-phosphogluconolactonase  1.15 1.71E-02 
GILT_HUMAN Gamma-interferon-inducible lysosomal thiol reductase  1.15 6.42E-02 
D3DRP5_HUMAN Chromosome 9 open reading frame 19 1.15 2.45E-06 
ITAM_HUMAN Integrin alpha-M  (CD antigen CD11b) 1.15 1.32E-02 
ANXA5_HUMAN Annexin A5  1.16 2.33E-04 
ACTN1_HUMAN Alpha-actinin-1  1.16 1.27E-06 
PRTN3_HUMAN Myeloblastin  1.16 4.05E-22 
Q6FHM9_HUMAN CD59 antigen 1.17 9.85E-03 
QSOX1_HUMAN Sulfhydryl oxidase 1  1.17 4.96E-03 
PSME2_HUMAN Proteasome activator complex subunit 2 ( 1.18 8.73E-03 
CAMP_HUMAN Cathelicidin antimicrobial peptide  1.20 1.45E-12 
Q5TD07_HUMAN Ribosyldihydronicotinamide dehydrogenase  1.23 1.84E-02 
A1AG1_HUMAN Alpha-1-acid glycoprotein 1  1.25 1.12E-05 
MMP9_HUMAN Matrix metalloproteinase-9  1.27 1.11E-08 
CALR_HUMAN Calreticulin  (Calregulin)  1.28 9.85E-07 
CAH2_HUMAN Carbonic anhydrase 2  1.28 6.40E-03 
B3AT_HUMAN Band 3 anion transport protein  (CD antigen CD233) 1.31 2.17E-02 
BLVRB_HUMAN Flavin reductase (NADPH)  1.31 2.68E-06 
PRG3_HUMAN Proteoglycan 3  1.32 7.72E-12 
HS71A_HUMAN Heat shock 70 kDa protein 1A  1.35 3.13E-04 
FCG3B_HUMAN 
Low affinity immunoglobulin gamma Fc region receptor 
III-B  (CD antigen CD16b) 
1.41 1.55E-02 
PRDX2_HUMAN Peroxiredoxin-2  1.42 7.53E-08 
CAH1_HUMAN Carbonic anhydrase 1  1.47 3.21E-11 
F189B_HUMAN Protein FAM189B (Protein COTE1) 1.60 3.78E-06 
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PMF vs Mut0 (JAK2(-) ET and PMF) comparison 
Protein group Protein description Ratio p value 
FOLR3_HUMAN Folate receptor gamma (FR-gamma) 0.63 4.64E-04 
CAP7_HUMAN Azurocidin (Cationic antimicrobial protein CAP37) 0.65 3.91E-09 
ITA2B_HUMAN Integrin alpha-IIb  0.71 1.29E-02 
CATG_HUMAN Cathepsin G  0.74 1.32E-13 
PERM_HUMAN Myeloperoxidase (MPO)  0.80 2.53E-15 
ELNE_HUMAN Neutrophil elastase  0.81 3.14E-05 
AL5AP_HUMAN Arachidonate 5-lipoxygenase-activating protein (FLAP)  0.83 4.31E-04 
H2B1O_HUMAN Histone H2B type 1-O 0.84 3.53E-02 
Q5U077_HUMAN L-lactate dehydrogenase  0.85 5.52E-03 
RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2  0.85 3.86E-02 
D3DPE6_HUMAN 
Wiskott-Aldrich syndrome protein interacting protein. 
isoform CRA_a 
0.86 2.47E-02 
VPS28_HUMAN Vacuolar protein sorting-associated protein 28 homolog  0.87 1.15E-02 
NDRG1_HUMAN Protein NDRG1  0.88 3.51E-02 
Q4W4Y1_HUMAN Dopamine receptor interacting protein 4 0.88 1.53E-04 
PYGL_HUMAN Glycogen phosphorylase. liver form  0.88 4.94E-14 
RHOG_HUMAN Rho-related GTP-binding protein RhoG 0.88 9.30E-05 
CHIT1_HUMAN Chitotriosidase-1 0.89 8.45E-03 
CATS_HUMAN Cathepsin S  0.89 3.54E-02 
Q86VG2_HUMAN Splicing factor proline/glutamine-rich  0.89 2.33E-02 
ILEU_HUMAN Leukocyte elastase inhibitor  0.90 6.15E-04 
1433B_HUMAN 14-3-3 protein beta/alpha  0.90 1.40E-03 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1  0.90 1.41E-05 
STK4_HUMAN Serine/threonine-protein kinase 4  0.90 3.35E-02 
TCTP_HUMAN Translationally-controlled tumor protein  0.90 3.95E-02 
ITAM_HUMAN Integrin alpha-M (CD11 antigen-like family member B)  0.90 1.85E-02 
ODO2_HUMAN 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex. 
mitochondrial 
0.91 4.29E-03 
GSTP1_HUMAN Glutathione S-transferase P  0.91 1.04E-07 
B3KRM8_HUMAN Translin. isoform CRA_b  0.91 1.02E-02 
B2R4C5_HUMAN Lysozyme  0.91 1.86E-17 
TWF2_HUMAN Twinfilin-2  0.91 3.83E-02 
KAP0_HUMAN 
cAMP-dependent protein kinase type I-alpha regulatory 
subunit  
0.91 4.57E-03 
D3DNA1_HUMAN Integrin beta 0.91 4.85E-02 
PRDX3_HUMAN 
Thioredoxin-dependent peroxide reductase. 
mitochondrial  
0.92 2.18E-02 
B7Z5J7_HUMAN 
cDNA FLJ58682. highly similar to Vesicle-fusing 
ATPase  
0.92 1.26E-03 
SPCS2_HUMAN Signal peptidase complex subunit 2  0.92 7.14E-03 
B4DQY1_HUMAN 
cDNA FLJ56133. highly similar to Serine/threonine-
protein phosphatase 2A 65 kDa regulatory subunit A  
0.93 2.11E-03 
B2RDW1_HUMAN 
Epididymis luminal protein 112 (Ribosomal protein 
S27a) 
0.93 1.05E-03 
GMFG_HUMAN Glia maturation factor gamma (GMF-gamma) 0.93 2.72E-03 
GSTO1_HUMAN Glutathione S-transferase omega-1  0.93 4.37E-05 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2  0.93 6.99E-04 
EHD1_HUMAN EH domain-containing protein 1  0.93 1.02E-03 
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RAB31_HUMAN Ras-related protein Rab-31  0.93 4.26E-03 
STMN1_HUMAN 
Stathmin (Leukemia-associated phosphoprotein p18) 
(Metablastin)  
0.94 2.17E-02 
CAMP_HUMAN Cathelicidin antimicrobial peptide  0.94 2.35E-11 
PARK7_HUMAN Protein deglycase DJ-1  0.94 1.22E-02 
BPI_HUMAN Bactericidal permeability-increasing protein  0.94 9.34E-07 
LKHA4_HUMAN Leukotriene A-4 hydrolase  0.94 1.84E-04 
PYGB_HUMAN Glycogen phosphorylase. brain form  0.94 4.97E-03 
PRDX2_HUMAN Peroxiredoxin-2  0.94 9.70E-03 
FLNA_HUMAN Filamin-A  0.94 3.01E-10 
Q05DH1_HUMAN Proteasome subunit alpha type  0.94 1.36E-02 
Q6IAT1_HUMAN 
Epididymis secretory sperm binding protein Li 46e 
(GDP dissociation inhibitor 2 isoform 1)  
0.94 6.32E-03 
CATA_HUMAN Catalase  0.94 1.55E-06 
ARP2_HUMAN Actin-related protein 2  0.94 4.52E-04 
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1  0.95 1.69E-03 
PERE_HUMAN Eosinophil peroxidase (EPO)  0.95 2.17E-02 
ANXA4_HUMAN Annexin A4  0.95 3.30E-02 
MDHC_HUMAN Malate dehydrogenase. cytoplasmic  0.95 4.48E-02 
RAB35_HUMAN Ras-related protein Rab-35  0.95 4.11E-03 
SURF4_HUMAN Surfeit locus protein 4 0.95 2.56E-03 
Q59F54_HUMAN Solute carrier family 2  0.95 4.51E-02 
1433Z_HUMAN 14-3-3 protein zeta/delta  0.95 4.43E-02 
CAN1_HUMAN Calpain-1 catalytic subunit  0.96 2.50E-02 
B4DMA2_HUMAN 
cDNA FLJ54023. highly similar to Heat shock protein 
HSP 90-beta 
0.96 3.53E-02 
ARPC5_HUMAN Actin-related protein 2/3 complex subunit 5  0.96 2.59E-02 
TYPH_HUMAN Thymidine phosphorylase  0.96 2.08E-02 
A4D0U5_HUMAN Testis derived transcript  0.96 6.38E-03 
Q5TZP7_HUMAN APEX nuclease (Multifunctional DNA repair enzyme)  0.96 4.77E-02 
CAPG_HUMAN Macrophage-capping protein  0.96 2.09E-03 
B2RDE1_HUMAN 
cDNA. FLJ96568. highly similar to Homo sapiens 
tropomyosin 3  
0.96 4.84E-02 
PRTN3_HUMAN Myeloblastin  0.96 9.41E-07 
MYH9_HUMAN Myosin-9  0.96 7.10E-10 
CH3L1_HUMAN Chitinase-3-like protein 1  0.96 2.24E-02 
PA2G4_HUMAN Proliferation-associated protein 2G4  0.96 4.21E-02 
ATPB_HUMAN ATP synthase subunit beta. mitochondrial  0.96 3.11E-02 
THIO_HUMAN Thioredoxin  0.97 8.32E-03 
ARLY_HUMAN Argininosuccinate lyase  0.97 1.05E-02 
S10AC_HUMAN Protein S100-A12  0.97 1.34E-02 
SODC_HUMAN Superoxide dismutase  0.97 1.97E-02 
HSP7C_HUMAN Heat shock cognate 71 kDa protein ( 0.98 4.45E-02 
VSTM1_HUMAN V-set and transmembrane domain-containing protein 1  0.98 3.49E-03 
SC22B_HUMAN Vesicle-trafficking protein SEC22b  0.98 3.24E-02 
VINC_HUMAN Vinculin  0.98 1.61E-02 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  0.98 2.74E-03 
S10A8_HUMAN Protein S100-A8 (Calgranulin-A) 1.02 1.10E-02 
GSHR_HUMAN Glutathione reductase. mitochondrial  1.04 2.42E-02 
TLN1_HUMAN Talin-1 1.06 1.29E-03 
ANXA1_HUMAN Annexin A1  1.06 4.95E-05 
ANXA3_HUMAN Annexin A3  1.06 2.00E-02 
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PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B  1.06 6.03E-03 
S10A4_HUMAN Protein S100-A4 (Calvasculin) 1.06 4.62E-02 
GDE_HUMAN Glycogen debranching enzyme 1.07 3.41E-02 
DOPD_HUMAN D-dopachrome decarboxylase  1.07 4.97E-02 
Q7Z4X0_HUMAN MO25-like protein 1.07 2.66E-02 
HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0  1.08 4.13E-02 
PUR6_HUMAN Multifunctional protein ADE2  1.08 1.33E-02 
CPNE3_HUMAN Copine-3  1.08 3.67E-02 
B7ZL14_HUMAN FNBP1 protein (Formin-binding protein 1) 1.08 4.37E-02 
GRP78_HUMAN 78 kDa glucose-regulated protein  1.08 1.96E-10 
Q59EL5_HUMAN Aldo-keto reductase family 1 1.08 4.50E-03 
APOBR_HUMAN 
Apolipoprotein B receptor (Apolipoprotein B-100 
receptor)  
1.08 2.17E-02 
GLRX1_HUMAN Glutaredoxin-1 1.08 1.24E-02 
S10A9_HUMAN Protein S100-A9 (Calgranulin-B)  1.09 1.53E-06 
D3DRP5_HUMAN Chromosome 9 open reading frame 19. isoform CRA_a  1.09 1.31E-03 
PFKAL_HUMAN ATP-dependent 6-phosphofructokinase. liver type  1.09 2.15E-02 
BLVRB_HUMAN Flavin reductase (NADPH) 1.09 1.97E-02 
PSA5_HUMAN Proteasome subunit alpha type-5  1.10 1.75E-02 
A8K9E4_HUMAN 
cDNA FLJ76459. highly similar to Homo sapiens matrix 
metallopeptidase 8 (neutrophil collagenase)  
1.10 2.80E-13 
MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate  1.11 9.83E-03 
NAMPT_HUMAN Nicotinamide phosphoribosyltransferase  1.11 1.42E-03 
Q53S24_HUMAN Prothymosin. alpha  1.12 4.22E-02 
Q5SRT3_HUMAN Chloride intracellular channel protein 1.12 3.73E-02 
S10AB_HUMAN Protein S100-A11 (Calgizzarin)  1.12 2.15E-02 
CATD_HUMAN Cathepsin D  1.13 6.74E-03 
B2RB57_HUMAN 
cDNA. FLJ95321. highly similar to Homo sapiens ATG7 
autophagy related 7 homolog  
1.13 4.88E-02 
Q53EM5_HUMAN Transketolase  1.13 2.00E-05 
PNCB_HUMAN Nicotinate phosphoribosyltransferase (NAPRTase) 1.13 1.94E-03 
TOLIP_HUMAN Toll-interacting protein 1.13 2.04E-02 
Q32Q12_HUMAN Nucleoside diphosphate kinase  1.14 2.98E-02 
THIC_HUMAN Acetyl-CoA acetyltransferase. cytosolic  1.14 1.26E-02 
Q5CAQ5_HUMAN Tumor rejection antigen (Gp96) 1 1.14 5.96E-03 
MMP9_HUMAN Matrix metalloproteinase-9  1.14 1.57E-09 
DEK_HUMAN Protein DEK 1.14 1.18E-02 
NIBAN_HUMAN Protein Niban  1.15 3.33E-03 
RNAS2_HUMAN Non-secretory ribonuclease  1.15 3.81E-12 
ACTN4_HUMAN Alpha-actinin-4 (Non-muscle alpha-actinin 4) 1.15 2.27E-02 
DPP3_HUMAN Dipeptidyl peptidase 3  1.16 2.39E-02 
LDH6B_HUMAN L-lactate dehydrogenase A-like 6B  1.17 3.72E-02 
SF3B2_HUMAN Splicing factor 3B subunit 2  1.18 2.30E-02 
MCEM1_HUMAN Mast cell-expressed membrane protein 1 1.20 4.31E-03 
Q2TU34_HUMAN Fructose-1.6-bisphosphatase 1  1.20 3.08E-02 
GLYG_HUMAN Glycogenin-1  1.21 7.78E-05 
PTBP1_HUMAN Polypyrimidine tract-binding protein 1  1.22 1.47E-02 
LEG10_HUMAN Galectin-10  1.22 1.43E-13 
B2RDW0_HUMAN 
cDNA. FLJ96792. highly similar to Homo sapiens 
calmodulin (CALM2) 
1.22 7.65E-03 
ANXA5_HUMAN Annexin A5  1.22 3.30E-10 
MVP_HUMAN Major vault protein  1.22 6.68E-03 
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CALR_HUMAN Calreticulin (CRP55) (Calregulin) 1.22 9.34E-07 
ECP_HUMAN Eosinophil cationic protein  1.26 7.74E-21 
LEG1_HUMAN Galectin-1  1.30 4.29E-02 
CYTB_HUMAN Cystatin-B  1.32 4.50E-02 
FCG3B_HUMAN 
Low affinity immunoglobulin gamma Fc region receptor 
III-B (CD antigen CD16b) 
1.38 1.27E-03 
LOX15_HUMAN Arachidonate 15-lipoxygenase  1.39 1.33E-06 
GILT_HUMAN Gamma-interferon-inducible lysosomal thiol reductase  1.41 2.02E-02 
OLFM4_HUMAN Olfactomedin-4  1.43 5.34E-13 
PRG3_HUMAN Proteoglycan 3  1.55 3.00E-17 
PV vs PMF comparison 
Protein group Protein description Ratio p value 
LEG10_HUMAN Galectin-10  0.64 7.28E-17 
LEG1_HUMAN Galectin-1  0.64 4.05E-03 
RUXF_HUMAN Small nuclear ribonucleoprotein F  0.70 3.45E-02 
B7Z466_HUMAN 
cDNA FLJ51491. highly similar to Arachidonate 15-
lipoxygenase  
0.71 1.01E-05 
PRG3_HUMAN Proteoglycan 3  0.72 1.01E-13 
ACTG_HUMAN Actin. cytoplasmic 2  0.72 8.35E-03 
ECP_HUMAN Eosinophil cationic protein  0.75 5.45E-29 
S10A4_HUMAN Protein S100-A4 (Calvasculin)  0.80 4.57E-05 
B2RDW0_HUMAN 
cDNA. FLJ96792. highly similar to Homo sapiens 
calmodulin 2 (CALM2) 
0.80 8.64E-04 
B4DVJ0_HUMAN Glucose-6-phosphate isomerase  0.81 7.51E-03 
ANXA5_HUMAN Annexin A5  0.83 1.61E-07 
COTL1_HUMAN Coactosin-like protein 0.84 3.89E-03 
Q53EM5_HUMAN Transketolase  0.84 1.43E-10 
B4DV10_HUMAN 
cDNA FLJ59142. highly similar to Epididymal secretory 
protein E1 
0.84 6.83E-03 
COF1_HUMAN Cofilin-1  0.85 4.51E-08 
OLFM4_HUMAN Olfactomedin-4  0.85 2.83E-06 
A4D275_HUMAN Actin related protein 2/3 complex 0.86 2.18E-02 
OSTF1_HUMAN Osteoclast-stimulating factor 1 0.87 1.49E-03 
Q53S24_HUMAN Prothymosin. alpha  0.87 6.11E-03 
MCTS1_HUMAN Malignant T-cell-amplified sequence 1  0.87 7.17E-03 
BPI_HUMAN Bactericidal permeability-increasing protein  0.90 3.18E-11 
Q9Y4A1_HUMAN Talin-related protein  0.90 1.00E-02 
TALDO_HUMAN Transaldolase  0.90 4.76E-11 
MYH9_HUMAN Myosin-9  0.90 2.43E-15 
ENOB_HUMAN Beta-enolase  0.90 1.08E-06 
S10A6_HUMAN Protein S100-A6 (Calcyclin)  0.90 2.47E-02 
GLRX1_HUMAN Glutaredoxin-1  0.91 9.49E-03 
H15_HUMAN Histone H1.5  0.92 4.38E-03 
PROF1_HUMAN Profilin-1  0.92 1.75E-15 
S10AC_HUMAN Protein S100-A12  0.93 4.89E-06 
A4QPB0_HUMAN IQ motif containing GTPase activating protein 1 0.93 1.57E-04 
AMPB_HUMAN Aminopeptidase B  0.93 1.83E-02 
PSA5_HUMAN Proteasome subunit alpha type-5  0.93 1.84E-02 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2  0.94 1.80E-02 
RNAS2_HUMAN Non-secretory ribonuclease  0.95 1.05E-02 
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RHOA_HUMAN Transforming protein RhoA  0.95 5.86E-03 
S10A9_HUMAN Protein S100-A9 (Calgranulin-B)  0.96 2.26E-06 
TPIS_HUMAN Triosephosphate isomerase 0.97 1.07E-02 
AL5AP_HUMAN Arachidonate 5-lipoxygenase-activating protein  0.97 3.18E-02 
ANXA1_HUMAN Annexin A1  0.97 7.07E-03 
COR1A_HUMAN Coronin-1A  0.97 2.95E-02 
PLSL_HUMAN Plastin-2  0.98 9.75E-03 
TLN1_HUMAN Talin-1 0.98 3.07E-03 
GSTP1_HUMAN Glutathione S-transferase P  1.00 1.35E-02 
D3DRP5_HUMAN Chromosome 9 open reading frame 19. isoform CRA 1.02 9.80E-03 
S10A8_HUMAN Protein S100-A8 (Calgranulin-A)  1.03 6.77E-09 
IF2A_HUMAN Eukaryotic translation initiation factor 2 subunit 1  1.08 2.52E-02 
B2R4C5_HUMAN Lysozyme  1.08 2.23E-02 
BLVRB_HUMAN Flavin reductase (NADPH)  1.09 8.27E-03 
HXK3_HUMAN Hexokinase-3 1.09 1.05E-02 
TERA_HUMAN Transitional endoplasmic reticulum ATPase  1.10 2.47E-02 
MMP9_HUMAN Matrix metalloproteinase-9  1.10 3.73E-05 
MCEM1_HUMAN Mast cell-expressed membrane protein 1 1.11 6.91E-03 
ANXA4_HUMAN Annexin A4  1.11 4.38E-04 
ACSL1_HUMAN Long-chain-fatty-acid--CoA ligase 1  1.11 1.36E-02 
GRP78_HUMAN 78 kDa glucose-regulated protein (GRP-78)  1.13 1.94E-10 
A8K9E4_HUMAN 
cDNA FLJ76459. highly similar to Homo sapiens matrix 
metallopeptidase 8 (neutrophil collagenase)  
1.13 1.82E-08 
ELNE_HUMAN Neutrophil elastase  1.15 6.81E-03 
CAMP_HUMAN Cathelicidin antimicrobial peptide  1.15 2.33E-15 
HS71A_HUMAN Heat shock 70 kDa protein 1A  1.15 2.44E-03 
HS71B_HUMAN Heat shock 70 kDa protein 1B  1.15 2.44E-03 
ITAM_HUMAN Integrin alpha-M (CD11 antigen-like family member B)  1.16 8.58E-03 
GSTO1_HUMAN Glutathione S-transferase omega-1  1.17 2.99E-05 
NIBAN_HUMAN Protein Niban (Cell growth-inhibiting gene 39 protein)  1.17 6.05E-03 
PRTN3_HUMAN Myeloblastin  1.18 1.42E-14 
CH3L1_HUMAN Chitinase-3-like protein 1 1.18 3.20E-05 
MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate  1.19 2.05E-02 
Q86SR2_HUMAN AZU1 protein 1.19 1.39E-04 
CAH1_HUMAN Carbonic anhydrase 1  1.20 3.10E-05 
PERM_HUMAN Myeloperoxidase  1.21 1.69E-09 
Q06AH7_HUMAN Transferrin 1.22 7.75E-03 
RETN_HUMAN Resistin  1.24 2.08E-10 
B2R6A3_HUMAN Na(+)/H(+) exchange regulatory cofactor NHE-RF 1.31 4.14E-02 
CATG_HUMAN Cathepsin G  1.36 2.08E-11 
FOLR3_HUMAN Folate receptor gamma  1.61 4.76E-03 
A8K4K0_HUMAN cDNA FLJ75006. highly similar to Homo sapiens CD177  1.69 5.18E-03 
ET vs PMFcomparison 
Protein group Protein description Ratio p-value 
ITAM_HUMAN Integrin alpha-M (CD11 antigen-like family member B)  0.54 2.23E-04 
FOLR3_HUMAN Folate receptor gamma (FR-gamma) (Folate receptor 3) 0.57 1.06E-04 
LEG10_HUMAN Galectin-10  0.66 3.54E-20 
B7Z466_HUMAN 
cDNA FLJ51491. highly similar to Arachidonate 15-
lipoxygenase  
0.66 1.24E-06 
OLFM4_HUMAN Olfactomedin-4  0.72 1.96E-09 
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ACTG_HUMAN Actin. cytoplasmic 2  0.72 1.86E-02 
B4DVJ0_HUMAN Glucose-6-phosphate isomerase  0.73 1.08E-02 
KSYK_HUMAN Tyrosine-protein kinase SYK  0.73 1.85E-02 
FCN1_HUMAN Ficolin-1  0.74 1.00E-03 
SDCB1_HUMAN Syntenin-1  0.75 1.45E-02 
B2RDW0_HUMAN 
cDNA. FLJ96792. highly similar to Homo sapiens 
calmodulin 2  
0.76 3.46E-04 
LEG1_HUMAN Galectin-1  0.77 3.44E-02 
Q53GC7_HUMAN Capping protein  0.78 5.09E-02 
Q15657_HUMAN Tropomyosin isoform 0.78 4.04E-03 
CATD_HUMAN Cathepsin D 0.80 3.19E-04 
B4DV10_HUMAN 
cDNA FLJ59142. highly similar to Epididymal secretory 
protein E1 
0.80 1.83E-02 
A4D275_HUMAN Actin related protein 2/3 complex. subunit 1B 0.80 2.04E-03 
Q5T5C7_HUMAN Serine--tRNA ligase. cytoplasmic 0.81 2.10E-02 
GILT_HUMAN Gamma-interferon-inducible lysosomal thiol reductase  0.82 2.98E-02 
Q53EM5_HUMAN Transketolase  0.83 1.10E-11 
B5BU52_HUMAN Non-specific protein-tyrosine kinase  0.84 3.16E-02 
TCPB_HUMAN T-complex protein 1 subunit beta  0.84 1.68E-04 
ECP_HUMAN Eosinophil cationic protein  0.85 1.46E-17 
RNAS2_HUMAN Non-secretory ribonuclease  0.85 1.30E-12 
PRG3_HUMAN Proteoglycan 3  0.85 2.45E-07 
BPI_HUMAN Bactericidal permeability-increasing protein  0.87 1.33E-07 
B2R4D5_HUMAN Actin-related protein 2/3 complex subunit 3  0.87 1.81E-03 
TCPE_HUMAN T-complex protein 1 subunit epsilon 0.87 2.28E-02 
Q53S24_HUMAN Prothymosin. alpha  0.88 9.21E-03 
LDH6B_HUMAN L-lactate dehydrogenase A-like 6B  0.88 3.63E-02 
CLH1_HUMAN Clathrin heavy chain 1  0.88 4.75E-03 
PERE_HUMAN Eosinophil peroxidase (EPO) 0.88 7.90E-04 
GLRX1_HUMAN Glutaredoxin-1  0.89 5.82E-03 
RAN_HUMAN GTP-binding nuclear protein Ran  0.89 2.23E-04 
Q5CAQ5_HUMAN Tumor rejection antigen (Gp96) 1 0.89 2.18E-02 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1  0.89 8.44E-03 
PLSI_HUMAN Plastin-1  0.90 4.49E-02 
GLYG_HUMAN Glycogenin-1  0.90 7.91E-03 
B2RDE1_HUMAN 
cDNA. FLJ96568. highly similar to Homo sapiens 
tropomyosin 3  
0.90 1.64E-03 
PSA5_HUMAN Proteasome subunit alpha type-5  0.90 2.85E-02 
Q2Q9H2_HUMAN Glucose-6-phosphate 1-dehydrogenase  0.91 3.40E-02 
HXK3_HUMAN Hexokinase-3  0.91 1.09E-04 
PLIN3_HUMAN Perilipin-3  0.91 2.67E-02 
B2RBR9_HUMAN 
cDNA. FLJ95650. highly similar to Homo sapiens 
karyopherin (importin) beta 1  
0.91 2.05E-04 
Q5SRT3_HUMAN Chloride intracellular channel protein 0.92 1.43E-02 
COF1_HUMAN Cofilin-1  0.92 6.12E-03 
ARPC2_HUMAN Actin-related protein 2/3 complex subunit 2  0.92 4.77E-02 
Q6IAM7_HUMAN Signal peptidase complex catalytic subunit SEC11  0.92 1.18E-02 
Q9Y4A1_HUMAN Talin-related protein  0.93 2.69E-02 
ARP3_HUMAN Actin-related protein 3  0.93 2.50E-03 
CPNE3_HUMAN Copine-3 (Copine III) 0.94 2.81E-02 
S10AC_HUMAN Protein S100-A12  0.94 1.15E-03 
A4QPB0_HUMAN IQ motif containing GTPase activating protein 1 0.95 3.85E-03 
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ANXA5_HUMAN Annexin A5 0.95 2.39E-02 
PLSL_HUMAN Plastin-2  0.96 1.61E-06 
PGK1_HUMAN Phosphoglycerate kinase 1  0.97 2.06E-04 
ALDOA_HUMAN Fructose-bisphosphate aldolase A  0.97 3.72E-02 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  0.98 2.07E-02 
PROF1_HUMAN Profilin-1  0.99 1.35E-02 
TALDO_HUMAN Transaldolase  1.02 7.10E-03 
ANXA1_HUMAN Annexin A1  1.05 2.42E-02 
S10A9_HUMAN Protein S100-A9 (Calgranulin-B)  1.06 1.64E-02 
COR1A_HUMAN Coronin-1A  1.06 1.38E-02 
MYH9_HUMAN Myosin-9  1.06 2.45E-03 
VINC_HUMAN Vinculin  1.07 2.60E-03 
ITB2_HUMAN Integrin beta-2  1.07 4.77E-03 
GDIA_HUMAN Rab GDP dissociation inhibitor alpha  1.09 1.92E-02 
Q59F54_HUMAN Solute carrier family 2  1.09 1.31E-02 
SODC_HUMAN Superoxide dismutase  1.09 8.73E-03 
ANXA4_HUMAN Annexin A4  1.09 6.41E-03 
RETN_HUMAN Resistin  1.10 6.39E-04 
CH3L1_HUMAN Chitinase-3-like protein 1  1.10 1.96E-03 
GSTO1_HUMAN Glutathione S-transferase omega-1  1.10 1.02E-02 
ACTN1_HUMAN Alpha-actinin-1  1.10 1.07E-03 
CATG_HUMAN Cathepsin G  1.11 1.55E-03 
MMP9_HUMAN Matrix metalloproteinase-9] 1.11 4.63E-04 
AL5AP_HUMAN Arachidonate 5-lipoxygenase-activating protein  1.12 8.69E-04 
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A  1.13 4.52E-03 
6PGL_HUMAN 6-phosphogluconolactonase  1.16 2.03E-02 
Q5NKU1_HUMAN Intercellular adhesion molecule 3  1.17 3.11E-02 
TERA_HUMAN Transitional endoplasmic reticulum ATPase  1.17 1.45E-03 
D3DNA1_HUMAN Integrin beta 1.17 1.02E-02 
A1AG1_HUMAN Alpha-1-acid glycoprotein 1  1.18 2.16E-03 
BLVRB_HUMAN Flavin reductase (NADPH)  1.21 1.28E-05 
BST1_HUMAN 
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (CD 
antigen CD157) 
1.21 9.28E-04 
CHIT1_HUMAN Chitotriosidase-1  1.21 2.86E-02 
B2R4C5_HUMAN Lysozyme  1.22 1.18E-08 
PERM_HUMAN Myeloperoxidase  1.22 1.82E-09 
PRTN3_HUMAN Myeloblastin  1.23 4.88E-31 
PSME2_HUMAN Proteasome activator complex subunit 2  1.23 1.09E-02 
CAH2_HUMAN Carbonic anhydrase 2  1.27 4.93E-03 
CAMP_HUMAN Cathelicidin antimicrobial peptide  1.28 2.41E-17 
ITAM_HUMAN Integrin alpha-M (CD11 antigen-like family member B)  1.31 1.16E-03 
HS71A_HUMAN y 
B 
Heat shock 70 kDa protein 1A y B 1.39 4.95E-04 
Q86SR2_HUMAN AZU1 protein 1.41 9.30E-08 
B3AT_HUMAN Band 3 anion transport protein  1.41 6.42E-03 
CAH1_HUMAN Carbonic anhydrase 1  1.44 2.29E-09 
PRDX2_HUMAN Peroxiredoxin-2  1.50 3.38E-09 
A8K4K0_HUMAN cDNA FLJ75006. highly similar to Homo sapiens CD177  1.52 2.58E-03 
F189B_HUMAN Protein FAM189B  1.60 9.27E-07 
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PV vs ET comparison 
Protein group Protein description Ratio p-value 
F189B_HUMAN Protein FAM189B  0.66 3.50E-07 
PRDX2_HUMAN Peroxiredoxin-2  0.74 2.24E-05 
S10A4_HUMAN Protein S100-A4 (Calvasculin)  0.77 4.20E-04 
CAH2_HUMAN Carbonic anhydrase 2  0.79 4.73E-04 
CAH1_HUMAN Carbonic anhydrase 1  0.83 1.37E-06 
LEG1_HUMAN Galectin-1  0.83 6.39E-03 
HS71A_HUMAN Heat shock 70 kDa protein 1A  0.84 1.45E-03 
PRG3_HUMAN Proteoglycan 3  0.85 1.17E-06 
A1AG1_HUMAN Alpha-1-acid glycoprotein 1  0.85 1.98E-04 
COTL1_HUMAN Coactosin-like protein 0.86 1.50E-02 
MYH9_HUMAN Myosin-9  0.87 1.80E-22 
ANXA5_HUMAN Annexin A5  0.88 1.70E-04 
Q86SR2_HUMAN AZU1 protein  0.88 2.70E-03 
H15_HUMAN Histone H1.5  0.89 1.47E-02 
TALDO_HUMAN Transaldolase  0.89 1.71E-08 
ACTN1_HUMAN Alpha-actinin-1  0.91 5.97E-04 
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A  0.91 2.85E-05 
CAMP_HUMAN Cathelicidin antimicrobial peptide  0.92 2.98E-04 
COR1A_HUMAN Coronin-1A  0.92 5.68E-05 
B2R4C5_HUMAN Lysozyme (EC 3.2.1.17) 0.92 2.48E-03 
PYGL_HUMAN Glycogen phosphorylase. liver form  0.92 1.12E-02 
CATA_HUMAN Catalase  0.93 7.55E-04 
AMPB_HUMAN Aminopeptidase B 0.93 9.42E-03 
ANXA1_HUMAN Annexin A1  0.95 3.23E-08 
PROF1_HUMAN Profilin-1  0.96 5.22E-06 
S10A8_HUMAN Protein S100-A8 (Calgranulin-A)  1.05 9.07E-06 
B2RBR9_HUMAN 
cDNA. FLJ95650. highly similar to Homo sapiens 
karyopherin (importin) beta 1  
1.10 1.40E-03 
A8K9E4_HUMAN 
cDNA FLJ76459. highly similar to Homo sapiens matrix 
metallopeptidase 8  
1.11 1.75E-05 
TCPB_HUMAN T-complex protein 1 subunit beta  1.12 1.14E-02 
GRP78_HUMAN 
78 kDa glucose-regulated protein (GRP-78) heavy chain-
binding protein) (BiP) 
1.13 1.56E-06 
RETN_HUMAN Resistin  1.14 1.64E-09 
MCEM1_HUMAN Mast cell-expressed membrane protein 1 1.14 1.39E-02 
RNAS2_HUMAN Non-secretory ribonuclease  1.14 1.31E-04 
PDIA6_HUMAN Protein disulfide-isomerase A6  1.17 1.08E-02 
MVP_HUMAN 
Major vault protein (MVP) (Lung resistance-related 
protein) 
1.20 6.67E-03 
OLFM4_HUMAN Olfactomedin-4  1.21 3.55E-04 
NIBAN_HUMAN Protein Niban  1.22 1.09E-03 
CLH1_HUMAN Clathrin heavy chain 1  1.23 2.31E-03 
CAN1_HUMAN Calpain-1 catalytic subunit  1.25 8.69E-04 
PERE_HUMAN Eosinophil peroxidase (EPO)  1.25 1.59E-05 
CATG_HUMAN Cathepsin G  1.25 7.68E-09 
HXK3_HUMAN Hexokinase-3  1.25 5.17E-08 
URP2_HUMAN Fermitin family homolog 3  1.27 1.43E-02 
CATD_HUMAN Cathepsin D 1.28 2.42E-04 
ITAM_HUMAN Integrin alpha-M (CD antigen CD11b) 1.68 7.50E-03 
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FOLR3_HUMAN Folate receptor gamma  2.85 5.45E-05 
Supplemental Data II-2 
Lists of deregulated pathways in granulocytes among the different subgroups PV. ET. PMF 
(all JAK2(+)) and Mut0 (JAK2(-) ET and PMF). 
PV vs Mut0 (JAK2(-) ET and PMF) comparison 
List of the significantly deregulated pathways in PV vs Mut0 (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name 
Entities 
found 
Entities 
total 
Entities 
pValue 
Glucose metabolism 6 76 9.39E-05 
Glycolysis 4 33 2.99E-04 
Nicotinamide salvaging 2 5 1.09E-03 
EPH-Ephrin signaling 5 94 2.12E-03 
RHO GTPases activate PKNs 4 60 2.69E-03 
Gluconeogenesis 3 31 3.36E-03 
ATF6-alpha activates chaperone genes 2 10 4.23E-03 
Metabolism of carbohydrates 8 271 4.37E-03 
Nicotinate metabolism 2 11 5.08E-03 
ATF6-alpha activates chaperones 2 12 6.01E-03 
Advanced glycosylation endproduct receptor signaling 2 13 7.01E-03 
Platelet degranulation  4 79 7.07E-03 
EPHB-mediated forward signaling 3 41 7.26E-03 
Response to elevated platelet cytosolic Ca2+ 4 84 8.72E-03 
Signaling by Rho GTPases 9 379 1.01E-02 
TGF-beta receptor signaling in EMT (epithelial to mesenchymal 
transition) 
2 16 1.04E-02 
RHO GTPases Activate ROCKs 2 17 1.17E-02 
RHO GTPases activate CIT 2 17 1.17E-02 
RHO GTPase Effectors 7 266 1.37E-02 
RHO GTPases activate PAKs 2 21 1.74E-02 
G2/M DNA damage checkpoint 3 58 1.83E-02 
Insulin effects increased synthesis of Xylulose-5-Phosphate 1 2 1.89E-02 
Collagen degradation 3 62 2.18E-02 
Sema4D induced cell migration and growth-cone collapse 2 24 2.23E-02 
Semaphorin interactions 3 67 2.66E-02 
Degradation of the extracellular matrix 4 118 2.67E-02 
Sema4D in semaphorin signaling 2 27 2.78E-02 
TAK1 activates NFkB by phosphorylation and activation of IKKs 
complex 
2 30 3.37E-02 
Axonal growth stimulation 1 4 3.75E-02 
Activation of Matrix Metalloproteinases 2 32 3.78E-02 
EPHA-mediated growth cone collapse 2 34 4.22E-02 
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ET vs Mut0 (JAK2(-) ET and PMF) comparison 
List of the significantly deregulated pathways in ET vs Mut0 (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name 
Entities 
found 
Entities 
total 
Entities 
pValue 
O2/CO2 exchange in erythrocytes 4 8 4.10E-06 
Erythrocytes take up oxygen and release carbon dioxide 4 8 4.10E-06 
Erythrocytes take up carbon dioxide and release oxygen 4 8 4.10E-06 
Detoxification of Reactive Oxygen Species 4 29 5.76E-04 
Platelet degranulation  6 79 5.90E-04 
Response to elevated platelet cytosolic Ca2+ 6 84 8.10E-04 
EPH-Ephrin signaling 6 94 1.43E-03 
Semaphorin interactions 5 67 1.84E-03 
EPHB-mediated forward signaling 4 41 2.05E-03 
Scavenging by Class F Receptors 2 7 3.80E-03 
Assembly of Viral Components at the Budding Site 2 7 3.80E-03 
Folding of actin by CCT/TriC 2 9 6.17E-03 
ATF6-alpha activates chaperone genes 2 10 7.56E-03 
Calnexin/calreticulin cycle 2 11 9.07E-03 
Virus Assembly and Release 2 11 9.07E-03 
Glycolysis 3 33 9.16E-03 
Platelet activation. signaling and aggregation 8 228 9.52E-03 
Hedgehog ligand biogenesis 4 64 9.71E-03 
HSF1 activation 2 12 1.07E-02 
ATF6-alpha activates chaperones 2 12 1.07E-02 
Reversible hydration of carbon dioxide 2 12 1.07E-02 
RHO GTPases Activate WASPs and WAVEs 3 35 1.07E-02 
Advanced glycosylation endproduct receptor signaling 2 13 1.25E-02 
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 2 13 1.25E-02 
Glucose metabolism 4 76 1.72E-02 
Sema3A PAK dependent Axon repulsion 2 16 1.84E-02 
Metabolism of Angiotensinogen to Angiotensins 2 16 1.84E-02 
Axon guidance 13 542 2.23E-02 
Formation of ATP by chemiosmotic coupling 2 18 2.29E-02 
Cell-extracellular matrix interactions 2 18 2.29E-02 
Extracellular matrix organization 8 271 2.42E-02 
Formation of tubulin folding intermediates by CCT/TriC 2 20 2.78E-02 
Hemostasis 12 515 3.36E-02 
Hh mutants abrogate ligand secretion 3 55 3.47E-02 
Hh mutants that don't undergo autocatalytic processing are 
degraded by ERAD 
3 55 3.47E-02 
BBSome-mediated cargo-targeting to cilium 2 23 3.59E-02 
Sema4D induced cell migration and growth-cone collapse 2 24 3.88E-02 
Prefoldin mediated transfer of substrate  to CCT/TriC 2 26 4.48E-02 
Cooperation of Prefoldin and TriC/CCT  in actin and tubulin 
folding 
2 27 4.79E-02 
Smooth Muscle Contraction 2 27 4.79E-02 
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Sema4D in semaphorin signaling 2 27 4.79E-02 
PMF vs Mut0 (JAK2(-) ET and PMF) comparison 
List of the significantly deregulated pathways in PMF vs Mut0 (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name 
Entities 
found 
Entities 
total 
Entities 
pValue 
Detoxification of Reactive Oxygen Species 8 29 8.54E-08 
Platelet degranulation  8 79 1.20E-04 
Response to elevated platelet cytosolic Ca2+ 8 84 1.81E-04 
Glycogen breakdown (glycogenolysis) 4 15 1.86E-04 
Glucose metabolism 7 76 5.60E-04 
Platelet activation. signaling and aggregation 11 228 3.45E-03 
Nicotinamide salvaging 2 5 3.95E-03 
Metabolism of nucleotides 6 81 4.06E-03 
Synthesis and interconversion of nucleotide di- and triphosphates 3 18 4.64E-03 
Regulation of mRNA stability by proteins that bind AU-rich 
elements 
6 87 5.70E-03 
MAP2K and MAPK activation 4 40 6.63E-03 
Synthesis of Leukotrienes (LT) and Eoxins (EX) 3 21 7.08E-03 
Sema4D induced cell migration and growth-cone collapse 3 24 1.02E-02 
Sema4D in semaphorin signaling 3 27 1.39E-02 
Hemostasis 17 515 1.41E-02 
GP1b-IX-V activation signalling 2 10 1.49E-02 
ATF6-alpha activates chaperone genes 2 10 1.49E-02 
Transcriptional Regulation by TP53 5 78 1.51E-02 
TP53 Regulates Metabolic Genes 5 78 1.51E-02 
Nicotinate metabolism 2 11 1.78E-02 
AUF1 (hnRNP D0) destabilizes mRNA 4 55 1.92E-02 
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 
complex 
2 12 2.09E-02 
ATF6-alpha activates chaperones 2 12 2.09E-02 
Activation of Matrix Metalloproteinases 3 32 2.17E-02 
Degradation of the extracellular matrix 6 118 2.25E-02 
Advanced glycosylation endproduct receptor signaling 2 13 2.42E-02 
RHO GTPases activate PKNs 4 60 2.54E-02 
p130Cas linkage to MAPK signaling for integrins 2 15 3.15E-02 
GRB2:SOS provides linkage to MAPK signaling for Integrins  2 15 3.15E-02 
Activation of BAD and translocation to mitochondria  2 15 3.15E-02 
Rap1 signalling 2 16 3.54E-02 
Metabolism of Angiotensinogen to Angiotensins 2 16 3.54E-02 
Semaphorin interactions 4 67 3.58E-02 
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PV vs PMF comparison 
List of the significantly deregulated pathways in PV vs PMF (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name Entities 
found 
Entities 
total 
Entities 
pValue 
EPH-Ephrin signaling 5 94 2.49E-03 
Activation of Matrix Metalloproteinases 3 32 4.07E-03 
Glycolysis 3 33 4.43E-03 
Semaphorin interactions 4 67 4.54E-03 
Platelet degranulation  4 79 8.03E-03 
EPHB-mediated forward signaling 3 41 8.03E-03 
Response to elevated platelet cytosolic Ca2+ 4 84 9.89E-03 
RHO GTPases Activate ROCKs 2 17 1.25E-02 
RHO GTPases activate CIT 2 17 1.25E-02 
Insulin effects increased synthesis of Xylulose-5-Phosphate 1 2 1.96E-02 
Sema4D induced cell migration and growth-cone collapse 2 24 2.39E-02 
Sema4D in semaphorin signaling 2 27 2.97E-02 
PERK regulates gene expression 2 28 3.18E-02 
Gluconeogenesis 2 31 3.82E-02 
Axonal growth stimulation 1 4 3.88E-02 
Glucose metabolism 3 76 4.01E-02 
Glutathione conjugation 2 33 4.27E-02 
EPHA-mediated growth cone collapse 2 34 4.51E-02 
ET vs PMF comparison 
List of the significantly deregulated pathways in ET vs PMF (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name 
Entities 
found 
Entities 
total 
Entities 
pValue 
Platelet degranulation  8 79 1.08E-05 
Response to elevated platelet cytosolic Ca2+ 8 84 1.68E-05 
EPH-Ephrin signaling 8 94 3.71E-05 
O2/CO2 exchange in erythrocytes 3 8 1.74E-04 
Erythrocytes take up oxygen and release carbon dioxide 3 8 1.74E-04 
Erythrocytes take up carbon dioxide and release oxygen 3 8 1.74E-04 
Glycolysis 4 33 9.94E-04 
EPHB-mediated forward signaling 4 41 2.19E-03 
Hemostasis 15 515 3.05E-03 
Platelet activation. signaling and aggregation 9 228 3.21E-03 
Glucose metabolism 5 76 3.41E-03 
Pentose phosphate pathway (hexose monophosphate shunt) 2 7 3.94E-03 
Folding of actin by CCT/TriC 2 9 6.40E-03 
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Gluconeogenesis 3 31 8.13E-03 
Formation of annular gap junctions 2 11 9.39E-03 
Gap junction degradation 2 12 1.11E-02 
Reversible hydration of carbon dioxide 2 12 1.11E-02 
RHO GTPases Activate WASPs and WAVEs 3 35 1.13E-02 
Advanced glycosylation endproduct receptor signaling 2 13 1.29E-02 
Metabolism of Angiotensinogen to Angiotensins 2 16 1.91E-02 
Cell-extracellular matrix interactions 2 18 2.37E-02 
Insulin effects increased synthesis of Xylulose-5-Phosphate 1 2 2.59E-02 
EPH-ephrin mediated repulsion of cells 3 50 2.86E-02 
Formation of tubulin folding intermediates by CCT/TriC 2 20 2.88E-02 
PCP/CE pathway 4 91 3.24E-02 
Hh mutants abrogate ligand secretion 3 55 3.63E-02 
Hh mutants that don't undergo autocatalytic processing are 
degraded by ERAD 
3 55 3.63E-02 
BBSome-mediated cargo-targeting to cilium 2 23 3.71E-02 
Lysosomal glycogen catabolism 1 3 3.86E-02 
Prefoldin mediated transfer of substrate  to CCT/TriC 2 26 4.63E-02 
Cooperation of Prefoldin and TriC/CCT  in actin and tubulin 
folding 
2 27 4.95E-02 
PV vs ET comparison 
List of the significantly deregulated pathways in PV vs ET (p-value < 0.05) ordered in 
increasing p-value according to reactome results. P-value represents the proportion of deregulated 
proteins from the MS analysis that belong to that pathway. Ratio is made between the number of 
deregulated proteins and the total number of proteins in that pathway. 
Pathway name 
Entities 
found 
Entities 
total 
Entities 
pValue 
Platelet degranulation 5 79 2.07E-04 
Response to elevated platelet cytosolic Ca2+ 5 84 2.74E-04 
O2/CO2 exchange in erythrocytes 2 8 1.40E-03 
Erythrocytes take up oxygen and release carbon dioxide 2 8 1.40E-03 
Erythrocytes take up carbon dioxide and release oxygen 2 8 1.40E-03 
Reversible hydration of carbon dioxide 2 12 3.10E-03 
Metabolism of Angiotensinogen to Angiotensins 2 16 5.42E-03 
Insulin effects increased synthesis of Xylulose-5-Phosphate 1 2 1.35E-02 
Detoxification of Reactive Oxygen Species 2 29 1.68E-02 
Platelet activation. signaling and aggregation 5 228 1.93E-02 
Lysosome Vesicle Biogenesis 2 37 2.65E-02 
Extracellular matrix organization 5 271 3.69E-02 
Reverse Transcription of HIV RNA 1 7 4.65E-02 
Minus-strand DNA synthesis 1 7 4.65E-02 
Plus-strand DNA synthesis 1 7 4.65E-02 
Pentose phosphate pathway  1 7 4.65E-02 
Degradation of the extracellular matrix 3 118 4.65E-02 
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Supplemental Data II-3 
 
Article: Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a 
Highlight on the mTOR Signaling Pathway 
 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135463 
 
..\Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on 
the mTOR Signaling Pathway.pdf 
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Besides genetic abnormalities, several studies have reported protein alterations in Ph-
Myeloproliferative neoplasms (MPN) which could participate to the clinical phenotype of patients. 
Nevertheless, little is known about protein alterations in these pathologies. In this context, we used 
an integrative proteomic approach to decipher the landscape of the erythrocyte and granulocyte 
proteome abnormalities that could be related to functional cell alterations and to MPN 
physiopathology. We could identify significant protein deregulations that varied not only according to 
genetic status JAK2(+), JAK2(-) or CALR(+) but also among JAK2(+) MPNs or depending on the 
JAK2V617F allele burden. These protein deregulations involved pathway alterations such as the 
IQGAP1/Rho GTPase signaling that could be related to thrombosis via alterations on the membrane 
integrity by deregulation of PAK1 or the actin cytoskeleton signaling. ROS or mTOR signaling 
alterations were also identified in granulocytes. Finally, we stress out that CALR protein could have 
a dual oncogenic role through its up-regulation in JAK2V617F MPNs different from its altered 
function described in CALR mutated patients. Altogether, we showed that proteomic deregulations 
might play an important oncogenic role in MPN physiopathology and could be implicated in 
complication as thrombotic accidents.  
 
 
En plus des anomalies génétiques, plusieurs études ont rapporté des altérations des protéines 
chez les patients atteintes de Syndromes Myéloprolifératifs (SMP) Ph- qui pourraient participer à 
leurs phénotypes cliniques. Néanmoins, les altérations protéiques dans ces pathologies ne sont pas 
bien connues. Dans ce contexte, nous avons utilisé une approche protéomique par spectrométrie de 
masse pour nous aider à déchiffrer le paysage des anomalies des protéomes érythrocytaire et 
granulocytaire qui pourraient être liées à des altérations cellulaires fonctionnelles et à la 
physiopathologie des SMP. Nous avons ainsi pu identifier des dérégulations importantes de protéines 
qui varient selon le statut génétique des patients, [JAK2(+), JAK2(-) ou CALR(+)], selon la charge 
allélique de JAK2V617F, mais aussi selon le type de SMP JAK2(+) ou selon la. Ces dérégulations 
protéiques perturbent des voies de signalisation comme la voie IQGAP1/Rho GTPase qui pourrait 
être liée aux thromboses par des modifications de l'intégrité membranaire via la dérégulation de 
PAK1 ou des protéines du cytosquelette d'actine. Des modifications des voies de signalisation des 
ROS ou mTOR ont été également identifiées dans les granulocytes. En outre, nous avons montré que 
la protéine CALR pourrait avoir un double rôle oncogénique grâce à son expression élevée dans les 
SMP JAK2V617F, différent de l'altération de sa fonction décrites dans les patients CALR mutés. En 
conclusion, nous avons montré que les dérégulations protéomiques pourraient jouer un rôle 
oncogénique important dans la physiopathologie des SMP Ph- et qu’elles pourraient être impliquées 
dans certaines complications de ces pathologies telles que les accidents thrombotiques. 
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